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Abstract 
 Microbial multicellular behaviors like biofilm formation and swarming motility are 
known to increase their tolerance against antimicrobials. From microbial standpoint, 
nonmicrobicidal agents that do not impede growth are tolerable and therefore, there is a lower 
propensity to develop resistance against such agents as compared to microbicidal ones 
(antibiotics). This study describes a new antibiofilm approach of using nonmicrobicidal 
saccharide derivatives for controlling the multicellular behaviors of gram-negative bacteria, 
Pseudomonas aeruginosa and fungus, Candida albicans. 
 Pseudomonas aeruginosa is known to secrete rhamnolipids, a class of biosurfactants that 
plays an important role in maintaining the architecture of its biofilm and promoting its swarming 
motility. Here we show the ability of certain synthetic nonmicrobicidal disaccharide derivatives 
(DSDs) to mimic the biofunctions of rhamnolipids. The rhlA mutant of P. aeruginosa is 
incapable of synthesizing rhamnolipids and also unable to swarm on semi-solid agar gel. When 
the natural ligands, rhamnolipids were externally added into the semi-solid agar gel in a 
concentration dependent manner, the swarming of the rhlA mutant reactivated at lower 
concentrations (10 μM) and then at relatively higher concentrations (15 μM), the swarming 
reactivation was reversed. When some active synthetic DSDs were tested on the rhlA mutant, the 
bacterial swarming first reactivated and then the activation reversed at higher DSD 
concentrations, similar to the effect of externally added rhamnolipids. Previously, a known 
bacterial signalling molecule has been shown to exhibit a similar concentration dependent 
activation and then activation reversal for light simulation by Vibrio fischeri. Some DSDs having 
disaccharide stereochemistries (cellobiose or maltose) and a bulky aliphatic tail (3, 7, 11-
 
 
trimethyl-dodecanyl) caused swarming reactivation of the rhlA mutant at concentrations lower 
than that caused by the externally added rhamnolipids.  
The synthetic nonmicrobicidal DSDs were also very effective at inhibiting the adhesion 
of P. aeruginosa to polystyrene surface, and at inhibiting the bacterial biofilm formation. These 
DSDs were also potent dispersers of pre-formed biofilm of P. aeruginosa. The potent antibiofilm 
(inhibition and dispersion) activities were observed for those DSDs that possessed a disaccharide 
(cellobiose or maltose) stereochemistry and a bulky aliphatic chain such as 3, 7, 11-trimethyl-
dodecanyl. These potent DSDs had half-maximal inhibitory concentrations for biofilm inhibition 
(IC50) and dispersion (DC50) comparable to those of known potent antibiofilm agents against P. 
aeruginosa. Gene-reporting assays indicate that the mechanism of action of such DSDs is not via 
the known las or rhl quorum sensing systems of P. aeruginosa but that the adhesin potein, pilin 
maybe a likely target of such molecules. 
 Biofilms formed under natural settings are usually formed by both bacteria and fungus 
that co-reside in the same microenvironment. Therefore, agents that can prevent mixed biofilms 
are desirable from a therapeutic standpoint. Despite being nonmicrobicidal to both fungal 
blastospores and hyphae, the synthetic DSDs were able to inhibit the biofilm formation of fungus 
Candida albicans. Microscopic evaluation showed that most DSDs did not prevent the 
blastospores-to-hyphae morphogenesis. The DSDs were effective at inhibiting biofilm formation 
of Candida albicans when applied within five minutes of seeding the test surface with fungal 
cells. Using a surface based assay it was shown that one DSD dramatically reduced the surface 
adhesion of Candida albicans hyphae. The antibiofilm activity of such DSDs against Candida 
albicans is probably due to their ability to prevent hyphae surface adhesion. 
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Chapter 1 
Introduction 
1.1 Treating microbial infections - two different approaches 
 
           The existence of strains exhibiting multidrug resistance (MDR) for many species of 
bacteria is a matter of grave concern and enormous magnitude in today's healthcare settings.
1-5
 
The result is that, infections from many nonlife threatening species are often being cured by the 
most potent drugs only. To add to the woes, the pace at which newer microbicidal agents or 
antibiotics are being discovered and approved has been sluggish  with only oxazolidinones and 
lipopeptides being inducted as potent new drugs in the recent years.
6-10
 Bacteria use at least three 
strategies to invoke MDR. These include, ability to destroy the activity of the drug compound, to 
undergo mutations that lead to expression of altered target proteins that do not recognize the 
antagonistic drug, and to deploy efflux pump mechanisms that lower cellular concentration of the 
drug at the active site.
11-13
 Another problem associated with bacteria is that they possess the 
ability to spread drug resistant genes to other  species through a phenomenon known as 
horizontal gene transfer (HGT).
14-16
 The occurrence of  HGT has ensured that over time, drug 
resistant genes have been disseminated from strain to strain and from species to species, resulting 
in strains exhibiting MDR.
17
  
            Taking a step back and assessing the conventional approach towards treating microbial 
infections, brings forward the underlying common principle, "microbicidal action of drugs".
18,19
 
Antibiotics target the cellular processes that are essential for bacterial survival; therefore bacteria 
employ the three strategies in their survival pack to overcome the effects of such microbicidal 
agents.
20-22
 From the human perspective, the "fightback" by microbes to our invasive 
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microbicidal agents has generated strains that are now sturdier and resistant to the action of most 
antibiotics and the occurrence of such resistant strains are on the increase due to easy transfer of 
genetic elements amongst strains.
3,23
 Therefore agents that prevent microbial infections without 
affecting their growth will have lower propensity to invoke drug resistance.
24
 To summarize, the 
two main problems associated with the conventional microbicidal strategies for treating bacterial 
infections are; (i) Antibiotics enhance the chances of inducing drug resistance in bacteria,
3,25,26
 
(ii) Antibiotics work better when bacteria exist as unicellular organisms.
27,28
 
            Alternatively, the newer strategies to treat bacterial infections should address the above 
mentioned problems associated with conventional antibacterial strategies. The issue of invoking 
drug resistance can be overcome or reduced with the use of nonmicrobicidal agents that do not 
impede bacterial cellular activities. In the present day, the notion that bacteria exist both as 
unicellular planktonic cells and as multicellular organisms has been widely acknowledged by the 
scientific community.
29-31
 Bacterial multicellular processes are known to be associated with most 
infections but are less important for bacterial survival.
32
 Employing strategies that look beyond 
bacteria as simple unicellular organisms necessitates an understanding of why and when bacteria 
switch between the two lifestyles.
33
 
1.2 Two different kinds of lifestyles that bacteria adopt: Unicellular and multicellular 
 
 Despite some earlier observations of coordinated activities, bacteria until recently were 
regarded as archetypal unicellular organisms.
34,35
 But advances in microbiology have since 
focused on why and when do bacteria choose a multicellular lifestyle over remaining loners.
31,33
 
The evolutionary benefits that have been identified as being important for establishing 
multicellularity in bacteria include resistance from predators and better management of 
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nutrients.
30,36
 To achieve these benefits, bacteria associate to form adherent clusters that give rise 
to various kinds of communities, both sessile and motile having different superficial 
morphologies.
37-40
 The formation of both kinds of multicellular communities is known to be 
initiated by different types of chemical signals that bacteria secrete, receive and interpret.
41-43
 
The signal transduction alters bacterial gene expression and sets into motion a series of changes 
that eventually leads to formation of multicellular communities.
44
 Once multicellularity is 
established, the resulting communities either create sessile complex 3-dimensional architectures 
or motile 2-dimensional patterns that ensure division of labor and coordination of nutrients.
36
  
1.3 Sessile and motile multicellular behaviors  
 
 Bacteria are able to perform at least two distinct multicellular processes; (i) Formation of  
biofilm, a sessile lifestyle and (ii) Swarming, a motile lifestyle . While both of these processes 
have distinct characteristics, where one is a stationary phenomenon and the other is a motile one, 
there exists evidence that both these processes are intertwined and have mechanistic 
intermingling.
38,45
 
1.3.1 Formation of biofilm is a developmental process: A sessile group behavior 
 
 Biofilms are highly hydrated surface attached microbial communities having structural 
and metabolic division of labor and where microbes reside within a matrix of secreted extra 
polymeric substances (EPS).
46-48
 The choice of planktonic bacteria to harbor themselves within 
multicellular communities confers many advantages (i) Biofilm architecture and framework 
allows easy flow and supply of nutrients. (ii) The formation of sturdy biofilms creates a 
protective barrier against physical and chemical assaults. (iii) Formation of biofilms renders the 
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community a thousand-fold more resistant to the action of antibiotics. (iv) Different kinds of 
species can inhabit the same matrix as nutrient requirements for specific species are easily met 
by slow diffusion of small molecules across the matrix. (v)Because many species or strains 
reside within the same scaffold, interspecies or inter-strain transfer of genetic material can occur 
to spread competitive advantages against particular environmental challenges.
49,50
 
1.3.2 Five stage differentiation of bacterial biofilms 
 
 In early reports, a biofilm was thought to be an unstructured slime of polymeric matrix 
which bore embedded bacteria.
51
 During these early years, it was not clear how such deeply 
embedded bacteria have access to nutrients or even oxygen. Later, with the use of confocal laser 
scanning microscopy (CLSM), Costerton and coworkers were the first to report that the three 
dimensional architecture of biofilms consists of matrix enclosed bacterial microcolonies that 
have voids or water-channels (Figure 1.1).
47,52,53
  
The formation of biofilm is a developmental process involving five key stages (Figure 
1.1).
54
 The first stage of biofilm development is the "reversible attachment" of bacteria to a 
surface. The planktonic bacteria at this stage are open to both mobile or sedentary lifestyle, and 
once environmental cues are favorable, the bacteria commit to a sessile lifestyle. Once attached 
onto surfaces the bacteria begin a second stage of multicellularity by secreting EPS and 
establishing "irreversible attachment".
55,56
 The composition of EPS secreted by microbes is quite 
diverse and varies from species to species but common elements include polysaccharides, 
nucleic acids, proteins and phospholipids.
57,58
 The matrix created by secretion of EPS helps 
"glue" cells together to initiate microcolony formation.
52
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The surface adhered bacteria then secrete chemical signals known as autoinducers into 
the surrounding environment to perform cell-to-cell communication, a process usually referred to 
as quorum sensing.
59-63
 Quorum sensing is carried out by bacteria to assess the cellular density of 
other bacteria in the environment.
42,64
 The assessment of cellular density is achieved by detection 
of secreted bacterial chemical signals in the environment.
43
 The increase in concentration of 
chemical signals in the environment is correlated with the cellular density of the bacteria. Once a 
threshold concentration for the chemical signals is achieved, individual bacteria transduce the 
signal and initiate a cascade of signaling pathways that eventually alter bacterial gene expression 
to initiate the third stage of biofilm formation which is the shift from planktonic lifestyle to a 
multicellular commune.
65-68
  
The sessile communities formed exhibit a fourth development stage of "maturation" 
where the biofilm takes complex shapes along with redistribution of bacterial cells for distinct 
roles and formation of water channels.
69
 One important change during the fourth stage is the 
alteration in the level of expression of many genes that are different from the genetic expression 
amongst planktonic bacteria.
47,70
  
 Formation of biofilm is a lifestyle change with the underlining principle of ensuring 
bacterial survival and propagation.
71
 Therefore, like other sessile communities, biofilms too have 
evolved dispersive strategies to colonize new surfaces.
72
 This is the final stage of biofilm 
development that includes both passive and active dispersal strategies.
73,74
 In passive dispersal, 
chunks of the existing biofilm may erode away due to fluid shear and move to newer 
uncolonized surfaces. On the other hand, active dispersal, also known as seeding dispersal, of 
free swimming planktonic bacteria from the mature biofilms is thought to be under the control of 
complex cellular signaling. The mechanism by which microorganisms manipulate cellular 
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dispersal from biofilms is still poorly understood but the concept finds broad applications in the 
field of antibiofilm strategies.
49
     
 
Figure 1.1 Different stages of biofilm development and dispersion. Insert-Criteria for developing 
antibiofilm strategies include interfering with one or multiple biofilm developmental stages. 
[Reprinted with permission from Citation:40 Bordi and de Bentzmann (2011) Hacking into 
bacterial biofilms: a new therapeutic challenge. Annals of intensive care, 2011, 1: 19. 
doi:10.1186/2110-5820-1-19; Image Credit: de Bentzmann; Copyright: © 2011 Bordi and de 
Bentzmann; licensee Springer. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License, which permits unrestricted use, distribution and 
reproduction in any medium, provided the original author and source are cited. 
1.3.3 Numerous medical and industrial problems are associated with formation of biofilms 
 
 Until three decades ago, bacteria were primarily regarded as unicellular entities, but since 
then the view about bacteria has evolved to appreciate that formation of biofilms may be a 
preferred bacterial lifestyle. The formation of biofilms by bacteria on both biotic and abiotic 
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surfaces causes immense monetary losses to both medical as well as industrial setups. 
Pseudomonas aeruginosa is the primary microbial dweller in the lungs of cystic fibrosis patients, 
where the bacteria's preferred mode of living is by forming biofilms. Bacteria are known to 
reside within oral cavities, form dental plaques and known to colonize a wide variety of medical 
devices by forming biofilms.
48
 Common diseases associated with formation of bacterial biofilms 
include burn wound infections, otitis media and bacterial endocarditis.
75
  (Table 1.1). Two 
important issues associated with formation of bacterial biofilms are enhanced resistance to 
antimicrobials and lack of strategies that can completely eradicate colonization.  
Table 1.1 Biofilm forming pathogen and the corresponding associated medical condition 
Organism Biofilm-associated diseases 
Pseudomonas aeruginosa Cystic fibrosis lung infection 
Burkholderia cepacia Cystic fibrosis lung infection 
Acinetobacter baumannii Burn wound, trauma infection 
Helicobacter pylori Gastrointestinal infection 
Escherichia coli Urinary, catheter infection 
Haemophilus influenzae Otitis media 
Bordetella pertussis Respiratory infection 
Legionella pneumophila Legionnaires disease 
Staphylococcus aureus Burn wound, catheter, trauma infection 
Staphylococcus epidermidis Sepsis, catheter infection 
Streptococcus mutans Dental plaques, gingivitis 
Vancomycin-resistant enterococci (VRE) Nosocomial infection 
 
The National Institute of Health (NIH) has estimated that 65-80% percent of bacterial 
infections in humans are associated with microbial multicellularity.
76,77
  It has been reported that 
formation of biofilm renders the bacteria about one thousand times more resistant to the action of 
antibiotics.
78-80
 From a monetary standpoint, microbial multicellularity is causes huge losses both 
in medical as well as industrial set-ups. The cost of treating biofilm related infections in the 
United states can be upward of US $ 1 billion. 
46,71
 Until recently, treating microbial infections 
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had been directed towards bacteria as an unicellular entity. But, since the appreciation of 
multicellularity being associated with persistent microbial infections, alternative strategies to 
treat such infections have been explored. 
1.3.4 Common antibiofilm strategies 
 
 Since biofilm formation is a developmental process, the antibiofilm strategies developed 
mainly aim to arrest various stages of colonization (Figure 1.1). The antibiofilm strategies use 
both chemical and physical methods.  
1.3.4.1 Quorum sensing inhibitors   
  
 Quorum sensing is the communication process that facilitates both inter and intra species 
cell-to-cell signaling that ultimately results in altered microbial gene expression leading to 
biofilm formation. The use of both synthetic and naturally occurring antagonists that interfere 
with the cell-to-cell chemical signaling in bacteria is a popular strategy to treat biofilms.
81-83
 
These antagonists are nonmicrobicidal and hence considered to be generally safe for use as they 
possess lesser propensity to induce drug resistance.
77,80
   
1.3.4.2 Bacteriophages that degrade biofilm matrix 
 
 Bacteriophages have co-evolved within bacterial biofilms and can replicate within their 
host cells.
84
 Although bacteriophages are structurally larger than chemical antibiotics, they are 
still comparatively much smaller than bacterial cells and therefore do infect microbes within 
biofilms.
84-87
 Such bateriophages secrete depolymerizing enzymes that reduce biofilm content by 
eliminating bacteria that produce the components of the biofilm matrix like EPS etc.
88-90
 
Bacteriophages can also reside within persister cells without causing any damage to the 
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metabolically inactive host cells, and when such such cells became active, the bacteriophages are 
able to use the host genetic cycle, multiply and cause biofilm elimination.
84
 
1.3.4.3  Surface modifications can prevent bio-fouling 
 
 The use of chemicals to create modified bio-inert surfaces that resist bio-fouling is 
another viable antibiofilm strategy. 
91-97
 Such strategies are directed towards blocking of initial 
bacterial adhesion and hence prevent early stages of biofilm development. The surface chemical 
modifications make include coating with antibiotics,
96
 changing hydrophobicity or 
hydrophilicity,
98,99
 changing surface texture/roughness,
100,101
 and coating with 
polyethyleneglycol (PEG) derivatives.
102
 The Type I pili of E. Coli are important adhesin 
proteins that are recognize mannose moieties presented by host cells. Therefore, mannoside 
derivatives have been deployed as agents that interfere with the natural binding process of Type I 
pili to mannose epitopes present on host cells.
103-106
 
1.3.4.4 Antibiofilm enzymes 
 While prevention of biofilm formation is difficult, it is still relatively easier than 
disrupting biofilms that have already formed, which is normally the problem on medical devices. 
Multiple enzymes have been used to degrade the components of the biofilm matrix, such as 
polysaccharide, eDNA and proteins. One such study has demonstrated the use of dispersin B to 
degrade the components of S. epidermidis biofilm EPS.
107
 One component of biofilm matrices is 
secreted extracellular DNA (eDNA), and hence Izano et al showed that DNAase I could be used 
to degrade the biofilm of S. aureus.
108
 Chaignon et al showed that proteases such as Proteinase K 
and trypsin degrade the biofilm formed by S. aureus.
109
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1.3.4.5 Small molecular chemical dispersers of preformed biofilms 
 A D-amino acid extracted from dispersing cells of B. subtilis was shown to degrade the 
existing biofilm and also prevent the formation of biofilm by S. aureus and P. aeruginosa.
110
 
Another molecule isolated from B. subtilus,  Norspermidine, was demonstrated to break down 
biofilm by targeting the exopolysaccharides. 
111
 Nitric oxide (NO) is known to trigger biofilm 
dispersal in mature biofilms.
112
 Therefore, the use of low-dose of NO synergistically with a 
antibiotic was shown to reduce the colonization of P. aeruginosa in the lungs of cystic fibrosis 
patients.
113,114
Apart from these agents, many of the small molecules used to prevent bacterial 
cell-to-cell communications (quorum sensing inhibitors) have been used effectively to disperse 
preformed biofilms of P. aeruginosa. 
80,115,116
  
1.3.4.6 Physical methods for treating biofilms 
 
 Apart from using chemicals to treat biofilms, many physical and mechanical techniques 
are also employed to treat or prevent biofilm related infections, especially in the food industry. 
Ultrasonication is used to decontaminate food. Decontamination of food and food containers is 
often done with the use of electrolyzed water . Sometimes, prevention of adhesion or removal of 
adhered biofilm on surfaces is done with the use of electrical techniques. 
1.3.5  Swarming on surfaces: A motile group behavior 
 
 While sessile lifestyle (biofilm formation) is critical, bacterial motility also plays an 
important role in microbial pathogenesis. There are different kinds of bacterial motilities that 
planktonic cells or a group of cells can perform. Among the various surface associated bacterial 
motilities, swarming is the fastest and is a coordinated multicellular phenomenon. Swarming is 
usually observed in both Gram-positive as well as Gram-negative bacterial strains that possess 
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flagella, including Salmonella, Vibrio, Yersinia, Serratia, Proteus and Pseudomonas. Apart from 
possession of flagella, the swarming phenomenon is also dependent on surface nutrients and 
surface "wettability" (surface tension). As a result of all the physico-chemical cues, the swarmer 
cells become hyperflagellated, elongated and undergo gene expression alteration as compared to 
vegetative cells. The differentiation of vegetative cells into swarmer cells suggests that swarming 
does not merely represent physical changes in the bacterial behavior but a more complex motile 
lifestyle adaption. Swarming colonies have distinct resistance to action of antibiotics. 
1.4 Synopsis of Chapters 2 & 3 
 
 This thesis brings forward a new way to modulate the two kinds of microbial 
multicellular behaviors; swarming (motile) and biofilm formation (sessile). Chapter 2 describes a 
study in which saccharide derivatives were used for modulating the swarming motility of a 
Gram-negative opportunistic bacterium, Pseudomonas aeruginosa. Some saccharide derivatives 
were able to mimic the functions of a naturally secreted biosurfactant, rhamnolipids, that 
Pseudomonas aeruginosa secrete. The most potent saccharide derivatives seemed to dominate 
the effect that the natural biosurfactant had on swarming motility of Pseudomonas aeruginosa. 
Chapter 3 demonstrates how the nonmicrobicidal saccharide derivatives can also prevent 
Pseudomonas aeruginosa biofilm formation, adhesion and cause biofilm dispersal. The 
antibiofilm (biofilm inhibition and dispersion) half-maximal inhibitory concentrations (IC50s) of 
the most potent saccharide derivatives were comparable to the most potent known 
nonmicrobicidal antibiofilm agents. Overall, Chapters 2 & 3 bring forward certain saccharide 
derivatives as modulators of Pseudomonas aeruginosa multicellular behaviors and also suggest 
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that the secreted biosurfactant, rhamnolipids may have more than just a physical significance in 
the bacterial lifecycle.  
1.5 Synopsis of Chapter 4  
 
 Prokaryotes (bacteria) are not the only organisms that exhibit biofilm formation; Biofilm 
formation is a common way of colonization in eukaryotes (fungus) like Candida albicans. In 
addition to the various effects  of DSDs on bacterium Pseudomonas aeruginosa, Chapter 4 
encompasses a study that demonstrates the versatility of saccharide derivatives to also inhibit the 
biofilm formed by fungus Candida albicans. Surface-chemistry experiments show how the 
antibiofilm activity of these nonmicrobicidal agents against Candida albicans is through their 
ability to prevent hyphal adhesion to surfaces. 
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Chapter 2 
Saccharide Derivatives Modulate the Swarming Motility of Pseudomonas aeruginosa 
Abstract 
Secretion of biosurfactant rhamnolipids by Gram-negative bacteria, Pseudomonas 
aeruginosa has been previously reported to be important for assisting swarming motility and for 
maintaining the architecture of water channels within the biofilm. In this chapter, the control of 
bacterial swarming by synthetic saccharide derivatives that function as rhamnolipids analogues 
has been reported. Few synthetic disaccharide derivatives (DSDs) were shown to be much more 
effective than both the naturally secreted and the externally added rhamnolipids at activating 
swarming of a nonswarming P. aeruginosa mutant. The study also brought forward a dose-
response phenomenon where the activation of swarming in a nonswarming P. aeruginosa 
mutant, rhlA by some DSDs and also rhamnolipids first increases with increasing doses and after 
a threshold dose, the swarming activation is reversed. Previously, a bacterial cell signaling 
molecule, N-(3-oxohexanoyl)-3-aminodihydro-2(3H)-furanone has been shown to exhibit a 
similar dose-response “activity reversal” phenomenon for a different multicellular behavior, i.e 
light simulation. It is therefore predicted that production and secretion of rhamnolipids by P. 
aeruginosa probably has a greater biological significance than mere physical impact on 
multicellularity.  
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2.1 Introduction                                                                                                                          
 Multicellularity offers at least three different advantages over planktonic lifestyle:
38,117
 (i) 
Increased tolerance to antagonists; (ii) Good management of limited nutrients, and (iii) 
Morphological differentiation helps in division of labor. The way free-living bacteria colonize a 
surface depends upon the immediate physio-chemical environment surrounding the bacterial 
population
29,42,45,64,118-121
 and as a consequence, multicellularity in bacteria can be manifested 
through either a sessile
29,34,35,46-48,64,71,75,77,115
 or a motile lifestyle.
38,45,117,119,121-125
 This chapter is 
dedicated to the study of how a class of small molecules modulate bacterial swarming motility. 
2.1.1 Types of bacterial motility 
 It is important to make clear distinctions of the various types of motilities that bacteria 
exhibit and why amongst these motilities, swarming is unique and important from an infection 
standpoint.
38,122
 The first classification of bacterial translocation was done by J. Henrichsen, 
where movements by hundreds of bacterial strains were classified into five main categories: 
swimming, swarming, gliding, twitching and sliding (Figure 2.1).
122,126-133
  
 While swimming motility is a flagellar dependent planktonic behavior of the bacteria in 
liquid medium (Figure 2.1a), swarming is a surface translocation that a group of thousands of 
bacteria perform in coordination (Figure 2.1b).
117,122
 The presence of flagella is known to be 
essential for the occurrence both swimming
132,133
 and swarming
123
 motilities. The direction of the 
rotation of the flagella decides the trajectory of the motility movement. While counterclockwise 
rotation ensures smooth linear trajectories with speeds of up to 40 µm/s, a clockwise rotation 
creates a random tumbling effect (0.1 µm/s).
38,117
  Swarming bacterial cells are generally multi-
flagellated and longer than vegetative counterparts.
38,117,122
 Although swarming is the movement 
of choice under natural colonization on surfaces, under laboratory settings swarming is usually 
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observed on the semisolid gels of agar (0.5 to 1 %) that contain energy rich solid media.
122
 Since, 
within a swarmer colony, each cell can move with a speed between 2 to 10 µm/s, swarming is 
considered the fastest mode of bacterial surface translocation.
117
  
 The extension and retraction of type IV pili is known to drive the slow surface associated 
twitching motility exhibited by planktonic bacteria (Figure 2.1c).
127
 In addition to this, gliding is 
a surface associated motility that bacteria perform without the use of flagella or pili (Figure 
2.1d).
128
 Beside the various models like, repulsion by macromolecule, movement of outer 
membrane or formation of focal adhesion complexes, no one model clearly explains the gliding 
movement of bacteria.
117
 Apart from this, the passive outward movement as a consequence of 
colonial growth on a surface is known as sliding motility (Figure 2.1e).
129-131
 The reduction of 
surface tension by secretion of surfactant has been observed during sliding movement.
122
  
                
Figure 2.1 Bacteria perform both unicellular and multicellular movements. (a) Swarming is 
multicellular movement of bacteria on a surface; (b) Individual bacteria are able to move in 
aqueous media by beating their flagella, known as swimming motility; (c) Twitching is a 
unicellular bacteria movement on a surface that is facilitated by extension of the pili; (d) Gliding 
(a)
(b)
(d)
(e)
(c)
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movement is also a unicellular movement that proceeds through formation of focal-adhesion 
points; (e) Sliding is passive movement across the surface that occurs due to the growth of 
bacterial population. The arrows in the diagram indicates the direction of movement. [Reprinted 
with permission from Citation
122
: Kearns, D. B. et al, A field guide to bacterial swarming 
motility. Nat. Rev. Microbiol. 2010, 8, (9), 634-644. 
2.1.2. Swarming motility is a multicellular phenomenon  
          Both swarming and biofilm formation are bacterial multicellular behaviors that contribute 
to the overall survival of the microbes in the environment and therefore are essential for 
maintaining virulence.
30,34,118
 A switch to swarming lifestyle will generally require a coordinated 
merger of many chemical and physical cues.
122
 Also, a certain cell density is requisite for this 
multicellular behavior to be initiated.
123
 The swarming phenomenon has been observed both in 
gram negative as well as gram positive bacterial species.
117
 So far swarming has been observed 
in three bacterial families including gamma-proteobacteria, alpha-proteobacteria and 
firmicutes.
122,134
 Under laboratory settings, the water content of the agar gel is critical for 
observing swarming. Under laboratory settings, while some bacteria can swarm on gels 
composed of a wide variety of agar concentrations, usually most bacteria swarm on gels above 
0.5% and below 1% agar.
135
 A concentration of below 0.5% agar is usually deemed suitable for 
swimming motility,
132
 while concentration above 1.5% is known to inhibit swarming.
136
  
        In general the key features important for ensuring that swarming occurs include: presence of 
flagella, cell-to-cell communication and biosynthesis of surfactants.
122,123
  
A number of studies have shown that mutations that reduce flagellar biosynthesis also 
abolish or reduce swarming motility.
123,125
 Contrary to this, enhanced expression of flagella 
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increases swarming in certain mutant species.
137-139
 Therefore, it is not surprising that most 
swarmer cells have a peritrichous arrangement of flagella.
122,137,140,141
 Bacteria form a bundle 
with these multiple flagella and the rotation of such a bundle powers the bacteria to move on a 
viscous media.
142,143
 Some bacteria like Pseudomonas aeruginosa synthesize a lateral flagella in 
addition to the existing polar flagella to move on a viscous surface.
123,136,141,144
  
       The number of cells are critical to initiate the swarming process and therefore many 
swarming processes are linked to the cell-to-cell communication process known as quorum 
sensing.
123,145
 The swr quorum sensing system in Serratia liquefaciens which is homologous to 
the lux system of Vibrio fischeri has been shown to control the swarming of Serratia 
liquefaciens.
145
 Autoinducers, N-acylhomoserine lactones (AHLs) are known to control the 
biosynthesis of a biosurfactant necessary for the swarming of a P. aeruginosa,
123
 and S. 
marcescens;
146
 and peptides autoinducers control surfactant synthesis in B. subtilis.
147,148
 One 
important aspect of swarming is cellular collaboration manifested through the formation of 
"rafts" where bacteria move side by side as groups.
122,137,140,145,149-151
 To the present date it is not 
exactly clear why the formation of rafts is necessary during swarming but it is appreciated that 
such a process would require communication between cells.
122
  
          Secretion of surfactants by bacteria is commonly observed during the swarming 
process.
121,123,137,140
 Surfactants, being amphiphilic molecules, reduce the surface tension 
between the bacterial cells and the substrate, hence allowing easy translocation. Under laboratory 
conditions, most bacteria swarm on moist semi-solid gels containing 0.5-1.0 % agar. However, 
some bacteria species like Proteus,
152
 Vibrio,
153
 Rhodospirllum,
154
 and Azospirillum
126
 possess 
the ability to swarm effectively on solid agar gels that normally inhibit swarming, i.e >1.5 % 
agar.
126
 Such bacterial species are known to secrete surfactants like polysaccharides to achieve 
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lower surface tension and create a more conducive micro environment for swarming.
134,152
 
Surfactants and polysaccharides are the major components of the slime that normally surround 
swarmer colonies.
134
 Production of surfactin, a surface active agent secreted by B. subtilis is 
critical for its swarming.
137
 While B. subtilis mutants that lacked surfactin biosynthesis lacked 
the ability to swarm, when externally added surfactin was introduced, the mutants were able to 
swarm again.
137
 P. aeruginosa is known to secrete a class of of lipopolysaccharide based 
molecules, known as rhamnolipids that have been shown to be critical for its swarming 
process.
123
 
2.1.3 Understanding the cell-to-cell communication process 
 Bacteria perform cell-to-cell communication with the use of unique chemical signals 
known as autoinducers (AI) that they produce and secrete out into their environment.
41,43,64,147,155-
157
 The accumulation of these chemical signals increases in proportion to the bacterial cell 
density and upon reaching a threshold concentration such signals are able to bind to the cognate 
receptors thereby altering population wide gene expression and inducing multicellular 
behaviors.
29,31,43,64,118,147,155,158
 This chemical cellular communication process also known as 
quorum sensing has features that are conserved amongst various species while at the same time 
each species has elements that are unique to its system.
29,43,64,118,147,155,158-160
 
The common elements amongst the various quorum sensing systems are;
29,147
 (i) Each 
system is able to synthesize a chemical signaling molecule that is secreted out and upon reaching 
a threshold concentration such molecules are detected and induce a response. (ii) The receptors 
for such signals may either exist in the cytoplasm or on cell surface membranes and signal 
transduction activates cooperative behaviors. (iii) Additionally, signal transduction causes 
autoinduction of the originally secreted chemical signal. The uniqueness of each quorum sensing 
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systems is manifested through the existence of signals and receptors that are structurally different 
for different systems but specific for each signal-receptor pair. 
         The Gram-negatives bacteria use small molecular autoinducers that are either acyl 
homoserine lactones (AHL or AI-1) or furanosyl borate diester (AI-2)
29,64,147,155,157
 (Figure 2.2 (a 
&d)). Contrary to the small molecular autoinducer signals of the Gram-negatives, the 
autoinducers secreted by the gram positive bacteria are oligopeptides known as autoinducing 
peptides (AIP)
29,64,147,155,157,161
 (Figure 2.2b). The secreted AIPs are able to bind to cognate 
membrane bound histidine kinase receptors and the binding causes a phosphorylation cascade 
that ultimately results in alteration of gene expression.
161-163
 Certain Gram positive species like 
Streptomyces employ γ –butyrolactones (Figure 2.2c) for regulation of antibiotic production and 
morphological differentiation.
155,164
 
 
20 
 
 
Figure 2.2 Chemical signals or autoinducers employed by bacteria for cell-to-cell 
communication process. The figure shows the chemical structure of an autoinducer and the 
corresponding bacterial species that secretes the signal (a) Example of acyl-homoserine lactone 
(AHL) based autoinducers used by some Gram-negative bacteria (also known as AI-I); (b) 
Autoinducing peptides (AIP) deployed by some Gram-positive bacteria to achieve cellular 
communication; (c) The butyrolactone based autoinducer secreted by the Streptomyces species; 
(d) The borate diester (AI-2) type of autoinducer (AI-II) used during inter-cellular 
communication by some gram negative bacteria. [Reprinted with permission from Citation:
155
 
a b 
c d 
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Quorum Sensing: Cell-to-Cell Communication in Bacteria Christopher M. Waters and Bonnie L. 
Bassler 
2.1.4 Components of a typical gram negative quorum sensing gene circuitry 
 All known quorum sensing systems described for gram negative bacteria are  
homologous to the LuxI/LuxR type quorum sensing system first described in Vibrio fischeri 
(Figure 2.3).
147,155,156,158,165-167
 In the LuxI/LuxR quorum sensing system the LuxI homologue is 
the AI synthase that couples the acyl group from specific donor proteins to the methionine on S-
adenosyl methionine (SAM) and produces AHLs.
156,168
 The synthesized AHLs are secreted out 
of the cell and as the cellular population of bacteria in the milieu increases, the concentration of 
secreted AHLs also increases proportionally.
169
 When the external AHL concentration reaches a 
specific threshold, the binding of AHLs to the cognate LuxR type protein becomes effective.
64
 
The LuxR-AHL binding results in the stabilization of the LuxR type protein and the ligand-
receptor complex eventually activates the transcription of genes including the ones that control 
the production of virulence factors like biofilm formation, swarming, biosurfactant, pyocyanine, 
elastate B, and bioluminescence.
170
  
The quorum sensing systems in more than hundred Gram-negative bacteria species are 
known to be typified by the LuxI/LuxR type quorum sensing of Vibrio 
fischeri.
42,147,155,156,158,159,165,166,171-173
 The differences are that the AHL secreted by these systems 
are unique and are distinguished by different lengths of side chains (between C-4 to C-18) or 
different functional group (hydroxyl or carbonyl) decoration on the side chains (Figure 
2.2a).
42,118,147,155,156,158,159,166,171,173
 Chemical diversity of the AHL chemical signals is matched by 
occurrence of corresponding homologous LuxR type receptor 
proteins.
42,118,147,155,156,158,159,166,171,173
 For each species the binding of the AHL signal to its 
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corresponding LuxR type protein is highly specific and critical for achieving intra species cell-
to-cell communication. Some Gram-negative bacteria species like P. aeruginosa use more than 
one LuxI/LuxR type quorum sensing systems in tandem to carry out cell-to-cell 
communication.
64,156,174
   
                                                           
Figure 2.3 The components and the representation of a typical quorum sensing process 
performed by Gram-negative bacteria [Reprinted with permission from Citation:
118
 Bassler, 
B. L. et al, The Languages of Bacteria. Genes Dev. 2001, 15, (Copyright (C) 2012 American 
Chemical Society (ACS). All Rights Reserved.), 1468-1480. 
2.1.5. Swarming in P. aeruginosa 
       Pseudomonas aeruginosa is a gram-negative bacteria and is the primary pathogen that 
colonizes the lungs of cystic fibrosis patients.
175-179
 P. aeruginosa uses many techniques for 
movement through either solution or on surfaces.
122,123,132,134,136,144,180
 Generally, the single 
flagellated planktonic Pseudomonas aeruginosa propels through aqueous media with regular 
"beating" of the flagella.
132,133,136
 Under laboratory conditions too, P. aeruginosa is able to 
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employ flagellar propulsion to swim in low-agar (<0.4 %) medium.
119,123,132,133,181
 Apart from 
using flagella, P. aeruginosa is known to use the extension and retraction of pilus filament to 
move on surfaces.
182
 The type-IV pili in Pseudomonas aeruginosa are also important for 
attachment to both epithelial cells and abiotic surfaces.
183
 However, the fastest mode of surface 
translocation that P. aeruginosa performs is swarming.
122
  
          The swarming colonies formed by P. aeruginosa (PA14) are typified by having an 
appearance of tendrils originating from the center point of inoculation.
123
 (Figure 2.5g) Other 
strains like PAO1 swarm by forming a circular colony with not very conspicuous tendril 
formation.
135
 Like other bacteria, the important features necessary for swarming of P. aeruginosa 
are presence of flagella and pili, quorum sensing dependent gene-regulation and the secretion of 
biosurfactants.
123
  
2.1.5.1 Swarming in P. aeruginosa requires flagella 
         Under the swarming mode the monotrichious Pseudomonas aeruginosa vegetative cells 
usually become elongated and acquire a second polar flagella.
136
 Kohler and coworkers reported 
that a mutant strain Pseudomonas aeruginosa PAO1, fliC that did not synthesize any flagellum 
had impaired swarming.
123
 These investigators also discovered that another surface appendage 
which is responsible for twitching motility, type-IV pili was essential for swarming in strains 
PT623 and PT612 of P. aeruginosa. The mutant strains of both PT623 and PT612, that is pilA 
and pilR, respectively were complete nonswarmers. Swarming was however partially restored in 
mutant pilR when a plasmid encoding for expression of pili was introduced.
123
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2.1.5.2 Alteration in gene expression of P. aeruginosa during swarming 
           Overhage and coworker were first to report that swarming is a bacterial lifestyle 
adaptation under a viscous environment.
180
 In adapting to a motile lifestyle, P. aeruginosa have 
been reported to up-regulate certain genes related to virulence and antibiotic resistance.
180,184
 On 
comparing swimming with swarming cells, they observed that there was a major shift in gene 
expression of virulence regulated genes like those encoding for Type-III secretion systems, 
extracellular proteases and iron transport.
180,184
 Amongst the up-regulated virulence genes, 
Overhage and coworkers showed that lasB and pvdQ were required for swarming motility in P. 
aeruginosa.
184
 The comparison of swimmer and swarmer cells also showed that the latter were 
more resistant to the action of at least three antibiotics, polymyxin B, gentamicin, and 
ciprofloxacin.
180
  
          Deziel and coworkers compared the gene expression of nonswarming Pseudomonas 
aeruginosa PA14 cells to cells both at the center and at the tendril tips of a swarming colony.
124
 
Deziel and co-workers’ screening showed the over-expression of 20 genes and down regulation 
of 121 genes by bacteria at tip of the tendril in comparison with bacteria in the swarm center of 
the swarming pattern. Using gene microarray they obtained transcriptomic profiles to show that a 
minority of the genes, including those for energy metabolism and transport of small molecules, 
were upregulated in cells found at the swarming tips. In contrast, they reported that genes 
responsible for virulence were repressed in cells found at the swarm edges as compared to the 
cells at the swarm center. This report of down regulation of virulence genes at swarming edges 
was distinct from the work of Overhage, where upregulation of virulence genes in cells at the 
swarming edge was reported in a direct comparison to cells found in broth.
124,180
 The work by 
Deziel and coworkers highlighted the existence of a bacterial subpopulation within a swarming 
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colony, a population of metabolically hyperactive swarmer cells ("hyperswarming") found at the 
edges and population of cells at the center of the colony that are more virulent 
("hyposwarming").  
         Bacterial multicellularity is initiated by quorum sensing and ultimately results in altered 
gene expression. Since swarming motility has also been shown to exhibit altered gene 
expression, it is important to establish a link between quorum sensing and swarming. 
2.1.5.3 The LasI-LasR and RhlI-RhlR Qurom Sensing Systems of P. aeruginosa are homologous 
to the LuxI/LuxR system found in Vibrio fischeri 
In P. aeruginosa, there exist a hierarchical system of two LuxI/LuxR type quorum sensing 
circuits known as LasI/LasR and RhlI/RhlR, respectively that work in tandem to control group 
behavior of a population (Figure 2.4).
160,165,172,185,186
 The LasI/LasR system functions similar to 
the homologous LuxI/LuxR QS-system of Vibrio fischeri. The LasI is the AHL synthase that 
catalyzes the synthesis of autoinducer N-(3-oxododecanoyl) homoserine lactone (PAI-1).
167
 At a 
particular higher cellular density, the concentration of secreted PAI-1 is sufficient to exhibit 
effective binding to its cognate receptor protein, LasR.
167,171
 The LasR-PAI-1 complex initiates a 
signaling cascade that induces transcription of genes (like lasB, lasA, apr, and toxA) responsible 
for production of virulence factors.
156,165,166,172,187,188
 The LasR-PAI-1 complex also auto 
regulates the lasI gene and directs it to synthesize more PAI-1, thus the name autoinducer is 
assigned to the N-acyl homoserine lactone (PAI-1) molecule.
156,165,166,172,187,188
 Additionally, the 
LasR-PAI-1 complex also activates the expression of rhlI and rhlR genes.
189
 The gene product of 
rhlI, RhlI catalyzes the synthesis of a second autoinducer, N-(butanoyl) homoserine lactone 
(PAI-2), which upon binding its cognate receptor protein, RhlR activates additional specific 
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target genes including rhlAB (Figure 2.4).
189
 The rhlAB operon encodes for the synthesis of 
rhamnolipids, a class of biosurfactants crucial for swarming motility.
189
 Therefore, the LasI-
LasR/RhlI-RhlR two component quorum sensing system in P. aeruginosa regulates a cell density 
dependent expression of various virulence genes. The expression of such virulence genes 
includes secretion of toxins such as exotoxin A and exoenzyme S, proteases such as elastase, 
LasA protease, secretion of alginate, formation of biofilm, induction of swarming and production 
of surface wetting agents such as rhamnolipids. 
 
Figure 2.4 Biosynthesis of rhamnolipids by P. aeruginosa. The two-component LasI-
LasR/RhlI-RhlR quorum sensing circuit of P. aeruginosa controls expression of various 
virulence genes, including biofilms formations, swarming and rhamnolipids biosynthesis 
[Adapted and modified with permission from Citation:
171
 E C Pesci, (1997), “Regulation of las 
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and rhl quorum sensing in Pseudomonas aeruginosa” Journal of Bacteriology (179), 3127-3132; 
Copyright: 1997, American Society for Microbiology.] 
2.1.5.4 Quorum sensing regulates synthesis of biosurfactant rhamnolipids 
Rhamnolipids are glycolipid biosurfactants secreted by P. aeruginosa. These molecules 
play crucial role in maintaining biofilm architecture and assisting swarming.
123,190,191
 The PAI-
2/RhlR complex activates the genes in the rhlAB operon.
174
 The gene product of rhlA, RhlA 
catalyses the synthesis of 3-(3-hydroxyalkanoyloxy)alkanoic acids (HAA).
174,189
 RhlB is the 
rhamnosyltransferase protein encoded by the rhlB gene which catalyses the reaction between 
dTDP-L-rhamnose and HAA to yield monorhamnolipids. A second rhamnosyltransferase RhlC 
encoded by the rhlC gene adds the second dTDP-L-rhamnose moiety to mono-rhamnolipids, 
thereby synthesizing di-rhamnolipids (Figure 2.4).
192
 The composition of the biosurfactant 
released by P. aeruginosa during swarming is usually a mixture of the different congeners that 
include di-rhamnolipids, mono-rhamnolipids and their intermediate precursor HAA. 
2.1.5.4.1 Role of biosurfactant rhamnolipids in swarming 
         Multiple scientific reports indicate that rhamnolipids secreted by P. aeruginosa play an 
important role in the two social activities displayed by bacteria, i.e swarming
121,123,181
 and 
biofilm formation.
191
 Scientific work elaborating the role of rhamnolipids in swarming is 
presented in this chapter, whilst work highlighting rhamnolipids' role in biofilm formation will 
be discussed in the next chapter (chapter 3, Section 3.1.3) 
         Kohler and coworkers used isogenic derivatives of wild type P. aeruginosa strain PT5 in 
which either of the four crucial quorum sensing genes were inactivated i.e, lasI, lasR, rhlI, or 
rhlR.
123
 Their findings revealed that the mutants having inactivated lasI and lasR exhibited 
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reduced swarming after prolonged incubation on semisolid swarm gels (0.5-0.7 % agar) where as 
rhlI and rhlR mutants were completely unable to swarm. Kohler and coworkers findings led 
them to hypothesize that certain factors under the control of quorum sensing genes was crucial 
for swarming. Since rhamnolipids have surface activity properties that could be crucial in the 
surface motility, and since production of rhamnolipids is directly under the control of the rhl 
cell-to-cell signaling system, Kohler and coworkers further studied the surface motility of mutant 
rhlA. The mutant rhlA strain PT712 which is deficient in the production of rhamnolipids but can 
synthesize the quorum sensing signaling molecule, N-(butanoyl) homoserine lactone (PAI-2) 
was completely incapable of swarming on semisolid gel. Co-inoculating the rhlA mutant strain 
PT712 with wild type strain PT5 that can synthesize rhamnolipids, reinstated the swarming in the 
mutant strain. By this experiment, Kohler and coworkers identified the presence of rhamnolipids 
as being crucial for swarming motility in P. aeruginosa. 
        The unique feature that a population of swarming P. aeruginosa cells exhibit is the 
formation of a fractal-like pattern on the swam plate, where many tendrils formed by the 
bacterial population exude out from the central point of inoculation (Figure 2.5g). O' Toole and 
coworkers were the first to demonstrate that the production of rhamnolipids were important for 
maintaining tendril formation and preventing colonization between tendrils.
119
 They observed 
that tendrils from two different swarming colonies avoided each other and when a nonmotile 
mutant of P. aeruginosa, flgK was placed in the course of a wild type swarm colony, the tendrils 
of the swarmer colony proximal to flgK mutant radiated away suggesting that both the wild type 
and flgK mutant secrete extracellular factors that cause repulsion between two colonies. Also, 
they observed that when wild type strain was inoculated onto a swarm plate containing spent 
supernatant prepared from a rhlA colony, the wild type strain swarmed normally, but when 
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grown with supernatant from a wild type colony, there was no swarming. The rhlA mutant is 
unable to synthesize di-rhamnolipids, its precursor mono-rhamnolipids and HAA and is also a 
nonswarming strain (Figure 2.5 k). To evaluate the effect of each component on swarming, they 
further constructed mutants rhlB and rhlC lacking the rhamnosyltransferase necessary to 
generate mono-rhamnolipid and di-rhamnolipid, respectively. The swarming patterns of wildtype 
had a radial array of fine tendrils, where as both rhlB and rhlC swarmed with short, thick and 
irregular tendrils, suggesting that di-rhamnolipids were important for pattern formation. They 
further showed that when both wild type and flgk mutant (nonswarming control) were co-
inoculated on plates containing spent supernatant from either rhlB or rhlC mutant, the wild type 
did exhibit swarming with rhlC supernatant but no swarming with supernatant from rhlB mutant. 
With their study, O' Toole and coworkers reported that since the rhlC mutant can produce mono-
rhamnolipids and rhlB mutant cannot, monorhamnolipids are the minimum component to cause 
swarming inhibition of wild type. 
     Deziel and coworkers made a deeper analysis of the role of each component from 
rhamnolipids biosynthesis (i.e HAA, mono-rhamnolipids and di-rhamnolipids) in creating swarm 
patterns of Pseudomonas aeruginosa.
121
 Deziel et al isolated and used pure HAA, mono-
rhamnolipids and di-rhamnolipids in their experiments. They reported that the tendrils of a wild 
type Pseudomonas aeruginosa (PA14) swarmer colony get attracted to a paper disk soaked with 
di-rhamnolipids and move away from a disk soaked with HAA (Figure 2.5 a & c). Further Deziel 
et al exogenously added drops of either di-rhamnolipids, mono-rhamnolipids or HAA on the 
center of swarm plates and then inoculated these plates with either wild type strain or the rhlA 
mutant. Their experiments showed that HAA inhibited the swarming of wild type and caused no 
restoration of swarming in the rhlA mutant (Figure 2.5 f & j, respectively). Mono-rhamnolipids 
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facilitated the formation of tendrils in wild type and dispersion of bacteria away from the swarm 
center and no biomass accumulation at the center for the rhlA mutant (Figure 2.5 e & i, 
respectively). Contrary to HAA, di-rhamnolipids promoted formation of fine tendrils and 
biomass accumulation at the swarm center for both wildtype and the rhlA mutant (Figure 2.5 d & 
h, respectively). With these experiments, Deziel and coworkers concluded that, with respect to 
the active swarming cells, di-rhamnolipids act as attractants, HAA act as repellants and that 
mono-rhamnolipids are mere surface wetting agents (Figure 2.5b). 
 
Figure 2.5 Swarming pattern of either wild type PA14 or its rhlA mutant. Wild type PA14 
inoculated on agar plates containing discs of either di-rhamnolipids, monorhamnolipids or HAA 
(a, b, and c, respectively). Swarm plates containing either dirhamnolipids or monorhamnolipids 
or HAAs or no agent inoculated with either wild type PA14 (d, e, f and g, respectively) or the 
rhlA mutant (h, i, j and k, respectively) [Adapted and modified with permission from Citation:
121
 
Deziel, E., Self-produced extracellular stimuli modulate the Pseudomonas aeruginosa swarming 
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motility behavior. Environ. Microbiol. 2007, 9, (Copyright (C) 2013 American Chemical Society 
(ACS). All Rights Reserved.), 2622-2630. 
       In order to postulate a theory for the formation of tendrils by swarming Pseudomonas 
aeruginosa cells, Deziel and coworkers further tested the rate of diffusion for di-rhamnolipids 
and HAA on agar plates. The results indicated that di-rhamnolipids diffuse faster and further on 
the agar plate as compared to HAA. Hence when swarmer cells are present at the center of an 
agar plate, the continuous secretion of di-rhamnolipids and HAA creates a positive concentration 
gradient of di-rhamnolipids/HAA. Since di-rhamnolipids diffuses faster in the agar and is an 
attractant for active swarming cells, there is a positive drive to move away from the slower 
diffusing repellant HAA. The occurrence of this positive concentration gradient creates tendrils 
which become more and more distinct as the cells migrate outward under continuously evolving 
di-rhamnolipids/HAA concentration gradient (Figure 2.6). 
     
Figure 2.6 (a) Diffusion rate for di-rhamnolipids and HAA on agar plates. (b) Positive 
concentration gradient of di-rhamnolipids/HAA mainatins tendril pattern [Reprinted with 
permission from Citation:
121
 Deziel, E., Self-produced extracellular stimuli modulate the 
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Pseudomonas aeruginosa swarming motility behavior. Environ. Microbiol. 2007, 9, (Copyright 
(C) 2013 American Chemical Society (ACS). All Rights Reserved.), 2622-2630. 
2.1.6 Concentration dependent activity reversal phenomenon previously reported for bacterial 
cell-signaling molecule 
Photobacterium fischeri is a marine bacteria that can emit visible light through a 
biochemical process known as bioluminescence.
120,193
 The bioluminescence in Photobacterium 
fischeri is controlled by the luciferase enzyme which is under the control of the quorum sensing 
system LuxI-LuxR.
29,118,147,155
 The LuxI-LuxR quorum sensing system is in turn activated by the 
cell-signaling molecules (AHLs) whose production increases in proportion to bacterial 
population. Upon activation, the luciferase enzyme catalyzes the oxidation of a long-chain 
aldehyde (RCHO) and reduced flavin mononucleotide (FMNH2)
193
 resulting in the release of 
excess free energy in the form of blue-green light at 490nm. 
 Eberhard and coworkers in the classical paper isolate and characterize N-(3-
oxohexanoyl)-3-aminodihydro-2(3H)-furanone (acyl homeserine lactone, AHL) as the cell cell-
signaling molecule that controls the quorum sensing of Photobacterium fischeri.
120
 In this work, 
Eberhard and coworkers demonstrated that both natural and synthetic AHLs molecules were able 
to simulate light production in Photobacterium fischeri. They also performed a dose-dependent 
study to understand effect of AHL concentration on light production. On doing a dose-response 
curve with synthetic AHLs, the bioluminescence increased over the range 0.003-3 μg/mL and 
then decreased at higher concentrations (Figure 2.7).
120
 The vague explanation the authors 
provided to describe this "activity reversal" is that the production of luciferase enzyme probably 
decreases as the bacteria reach the stationary phase. However, since it was first reported, the 
mechanism of how such an “activity reversal” operates appears to have been overlooked. 
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Figure 2.7 Dose-response curve for simulation of light production with increasing 
concentration of acyl homeserine lactone (AHL). Bioluminescence increased over the range 
0.003-3 μg/mL and then decreased at higher concentrations. [Reprinted with permission from 
Citation:
120
 Eberhard, A.; Burlingame, A.; Eberhard, C.; Kenyon, G.; Nealson, K.; Oppenheimer, 
N., Structural identification of autoinducer of Photobacterium fischeri luciferase. Biochemistry 
1981, 20, (9), 2444-2449. 
2.2 Results and discussion  
2.2.1 Design of synthetic saccharide derivatives library  
      The initial thought was to investigate if rhamnolipids exhibit a mere physical effect on 
swarming or whether their secretion is correlated with a more complex biological process. 
Rhamnolipids and its congeners are glycolipids biosurfactants and the amphiphiles have a 
disaccharide polar head group and greasy aliphatic tail. Due to the amphiphilic structure of 
rhamnolipids the initial inclination was to evaluate the effect of different types of generic 
surfactants (anionic, cationic, and nonionic) on bacterial swarming.
194
 The generic surfactants 
that were used included two non ionic surfactants, dodecyl-β-maltoside (DβM, 1) and 
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tetra(ethylene glycol) monododecyl ether (C12EG4OH), one anionic surfactant, sodium dodecyl 
sulfate (SDS), and one cationic surfactant, dodecyl trimethylammonium chloride (DTAC). Since 
microbes possess the ability to recognize a diverse range of saccharide stereochemistries,
195-199
 
the chemical library also included amphiphiles that had a stereochemistry other than rhamnose 
and an aliphatic chain different from rhamnolipids (Figure 2.8). The chemical library included 
three disaccharide stereochemistries, cellobiose (Glcβ(14)Glcβ), maltose (Glcα(14)Glcβ) 
and lactose (Galβ(14)Glcβ), two monosaccharide stereochemistries, glucose (Glcβ), and 
rhamnose (Rhaα) and one large cyclic hepta-saccharide, β-cyclodextrin (βCD). The disaccharide 
derivatives (DSDs) comprising of maltose (Glcα(14)Glcβ)-based stereochemistry included 
dodecyl-β-maltoside (DβM), 1; saturated farnesyl-β-maltoside (SFβM), 14; and those comprised 
of cellobiose (Glcβ(14)Glcβ)-based stereochemistry included dodecyl-β-cellobioside (DβC), 
4; decyl-β-cellobioside (DeβC), 2; undecyl-β-cellobioside (UβC), 3; tridecyl-β-cellobioside 
(TβC), 5; dodecyl-α-cellobioside (DαC), 6; undecylenyl-β-cellobioside (UDβC), 10; farnesyl-β-
cellobioside (FβC), 11; saturated farnesyl-β-cellobioside (SFβC), 12; saturated farnesyl-α-
cellobioside (SFαC), 13; 2-octyl-dodecyl-β-cellobioside (2-ODβC), 16; 2-octyl-dodecyl-α-
cellobioside (2-ODαC), 17; and that comprised of lactose (Galβ(14)Glcβ)-based 
stereochemistry included dodecyl-β-lactoside (DβL), 7; saturated farnesyl-β-lactoside (SFβL), 
15. The monosaccharide derivatives (MSDs) included dodecyl-β-glucoside (DβG), 8, and 
dodecyl-α-rhamnoside (DαR), 9. To examine the effect of a large oligo-saccharide group, 
dodecyl-β-cyclodextrin (DβCDS), 18, was synthesized. It is to be noted that the aliphatic 
derivatizations included derivatives with different length of hydrocarbons chains (2, 3, 4, 5), 
different degree of aliphatic unsaturation (10 and 11), and possessing or lacking methyl branches 
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(1, 4, 6, 7, 12, 13, 14, 15). The methyl branched hydrocarbons were derived from hydrogenation 
of the farnesyl moiety to yield 3, 7, 11-trimethyl-dodecanyl group. 
Figure 2.8. Structures of synthetic saccharide based derivatives that include maltose, 
cellobiose, lactose, glucose, rhamnose, and β-cyclodextrin stereochemistries; and hydrocarbons 
derived from farnesyl and “saturated” farnesyl molecules. The structures of di-rhamnolipid and 
mono-rhamnolipid are also shown.  
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2.2.1. 1 Synthesis of saccharide derivatives (SDs) 
Most disaacharide and monosaccharide derivative were synthesized using the Fischer 
glycosylation and Zemplem deacetylation conditions mentioned in Scheme 2. 1.
200
 General 
synthetic route for the monosaccharide and the disaccharide derivatives involved the 
simultaneous peracetylation and monobromination at the anomeric position of desired sugar 
using a binary mixture of AcBr/AcOH, followed by Fischer glycosylation with either a synthetic 
or a commercially available alcohol in presence of Lewis acid catalyst. For obtaining β-anomer 
as the major glycosidation product, the solvent used was MeCN, where as substituting the 
solvent to MeNO2 primarily gave α-anomer. The α/β anomers were purified with normal phase 
silica chromatography (β anomer usually eluted first). The per-acetylated saccharide-dervatives 
were deacetylated using Zemplen deacetylation conditions of methanolic sodium methoxide 
solution and neutralized further to pH ~6.5 with H
+
 ion-exchange amberlite resins. 
 
 
 
     
 
                                                                                                                                                               
                            
Scheme 2.1. Synthesis of saccharide derivatives (SDs). (i) AcBr/AcOH, rt or 60 ⁰C, ~ 1h; (ii) 
ROH, FeCl3 or Hg(CN)2, MeCN, rt, 1h; (iii) ROH, FeCl3, MeNO2, rt, 1h; (iv) MeONa/MeOH, 
12h, H
+
 amberlite resin, Neutralize, (pH ~6.5).  
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2.2.1. 2 Synthesis of oligosaccharide derivative 
The synthesis of the oligosaccharide derivative involved a longer six step convergent synthesis 
(Scheme 2.2). The intermediates 18a and 18c were synthesized via previously reported literature 
procedure.
201
 Substituting one of the difluorophenoxyl group on 18a with dodecylamine yielded 
18b. Subsequently, the remaining difluorophenoxyl group on 18b was substituted with βCD-NH2 
over four days in a ternary solvent system comprising of water/DMF/acetone to yield DβCDS 
(18). The compound was purified by repeated precipitation from aqueous solution with acetone.                                                                                                                                                                                                                           
 
 
 
     
                                                                                                                                                                      
 Scheme 2.2 Synthesis of β-cyclodextrin (βCD) based saccharide derivative  
(i) CH3(CH2)11NH2, THF, -78⁰C, ~ 12h; (ii) DMF, acetone, rt, 4days  
2.2.2. All saccharide derivatives (SDs) were nontoxic to the growth of planktonic bacteria 
 At the onset it was necessary to establish that the observed impact of these molecules on 
swarming, and biofilm formation did not originate from the ability of these agents to impede 
bacterial growth. Also, establishing the nonmicrobicidal action was necessary to ascertain 
whether these SDs have the potential to change or control bacterial behavior with low or no 
propensity to invoke drug resistance.
77
 Therefore, the initial test after synthesis of the SDs was to 
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check the toxicity of these agents on the growth of planktonic bacteria in culture media. The 
concentration (170 μM) of SDs chosen for the toxicity studies was either relatively higher than or 
equivalent to the highest concentrations at which all the other bioassays (swarming in this 
chapter, and inhibition of bacterial adhesion and biofilm formation in chapter 3) were done. At 
170 μM none of the SDs inhibited the growth of planktonic wild type Pseudomonas aeruginosa 
(PAO1) in Luria-Bertani (LB) broth (Figure 2.9).  
Figure 2.9 Growth curve (24 h) of PAO1 with or without agents to confirm that the effects 
on swarming and biofilm formation are not due to toxic effects. Resultant concentration of 
each agent within wells ~ 170 μM. 
a
Concentration of agent ~ 110 uM. 
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2.2.3 The nonswarming mutant rhlA was used to screen swarming agonists and the wild type P. 
aeruginosa brought forward the swarming antagonists 
 Previously, in separate works both Deziel et al
121
 and O' Toole et al
119
 demonstrated that 
on supplementing the swarm agar plate (~0.5% agar) with exogenous rhamnolipids the swarming 
of the inoculated rhlA mutant was reactivated. These seminal works by others showed that either 
rhamnolipids were ligands for specific target proteins that control or activate swarming or that 
secretion of the biosurfactant rhamnolipids is simply required to reduce surface tension and 
enable swarming. To decipher what role rhamnolipids played in swarming (biological or 
physical) and to test whether the synthetic saccharide derivatives could mimic rhamnolipids, two 
kinds of swarming assays were constituted, swarming agonist and swarming antagonist.                               
 A transposon mutation that impairs a gene in the rhamnolipids biosynthesis pathway of P. 
aeruginosa (PAO1) generates a rhamnolipids nonproducing and therefore a nonswarming mutant 
strain, rhlA (genotype, rhlA-E08::ISphoA/hah)
123,202-204
 Therefore, swarming agonist assays were 
constituted by adding various SDs into the swarm plates and then inoculating the plate with the 
rhlA mutant. Agents that can mimic the functions of rhamnolipids and thereby reactivate 
swarming in such a nonswarming mutant would therefore qualify as swarming agonists. 
Contrary to this, a swarming assay with wild type PAO1 where both the naturally secreted 
rhamnolipids and the externally added agent are present constitutes an antagonist assay because 
the wild type strain can inherently synthesize rhamnolipids,
123
 therefore  agents that have the 
ability to modulate swarming of such a strain will have to first compete with the natural ligand 
(rhamnolipids) for the putative receptor before exhibiting their effects. While inhibition of 
swarming by an added SD in such an antagonist swarming assay is a clear indicator of 
antagonistic behavior, a promotion of PAO1 swarming motility to form a bigger swarm ring is 
 
40 
 
more complex to interpret. Therefore, in the antagonist swarming assay, antagonistic behavior 
was primarily gauged by the ability to reduce or completely inhibit the swarming of wild type 
PAO1.   
 Firstly, the test of whether surface activity alone was critical for enabling swarming was 
performed by Shetye et al where, one anionic (SDS), one cationic (DTAC) and two nonionic 
(C12EG4OH and DβM (1)) generic surfactants were tested for their ability to reactivate 
swarming of the rhlA mutant, (screening for swarming agaonists) (Figure 2.10a&b). The results 
indicated that when tested at110 μM, three out of the four tested generic surfactants, anionic 
SDS, cationic DTAC and nonionic C12EG4OH were not able to reactivate the swarming of the 
rhlA mutant (Figure 2.10 d, e & f, respectively). However, when the disaccharide based nonionic 
surfactant, DβM (1) was added to the semisolid swarm gel at 110 μM, swarming of the 
inoculated rhlA mutant was fully restored and the swarm colony formed a pattern of radiating 
tendrils (Figure 2.10c).  
                                  
Figure 2.10 Images of swarm agar plates inoculated with either PAO1 (Control) or the 
rhlA mutant containing various generic surfactants. (a) Control swarm plate with no 
(a) (b) (c)
(d) (e) (f)
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surfactants inoculated with PAO1; Swarm plate inoculated with the rhlA mutant containing; (b) 
No agent; (c) DβM (1); (d) DTAC; (e) SDS and (f)  C12EG4OH. Concentration of the generic 
surfactants in the swarm plates ~ 110 uM. [Reprinted with permission from Citation:
194
 Shetye, 
G. S.; Singh, N.; Jia, C.; Nguyen, C. D. K.; Wang, G.; Luk, Y.-Y., Specific Maltose Derivatives 
Modulate the Swarming Motility of Nonswarming Mutant and Inhibit Bacterial Adhesion and 
Biofilm Formation by Pseudomonas aeruginosa. ChemBioChem 2014, 15, (10), 1514-1523.  
2.2.4 Disaccharide derivatives and rhamnolipids exhibit dual functions of activating and 
inhibiting swarming motility of Pseudomonas aeruginosa 
The antagonistic or agonistic effect of various SDs was initially screened at a constant 
concentration of 85 μM, except for DβC (4) and rhamnolipids, for which results from 160 μM 
and 30 μM are shown, respectively (Figure 2.11). The commercially available rhamnolipids used 
in the swarming experiments contained two congeners of rhamnolipids, dirhamnolipids (79%) 
and monorhamnolipid (16%) (Figure 2.8). The average molecular weight of the rhamnolipids 
extract calculated by using the percent composition of each cogener was 626 g/mol, and the 
rhamnolipids sample preparation for the swarming studies was done using this average molecular 
weight.  
Based on the effects that the saccharide derivatives had on the swarming of both wt 
PAO1 and its rhlA mutant at 85μM, they can be classified into four groups (Figure 2. 11). Two 
SDs, DβCDS (18) and UDβC (10), that exhibited no apparent effect on the swarming motility of 
both the wild type PAO1 and its rhlA mutant were categorized as group I. The two SDs that were 
categorized as group II, DeβC (2) and FβC (11) showed weak swarming activation in rhlA 
mutant and slight promotion of the swarming motility in wild type PAO1. The results of one of 
the group II agents, DeβC (2) shown in Figure 2.11 was the effect observable at a concentration 
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of 160 μM and at 85 μM, DeβC (2) did not cause a noticeable effect on the swarming motility of 
either strains (Figure 2.12). It is noted that there was a complete abolition of bacterial growth 
(both PAO1 and rhlA) on the semisolid gel (~0.5 % agar) when FβC (11) was used at higher 
concentration of 160 μM (Figure 2.12). Contrary to the toxic effect on a swarm plate, there was 
no bacterial growth inhibition when planktonic PAO1 was grown in LB media containing 160 
μM of FβC (11) (Figure 2.9).  
All of the five disaccharide derivatives (DSDs) in group III, DβM (1), UβC (3), DβC (4), 
TβC (5), and DαC (6), were able cause significant tendril formation in the swarm colony of the 
otherwise nontendril forming wild type PAO1 strain.
121,204,205
 Without the presence of these five 
group III DSDs, the wild type PAO1(control) swarms outward with a fairly circular front, but 
when the DSDs were added, the swarm pattern obtained contained protrusions that radially 
extended outward from the central spot of bacterial inoculation. The type of tendrils formed by 
wild type PAO1 in presence of these five DSDs also varied slightly. Two DSDs from group III, 
DβM (1) and DβC (4) created PAO1 swarm patterns having fine straight tendrils that protruded 
out from the center and these tendrils itself did not branch out further. However, the three other 
DSDs in this group, UβC (3), TβC (5) and DαC (6) caused the main radial tendrils to branch out 
and form a self-similar, fractal-like pattern (Figure 2. 11). Among the DSDs in group III, three 
DSDs, DβM (1), UβC (3) and DβC (4), were able to fully reactivate the swarming of the rhlA 
mutant with a swarm area that was comparable to that of the wild type PAO1 without any agents 
(Control, Figure 2.11). The other two DSDs in group III, TβC (5) and DαC (6) at the tested 
concentration of 85 μM exhibited no apparent swarming activation of the rhlA mutant.  
The group IV consisted of six DSDs, DβG (8), DαR (9), SFβC (12), SFαC (13), SFβM 
(14), and 2-ODβC (16) that at 85 μM were able to completely inhibit the swarming motility of 
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wild type PAO1 (Figure 2.11). Also, the six group IV DSDs at 85 μM concentration in the 
swarm plate exhibited no apparent effect on the inoculated rhlA mutant (Figure 2.11).  
For the swarming studies done with the rhamnolipids extract at a concentration of 10 μM 
there was a ~38 % increase in the swarming area of the rhlA mutant. Also, when used at 30 μM, 
the rhamnolipids extract caused a ~51 % decrease in swarming area for wild type PAO1 (to see 
the calculation of how the swarming areas and percentage increase or decrease in areas were 
calculated, refer to Materials and Methods section). The change in percent swarming area was 
obtained by comparing the swarm area in presence of the agents to that by the wild type PAO1 
under the same conditions with no added agents in the swarm plate (~0.5 % agar). Apart from 
changing the swarm pattern qualitatively, certain DSDs also had an impact on the swarm area of 
either or both PAO1 and the rhlA mutant. By measuring the increase in the swarming area, the 
DSDs grouped as II appear to promote swarming in both PAO1 and the rhlA mutant at 85 μM. 
The effect of group III DSDs was more complex because at 85 μM while they inhibit the 
swarming of PAO1 they seem to activate the swarming of the rhlA mutant. The DSDs in group 
IV at 85 μM drastically reduce the swarm area of PAO1 and have no apparent effect on the 
swarm area of the rhlA mutant (decrease in swarm area cannot be detected because the rhlA 
mutant is inherently nonswarming). Three DSDs, DβL (7), SFβL (15) and 2-ODαC (17) had 
poor water solubilities and therefore were not tested in the swarming agonist or antagonist 
assays.  
Two important observations from the swarming studies done with various agents were (i) 
Rhamnolipids inhibit swarming of PAO1 at 30 μM whereas at 10 μM they activate or promote 
swarming of the rhlA mutant; (ii) The DSD DeβC (2) seemed to promote swarming of PAO1 
and activate swarming of the rhlA mutant only at relatively higher concentration (160 μM). 
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Because these two agents exhibited the dual functions of either activating or inhibiting swarming 
at different concentrations, it was speculated that the other SDs, in general would also possess 
these dual-functions, and may manifest different activities at different concentrations. Therefore, 
a concentration dependent study with selected SDs from various groups (II, III and IV) was done 
next. 
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Figure 2.11 Four different types of swarming motility behaviors exhibited by wild type 
PAO1 and the rhlA mutant on semisolid gel (~0.5 % agar, M8 media) in presence of various 
DSDs (at ~85μM), except for 
a
DeβC (2) (160 μM), and 
b
Rhamnolipids (30 μM for PAO1) and 
(10 μM for rhlA). Controls are without added agents in the gel. Images were taken 24 h after 
inoculation with bacteria.  
                
Figure 2.12 Semisolid gels (~0.5 % agar) with 0 (no agent) or 85 μM concentration of DeβC 
(2) or 160 μM concentration of FβC (11) inoculated at the center with either wt PAO1 (row 
1) or rhlA mutant (row 2). Images were taken 24 h after inoculation with bacteria.  
2.2.5 Disaccharide derivatives and rhamnolipids exhibited “activity reversals" that transitioned 
from swarm-activating to swarm-inhibiting as the concentration was increased  
The fact that concentration of the DSD determined the overall effect on swarming was 
clearly observable when a switch in DeβC (2) concentration from 85 to 160 μM increased the 
rhlA swarming area by ~38% with respect to swarming area of PAO1 without agents. The effect 
that different concentrations of either rhamnolipids or DeβC (2) had on swarming of PAO1 and 
its rhlA mutant alluded to two opposites bioactivities – concentration dependent activation and 
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inhibition of swarming motilities. Comparison of the PAO1 swarm area on a plate with no added 
agent (~24 cm
2
) to a plate containing 85μM of DSD DβC (4) (~13 cm
2
 ), showed that swarm 
area decreased by a value of ~46 % (Figure 2.11). Therefore, intriguingly at 85μM, DβC (4) 
displayed the ability to both activate swarming in the rhlA mutant and at the same time cause an 
overall apparent inhibition for PAO1 swarming.  
It is has been reported before by Deziel and coworkers that the bacteria at the swarming 
tip are genetically different than bacteria in the swarm center (See section 2. 1. 5. 2).
124
 The 
ability of certain group III DSDs, DβM (1), UβC (3) and DβC (4) to activate the swarming of 
the rhlA mutant and also induce tendril formation in PAO1 swarms suggested that newer 
bacterial phenotypes may be generated by different DSDs. It can be hypothesized that the tip of 
the tendril may be populated with swarming hyperactive and the stem of the tendril along with 
the center of the colony may be populated with hyposwarming phenotype, termed as "phenotypic 
bifurcation" here. To see if "phenotypic bifurcation" could be achieved by rhamnolipids and 
other DSDs and see if such an effect depends on the concentration of the agent in the plate, a 
dose-dependent study with rhamnolipids and selected DSDs from group II, III and IV was 
performed. 
First, the concentration effect of the rhamnolipids extract on swarming of both PAO1 and 
its rhlA mutant was investigated. When the concentration of rhamnolipids in the swarm plate was 
increased from 0 to 5 μM, the swarming of the inoculated nonswarming rhlA mutant appeared to 
be reactivated; and the size of the PAO1 swarm ring appeared increase in area in comparison to 
the control (Figure 2.13, row 1). The trend in swarming reactivation for the rhlA mutant by 
rhamnolipids extract reversed at about 10 μM, at which concentration the size of the swarming 
ring was maximum (~9 cm
2
). The reversal in swarming activation beyond 10 μM ultimately 
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culminated with no observable swarming at 20 μM or higher by rhlA (swarm ring size was 
reduced to a dot). With PAO1, 10 and 15 μM of externally added rhamnolipids caused the 
swarming rings to appear larger than the control (with no added agents), but with 30 μM of 
added rhamnlipids, a significant reduction in the swarming ring was observed. Quantitatively, 
with 30 μM of rhamnolipids in the swarm plate, the wild type PAO1 covered an area of ~11 cm
2
 
and with no rhamnolipids the swarm area was ~24 cm
2
. This observation indicated that, as the 
concentration of rhamnolipids is gradually increased, a shift from swarm-activation to swarm-
inhibition occurs. The occurrence of an activity reversal with increasing ligand concentration has 
also been reported for another bacterial multicellular behavior, simulated light production by 
Photobacterium fischeri (section 2.1.6). In this classical work, Eberhard and coworkers had 
demonstrated that when the concentration of the AHL (ligand) is gradually increased, the 
production of light by Photobacterium fischeri first increases, reaches a threshold and ultimately 
decreases.  
Similar to the effects that rhamnolipids extract had, the active DSDs (Group II, III and IV 
from Figure 2.11) also caused swarming promotion at lower concentration and swarming 
inhibition at relatively higher concentration. The dose-dependent swarming results with five 
DSDs using wild type PAO1 and its rhlA mutant are summarized in Figure 2.13. The images of 
swarming plates in Figure 2.13 containing various concentrations of DSDs clearly show the 
transitions from swarming activating to swarming inhibiting for both bacterial strains. For all the 
active DSDs, the concentrations at which the swarming transitioned from being activated or 
promoted to deactivated or inhibited for rhlA and PAO1, respectively were different. In general, 
the concentrations at which the swarming activity reversed (from activated to deactivated) for the 
rhlA mutant were slightly lower than the concentrations at which swarming of PAO1were 
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inhibited (Table 2.1). Apart from this, the DSDs themselves could be classified into two 
categories; those that caused an early swarming "activity reversal" at lower concentration and 
those caused a late "activity reversal" at relatively higher concentrations (Figure 2.13 & Table 
2.1). The low transition concentration agents included rhamnolipids, SFβM (14) and SFβC 
(12) that caused an activity reversal for the rhlA mutant at 10 μM, 10 μM and 8 μM; and 
swarming inhibition for PAO1 at 20-30 μM, 7-20 μM, 10-20 μM, respectively. The DSDs with 
high transition concentration, DSDs DβC (4), TβC (5) and DβG (8) exhibited the activity 
reversal at 45-56 μM, 40 μM and 35 μM for the rhlA mutant; and swarming inhibition for PAO1 
at 20-30 μM, 20-30 μM and 35-50 μM, respectively. As visible in the swarming images with 
rhlA mutant (Figures 2.13), the low transition agents, SFβC (12), SFβM (14) and rhamnolipids 
created smaller swarming rings in comparison to the agents with high transition concentration, 
DβC (4), TβC (5) and DβG (8). These results imply that agents with poor swarming inhibition 
capabilities (for PAO1) were better swarming activators (for the rhlA mutant) than agents that 
had strong potencies to inhibit the swarming of PAO1. Another observation that the dose-
response study brought forward was that certain DSDs beyond the transition concentration were 
able to induce tendril formation while others were not. Amongst the plates inoculated with the 
rhlA mutant, only DβC (4) induced tendril formation around ~56 μM (Figure 2.13); whereas for 
the plates inoculated with PAO1, tendrils formation was caused by DβC (4) at 20 μM, TβC (5) 
at ~30 μM,  SFβM (14) at ~2 μM and SFβC (12) at ~1μM (Figure 2.13).  
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Figure 2.13 Images of swarming motilities of the rhlA mutant (left) and PAO1 (right) on 
semisolid gel (~0.5 % agar) containing increasing concentrations of DSDs and 
rhamnolipids. The concentrations are indicated above the images, and the identities of the 
agents are shown to the left. Red boxes highlight the swarming patterns that reveal the 
dominance of DSDs over rhamnolipids at comparable concentrations.  
The swarming patterns of rhlA with additional concentrations of DβC (4), and TβC (5) 
apart from those included in Figure 2.13 are shown in Figure 2.14. Interestingly, quantitative 
measurement of the rhlA mutant's swarm areas with these two DSDs, DβC (4), and TβC (5), 
indicated that after the first activity reversal around 50 μM, there was a second increase in swarm 
area at a higher concentration of 160 μM (Figure 2.14). This increase, then decrease followed by 
another increase in swarming area of the rhlA mutant in response to the changing concentrations 
rhlA (agonist assays) 
SFβC (12)
Rhamnolipids
SFβM (14) 
DβC (4) 
TβC (5) 
DβG(8) 
[μM] 3.0       5.0        10.0        15.0       20.0                    5.0        10.0      15.0        20.0       30.0
2.5 5.0         8.3       12.0       17.0                     0.1         1.0       10.0       20.0        85.0
PAO1(antagonist assays) 
2.0        3.0          5.0        10.0       15.0                    5.0          7.5       10.0       18.0        25.0
0        20.0       45.0       85.0     170.0                       0       20.0        45.0       85.0     170.0
10.0       20.0        30.0       40.0       85.0                  10.0        20.0       30.0       40.0       85.0
20.0       30.0      35.0        50.0       60.0                  30.0       35.0        50.0       60.0       85.0
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of the two DSDs is indicative of an oscillatory response by the bacteria.
206
 Overall the dose-
response study indicated that both rhamnolipids and the active DSDs possess the unique dual 
abilities to both activate swarming at lower concentration, an agonistic behavior as well as 
inhibit swarming at relatively higher concentrations, an antagonistic behavior.  
Table 2.1. Transition concentrations of DSDs that exhibit activity reversal from activating to 
inhibiting swarming motilities of the rhlA mutant and PAO1. 
Compound  
a 
Transition 
concentration 
(rhlA)  
b 
Transition 
concentration 
(PAO1) 
Rhamnolipids  ~10-15 μM  ~20-30 μM  
 SFβM (14)  ~10-15 μM  ~7.5-25 μM  
 SFβC (12)  ~8-12μM  ~10-20 μM  
 DβC (4)  
e 
~45-56 μM
 
 ~20-30 μM  
 TβC (5)  ~40 μM  ~20-30 μM  
 DβG (8)  ~35-50 μM  ~50-60 μM  
SFαC (13) 
c
-- 
c
-- 
a
From activating to inhibiting swarming motility of the rhlA mutant. 
b
From promoting to 
inhibiting swarming motility of PAO1; 
c
Not determined. 
Figure 2.14 Swarm agar plates with additional concentrations of DβC (4) or TβC (5) for 
TβC (5)                    0            10.0        20.0 30.0      40.0                 85.0                 110.0               160.0 μM
rhlA
DβC (4)                  0                  20.0      45.0    56.0         73.0          85.0               160.0               250.0 μM  
rhlA
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their effects on the swarming of the rhlA mutant. Both the DSDs caused swarming “activity 
reversal.” Nonswarming mutant rhlA was inoculated at the center of the semisolid gels (~0.5 % 
agar). Pictures were taken 24 h after inoculation with bacteria.  
2.2.6 Disaccharide derivatives, SFβC (12), SFβM (14) and DβC (4) dominated rhamnolipids at 
inhibiting the swarming motility of PAO1 
 The activation-to-inhibition “activity reversal” effect on swarming in response to 
concentration of both rhamnolipids and some DSDs suggests a regulatory response by PAO1 to 
such agents.
120
 On evaluating the potencies of the active DSDs, two separate dominating effects 
over rhamnolipids seem to stand out. Firstly, the swarming motility of wild type PAO1 that is 
facilitated by in situ secretion of natural rhamnolipids was inhibited by all the five DSDs tested, 
i.e SFβC (12), SFβM (14), DβC (4), TβC (5), and DβG (8). The concentrations at which each of 
these DSDs dominated and inhibited the in situ produced rhamnolipids were different, with 
SFβC (12), SFβM (14), DβC (4), being more potent than TβC (5) and DβG (8) (Figure 2.13, 
right column and Figure 2.15). Secondly, for PAO1, three DSDs, SFβC (12), SFβM (14) and 
DβC (4) exhibited stronger swarming inhibition than externally rhamnolipids at the same 
concentrations. The dominance of SFβC (12) over externally added rhamnolipids is evident at 20 
μM, where at this concentration SFβC (12) completely reduced the swarmer colony to a dot 
occupying an area of 1.2 cm
2
 which is about 5% of the 24 cm
2
 exhibited by PAO1 without any 
added agents; at this concentration, the external rhamnolipids caused no apparent swarming 
inhibition and the swarm area was equivalent to the control (i.e. 24 cm
2
) (Figure 2.13). Apart 
from this, as tendril formation amounts to an overall reduction in swarming area, two other 
DSDs SFβM (14) and DβC (4) at concentrations lower than 20 μM exhibited stronger swarming 
inhibition of wild type PAO1 than externally added rhamnolipids. Additionally, the unique 
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characteristic of DSDs, SFβM (14) and DβC (4) to induce tendrils and cause phenotypic 
bifurcation of wild type PAO1 swarms was also not achieved by the externally added 
rhamnolipids at the tested concentration range (1-30 μM). A prominent activation dominance of 
DSD SFβM (14) over externally added rhamnolipids was also exhibited by the rhlA swarm 
colony. When the areas of swarm colonies at 10 μM of either SFβM (14) or external 
rhamnolipids were compared, the SFβM (14) caused swarming activation to generate a ring of 
~38 cm
2
 whereas only a 9 cm
2
 ring was observed for rhamnolipids (Figure 2.13 and Figure 2.15). 
When viewed together, these results highlight that DSDs, SFβC (12), SFβM (14) and DβC (4) 
are more potent than both the in situ produced (and secreted) and the externally added 
rhamnolipids. The rhlA swarming results with increasing concentrations of rhamnolipids and one 
DSD, SFβM (14) was repeated three times to obtain an error bar for swarming area at each each 
concentration (see Materials and Methods, Figure S1). 
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Figure 2.15 Plot of the rhlA mutant’s swarm area (after 24 h) versus increasing 
concentrations of rhamnolipids, DβC (4), TβC (5), SFβM (14), DβG (8) and SFβC (12) in 
the semisolid gel (~ 0.5% agar). Insert shows the curves that had low transition concentrations 
from swarm-activating to swarm-inhibiting. (Also see Materials and Methods, Figure S1) 
2.2.7 Competition assays indicated SFβC (12) to be a stronger swarming inhibitor than DβC (4)  
 While results indicate that both SFβC (12) and DβC (4) could activate and inhibit the 
swarming motility of P. aeruginosa, SFβC (12) had a lower transition (from activating to 
inhibiting) concentration than DβC (4) (Table 2.1). From the previous dose-dependence study 
(Figure 2.13), it was evident that 20 μM of SFβC (12) did not activate the swarming motility of 
the rhlA mutant. However, from these results it was difficult to speculate whether at this 
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concentration (20 μM), SFβC (12) had an inhibiting effect or whether it had no effect on the 
swarming of the rhlA mutant. SFβC (12) did inhibit the swarming motility of wild type PAO1 at 
20 μM and hence there was some indication that the corresponding effect on the rhlA mutant 
may be primarily inhibition and not no effect. Contrary to the effect of SFβC (12), the swarming 
activation of the rhlA mutant by 40 μM DβC (4) was quite unambiguous. Considering the results 
of these DSDs, it was hypothesized that the DSDs with low transition concentrations for the 
“activity reversal” dominated the DSDs with high transition concentrations. In order to validate 
this hypothesis, a competitive swarming assay was constructed where both DβC (4) and SFβC 
(12) were introduced into the swarming gel. For this swarming assay, the bacteria of choice was 
the rhlA mutant primarily because it lacks production of rhamnolipids and hence the swarming 
results would be unambiguous. In the competition swarming assay the concentration of DβC (4) 
was kept constant at 40 μM in all the plates, but the concentration of SFβC (12) was 
incrementally increased from 0.5 to 10, 20, and 40 μM (Figure 2.16) from one plate to another. 
The competition assay demonstrated that when 10 μM of SFβC (12) was added into the gel 
containing did 40 μM of DβC (4), there was no inhibition of rhlA swarming activation. But when 
the concentration of SFβC (12) was increased to 20 μM, the swarming activation brought about 
by 40 μM of DβC (4) was completely inhibited. Parallel to what was hypothesized, this result 
suggested that SFβC (12) (having low transition concentration) is a stronger antagonist than 
DβC (4) (having relatively higher transition concentration) for the putative swarming receptor. 
Also, the experiment confirmed that SFβC (12) has a dominating effect on swarming at high 
enough concentrations for both wild type PAO1 and its rhlA mutant.  
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Figure 2.16 Images of the rhlA mutant inoculated on semisolid surface (~0.5 % agar) 
containing 40 μM of DβC (4) and increasing concentrations of SFβC (12). The images were 
taken 24 hours after inoculation of the surface with bacteria.  
2.3 Conclusion 
 A surfactant having a saccharide head and an aliphatic tail, DβM (1) was the only generic 
surfactant that reactivated the swarming of the rhlA mutant. These swarming results with generic 
surfactants showed that while surface activity may be important for swarming, not any surfactant 
could instill swarming in the rhlA mutant. Amongst the saccharide derivatives (SDs), few 
specific structures showed the ability to activate and inhibit the swarming motility of both P. 
aeruginosa and its nonswarming mutant rhlA. For controlling swarming motility, all the active 
DSDs and the rhamnolipids extract exhibited a dual function that transitioned from swarm-
activating at low concentrations to swarm-inhibiting at higher concentrations. Certain DSDs, 
SFβC (12), SFβM (14) and DβC (4) were able to dominate the effect of both in situ produced 
(and secreted) and the externally added rhamnolipids. The dominance of these DSDs over 
rhamnolipids is probably a result of better binding to putative swarming receptor or the ability to 
bind effectively to an allosteric site on the receptor. Competition swarming assay revealed that a 
DSD with lower transition concentration (SFβC (12)) was a better antagonist than a DSD with 
higher transition concentration DβC (4). Results implied that secretion of rhamnolipids is sensed 
DβC (4)  40.0 μM                     40.0                     40.0                      40.0                      40.0
SFβC(12)     0 μM                       0.5                     10.0                       20.0                     40.0
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by the bacteria and the binding of these rhamnolipids to the putative swarming receptor relays a 
biological response. Results also demonstrated that certain DSDs are the functional analogues of 
rhamnolipids and that certain DSDs overpower the effects of rhamnolipids.  
2.4 Materials and methods 
General experimental information for synthesis 
 Standard solvents and reagents were purchased from commercial sources (Sigma-
Aldrich, Fisher, Acros) and used as received. Solvents were removed in vacuo using Bűchi 
rotary evaporator below 40⁰C. EMD silica gel 60 F254 pre-coated plates (0.25-mm thickness) 
were used for TLC. Unless otherwise stated, TLC visualization was done using ceric ammonium 
molybdate (CAM) stain. 
1
H-NMR spectra were recorded in deuterated NMR solvents at 300 and 
400 MHz (
1
HNMR) and 75 and 100 MHz (
13
CNMR) Bruker instruments respectively. 
1
H 
chemical shifts are reported in ppm relative to CDCl3 δ 7.26, D2O δ 4.80, or CD3OD δ 3.31. 
13
C 
chemical shifts are reported relative to CDCl3 δ 77.23and CD3OD δ 49.0. Couplings are reported 
in hertz (Hz). HRMS was obtained through positive ESI on Bruker 12 Tesla APEX-QE FTICR-
MS with an Apollo II ion source, at Cosmic instrumentation center, Virginia. Unless otherwise 
stated, the % yield indicates the pure anomeric products that were successfully isolated by 
column chromatography resolution (the yield for mixture of anomers has not been accounted 
for). Anomeric configurations are assigned from the magnitude of J1,2 (7–9 Hz for the diaxial 
coupling, β-configuration; 2–4 Hz indicates equatorial-axial coupling, α-configuration).
207
  
MALDI-TOF.
201
 Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-
MS). A saturated solution of 2,4,6-trihydroxyacetophenone monohydrate (matrix) (10 mg) was 
prepared in acetonitrile (1 mL). The saturated βCD compound solution (in water) and matrix 
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solution in 1:1 ratio were spotted on a MTP 384 target ground steel plate (Bruker Daltonics, 
Billerica, MA). Mass spectra were obtained on a Bruker AutoFlex III instrument (Bruker 
Daltonics, Billerica, MA). Molecular ion peak was detected in positive ion linear mode. 
Synthetic procedures and spectral data. The synthetic procedures and spectral data for the 
compounds used in this work are given below.  
 Synthesis of per-acetylated-bromo-sugars (Scheme 1). The synthesis of saccharide 
derivatives was done by using a reported literature procedure with some modifications.
208
 
Briefly, to an oven dried round bottom flask, disaccharide (maltose, lactose and rhamnose) (1.0 
g, 2.8 mmol), AcBr (~3.6 mL, 44.4mmol), and AcOH (19 mL) were added and stirred at room 
temperature (25 ⁰C) for ~ 1 h. Reaction mixture was concentrated in vacuo at 35 ⁰C and then co-
evaporated three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask 
was further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugars. The 
crude aceto-bromo sugars were immediately used in next step without any further purification. 
 The synthesis of per-acetyl-bromo cellobiose was done under more vigorous conditions. In an 
oven dried round bottom flask cellobiose (1.0 g, 2.8 mmol), AcBr (~7.2 mL, 88.8 mmol), and 
AcOH (19 mL) were added and stirred at 60 ⁰C for ~ 1 h. The work up of aceto-bromo 
cellobiose (4b) involved similar steps as done for aceto-bromo lactose/rhamnose to obtain crude 
as foamy solid. The crude aceto-bromo sugars were immediately used in next step without any 
further purification. 
General synthesis of n-alkyl glycosides (cellobiosides, maltoside, rhamnoside and lactoside) 
For obtaining β-anomer as major product, the crude aceto-bromo sugars were the dissolved in 
MeCN (10 mL) and various alcohols (5.6 mmol, 2 equiv) were added along with two equivalents 
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of FeCl3 or Hg(CN)2. The α-anomers were obtained as major products by using MeNO2 as 
solvent. The reaction mixture was stirred vigorously for about ~45-60 min at rt. After stirring at 
rt, aq KBr (10%, 25 mL) and then PhMe (60 mL) were added under stirring. The organic phase 
was washed twice with aq KBr (10%, 2×25 mL), once with aq NaHCO3 (5%, 25 mL) and twice 
with H2O (2×25 mL). The crude product was then purified by column chromatography using 
gradient elution (100 % hexane to 35 % ethyl acetate in hexane).  
Zemplén deacetylation. For all acetylated sugar derivatives, the deprotection of acetyl groups 
were achieved by Zemplén deacetylation using MeONa/MeOH (10 mM solution) conditions 
followed by neutralization (pH ~6.5) over H
+
 amberlite resins. The resins were filtered off and 
products dried under high vacuum overnight. 
Spectral data 
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Acetylated decyl-β-cellobioside, ADeβC (2a) Colorless powder, 0.302 g, 19.7 % (2-step), Rf = 
(0.30, 40 % EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.21 (m, 3H), 4.92 (q, J1-2 = 8.4 
Hz, 2H), 4.54-4.43 (m, 3H), 4.39 (dd, J1-3 = 12.9 Hz, J1-2 = 4.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.87- 
3.74 (m, 2H), 3.69-3.56(m, 2H), 3.44 (q, J1-2 = 8.4 Hz, 2H), 2.13-1.99 (s, 7 X 3H), 1.57-1.48 (m, 
2H), 1.26 (br, s, 14 H), 0.88 (t, J= 6.3 Hz, 3H).
13
C NMR (75 MHz, CDCl3): δ 170.0, 169.9, 
169.8, 169.1, 168.8, 168.6, 100.3, 100.2, 72.5, 72.2, 72.1, 71.5, 71.2, 69.8, 67.3, 61.5, 61.1, 31.4, 
29.1, 29.1, 28.9. 28.8, 28.8, 25.3, 22.2, 20.4, 20.1, 20.1, 13.6. HRMS (ESI) m/z: Calcd. 
(C36H56O18)Na
+
: 799.3358; Found: 799.3339, Difference: -2.4 ppm. 
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Decyl-β-cellobioside, DeβC (2): Colorless powder, 0.025 g, 87 %. 
1
H NMR (300 MHz, CD3OD) 
δ: 4.36 (d, J = 7.8 Hz, 1H), 4.28 (d, J = 7.8 Hz, 1H), 3.87 (br, s, 4H), 3.69-3.47 (m, 4H), 3.40-
3.31(m 4H, overlapping with MeOH), 3.27-3.18 (m, 2H), 1.68-1.56 (m, 2H), 1.30 (br, s, 14H), 
0.91 (t, J = 6.6 Hz, 1H). 
13
C NMR (75 MHz, CD3OD): δ 102.8, 102.4, 78.9, 76.3, 76.0, 74.6, 
73.1, 73.0, 69.5, 69.2, 60.6, 60.0, 31.3, 29.1, 29.0, 28.9, 28.9, 28.8, 28.7, 25.3, 21.9, 12.7. HRMS 
(ESI) m/z: Calcd. (C22H42O11)Na
+
: 505.2619; Found: 505.2611, Difference: -1.5 ppm 
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Acetylated undecyl-β-cellobioside, AUβC (3a): Colorless powder, 0.313 g, 13.5 % (2-step), Rf 
= (0.52, 1:1 Hexane:EtOAc). 
1
H NMR (300 MHz, CDCl3): δ 5.16-4.96 (m, 3H), 4.90-4.81 (m, 
2H), 4.51-4.27 (m, 4H), 4.02 (t, J = 13.2, 2H), 3.84-3.67 (m, 2H), 3.65-3.49 (m, 2H), 3.46-3.24 
(m, 1H), 2.07-1.89 (s, 7 x 3H), 1.57-1.31 (m, 2H), 1.20 (br, s, 16H), 0.82 (br, s, 3H). δ 170.0, 
169.9, 169.8, 169.8, 169.81, 168.8, 168.5, 100.4, 95.1, 72.6, 71.4, 71.2, 71.1, 70.6, 69.3, 68.2, 
67.6, 67.3, 61.1, 61.0, 31.4, 29.1, 28.8, 28.8. 28.7, 25.5, 25.3, 22.2, 20.4, 20.2, 20.1, 20.0, 13.6. 
HRMS (ESI) m/z: Calcd. (C37H58O18)Na
+
: 813.3545; Found: 813.3496, Difference: -2.4 ppm 
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Undecyl-β-cellobioside, UβC (3): Colorless powder, 0.024 g, 84 %. 
1
H NMR (300 MHz, 
MeOD) δ: 4.38 (d, J = 7.8, 1H), 4.25 (d, J = 7.8, 1H), 3.91 (br, s, 4H), 3.79-3.68 (m, 1H), 3.58-
3.44 (m, 3H), 3.39-3.26 (m, 2H, overlapping with MeOD), 3.25-3.15 (m, 2H). 
13
C NMR (75 
MHz, CD3OD): δ 102.8, 102.4, 78.9, 76.3, 76.0, 74.6, 73.1, 73.0, 69.5, 69.2, 60.6, 60.0, 31.3, 
29.0, 29.0, 28.8, 28.7, 25.3, 22.0, 12.7. HRMS (ESI) m/z: Calcd. (C23H44O11)Na
+
: 519.2776; 
Found: 519.276, Difference: -1.5 ppm 
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Acetylated dodecyl-β-cellobioside, ADβC (4a): Colorless powder, 0.330g, 14 % (2-step), Rf = 
(0.47, 42% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.19-5.01 (m, 3H), 4.90 (q, J1-2 = 
8.1 Hz, 2H), 4.50-4.40 (m, 3H), 4.10-4.00 (m, 2H), 3.82-3.72 (m, 2H), 3.66-3.55 (m, 2H), 
3.43(q, J1-2 = 2.7 Hz, 1H), 2.10-1.96 (s, 7 X 3H), 1.50 (br, s, 2H), 1.23 (br, s, 18H), 0.86 (t, J = 
6.6 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.1, 169.9, 169.8, 169.5, 169.2, 168.9, 168.7, 
100.4, 100.3, 76.2, 72.5, 72.2, 72.1, 71.5, 71.2, 69.8, 67.3, 61.5, 61.1, 31.5, 29.3, 29.2, 29.2, 29.2, 
29.0, 29.0, 28.9, 28.8, 28.7, 25.4, 22.3, 14.1. HRMS (ESI) m/z: Calcd. (C38H60O18)Na
+
: 
827.3672; Found: 827.3665, Difference: -1.0 ppm 
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Dodecyl-β-cellobioside, DβC (4): Colorless powder, 0.082 g, 92.0 %. 
1
H NMR (300 MHz, 
MeOD) δ 4.39 (d, J = 7.5 Hz, 1H), 4.26 (d, J = 8.1 Hz, 1H), 3.85 (br, s, 4H), 3.66-3.40 (m, 4H), 
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3.35-3.31 (m, 2H, overlapping with MeOD), 3.29-3.16 (m, 2H), 1.65-1.54 (m, 2H), 1.27-1.22 
(br, s, 18 H), 0.88 (t, J = 7.5 Hz, 3H). 
13
C NMR (75 MHz, CD3OD): δ 102.8, 102.4, 78.9, 76.3, 
76.0, 74.6, 73.1, 73.0, 69.5, 69.2, 60.6, 60.0, 31.3, 29.0, 28.9, 28.8, 28.7, 25.3, 21.9, 12.7. HRMS 
(ESI) m/z: Calcd. (C24H46O11)Na
+
: 533.2932; Found: 533.2931, Difference: <-1.0 ppm 
O
AcO OAc
AcO
O
AcO
AcO
OAc
O
OAc
O
11
 
Acetylated tridecyl-β-cellobioside, ATβC (5a): Colorless powder, 0.345g, 14.4 % (2-step), Rf 
= (0.50, 1:1 Hexane: EtOAc). 
1
H NMR (300 MHz, CDCl3) δ 5.16-4.98 (m, 3H), 4.85 (q, J1-2 = 
8.4 Hz, 2H), 4.48-4.29 (m, 4H), 4.06 - 3.97 (m, 2H), 3.82 - 3.69 (m, 2H), 3.66 -3.50 (m, 2H), 
3.44 - 3.34 (m, 1H), 2.07-1.93 (s, 7 X 3H), 1.56 -1.32 (m, 2H), 1.20 (br, s, 20 H), 0.83 (t, J = 8.7 
Hz, 3 H). 
13
C NMR (75 MHz, CDCl3): δ 170.1, 169.9, 169.8, 169.5, 169.2, 168.9, 168.7, 100.4, 
100.3, 76.2, 72.5, 72.2, 72.1, 71.5, 71.2, 69.9, 67.3, 61.5, 61.1, 31.5, 29.3, 29.2, 29.1, 28.9, 25.4, 
22.3, 20.5, 20.3, 20.2, 13.7. HRMS (ESI) m/z: Calcd. (C39H62O18)Na
+
: 841.3828; Found: 
841.3808, Difference: <-2.3 ppm 
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Tridecyl-β-cellobioside, TβC (5): Colorless powder, 0.052 g, 91.0 %. 
1
H NMR (300 MHz, 
MeOD) δ 4.38 (d, J = 7.8 Hz, 1), 4.24 (d, J = 7.8 Hz, 1H), 3.83 (br, s, 4H), 3.62 (dd, J1-3 = 12.0 
Hz, J1-2 = 5.1 Hz, 1H), 3.56-3.44 (m, 3H), 3.37-3.27 (m, 5H, overlapping with MeOD), 3.22-3.16 
(m, 2H), 1.61-1.54 (m, 2H), 1.25 (br, s, 20 H), 0.86 (t, J = 6.6 Hz, 3H). 
13
C NMR (75 MHz, 
CD3OD): δ 102.8, 102.4, 78.9, 76.3, 76.0, 74.6, 73.1, 73.0, 69.5, 69.2, 60.6, 60.0, 31.3, 29.0, 
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28.9, 28.8, 28.7, 25.3, 22.0, 12.7. HRMS (ESI) m/z: Calcd. (C25H48O11)Na
+
: 547.3089; Found: 
547.3080, Difference: <-1.5 ppm 
O
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Acetylated dodecyl-α-cellobioside, ADαC (6a): Colorless powder, 0.050 g, 2.1 % (2-step)}, Rf 
= (0.39, 42 % EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.46 (t, J = 8.4 Hz, 1H), 5.21 - 
4.87 (m, 4H), 4.78 (dd, J1-3 = 10.8, J1-2 = 4.8, 1H), 4.56-4.34 (m, 3H), 4.16-3.87 (m, 4H), 3.73-
3.63 (m, 3H), 3.44-3.35 (m, 1H), 2.13-1.99 (s, 7 x 3H), 1.65-1.56 (m 2H), 1.26 (br, s, 18 H), 0.88 
(t, J = 7.2 Hz, 3H). HRMS (ESI) m/z: Calcd. (C38H60O18)Na
+
: 827.3671; Found: 827.3663, 
Difference: -1.0 ppm. The spectroscopic data was consistent with a previously reported report.
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Dodecyl-α-cellobioside, DαC (6): Colorless powder, 0.010 g, 80.2 %. 
1
H NMR (300 MHz, 
MeOD) δ 4.76 (d, J = 3.9, 1H), 4.39 (d, J = 7.8, 1H), 3.86 (t, J = 11.4, 2H), 3.79-3.76 (m, 1H), 
3.71-3.63 (m, 2H), 3.60-3.43 (m, 3H), 3.40-3.31 (m, 5 H, overlapping with MeOD), 3.23 (t, J = 
8.7, 1H), 1.72-1.56 (m, 2H), 1.29 (br, s, 18 H), 0.90 (t, J = 6.9, 3H). 
13
C NMR (75 MHz, 
CD3OD): δ 100.4, 98.9, 72.4, 72.1, 71.3, 69.9, 69.6, 69.0, 68.0, 61.9, 61.1, 47.8, 31.5, 29.2, 29.0, 
25.4, 22.3, 20.6, 20.5, 20.4, 13.7. HRMS (ESI) m/z: Calcd. (C24H46O11)Na
+
: 533.2932; Found: 
533.2931, Difference: <-1.0 ppm. The spectroscopic data was consistent with a previously 
reported report.
208
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Acetylated dodecyl-β-lactoside, ADβL (7a): Colorless powder, 0.282 g, 12 % (2-step), Rf = 
(0.40, 1:1 Hexane:EtOAc). 
1
H NMR (300 MHz, CDCl3): δ 5.35 (d, J = 0.6 Hz, 1H), 5.34-5.08 
(m, 2H), 4.97-4.85 (m, 2H), 4.46 (t, J = 17.4 Hz, 3H), 4.14-4.04 (m, 3H), 3.62-3.48 (m, 2H), 
2.17-1.97 (s, 7 X 3H), 1.61-1.47 (m, 2H), 1.22 (br, s, 18 H), 0.88 (t, J = 7.2 Hz, 3H). 
Spectroscopic data is consistent with reported literature.
209
 HR-MS: Calcd. (C38H60O18)Na
+
: 
827.3671; Found: 827.3677, Difference: < 1.0 ppm. 
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Dodecyl-β-lactoside, DβL (7): Colorless powder, 0.150 g, 85 %. 
1
H NMR (300 MHz, CD3OD): 
δ 4.29 (t, J = 7.2 Hz, 1H), 4.08 (t, J = 6.6 Hz, 1H), 3.92-3.78 (m, 3H), 3.75-3.66 (m, 5H), 3.55-
3.44 (m, 5H), 3.41-3.32 (m, 2H overlapping with MeOD), 3.18 (dd, J1-3 = 16.2 Hz, J1-2 = 3 Hz, 
2H), 1.66-1.55 (m, 2H), 1.29 (br, s, 18 H), 0.90 (t, J = 7.2 Hz, 3H). Spectroscopic data is 
consistent with reported literature.
209
 HRMS (ESI) m/z: Calcd. (C24H46O11)Na
+
: 533.2932; 
Found: 8533.2923, Difference: -1.7 ppm 
O
O
AcO
AcO
OAc
10
 
Acetylated dodecyl-α-rhamnoside, ADαR (9a): Colorless powder, 0.200 g, 7.3 % (2-step), Rf 
= (0.30, 40 %:EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ5.30 (dd, J = 10.1, 3.7 Hz, 1H), 
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5.23 (dd, J = 3.7, 1.9 Hz, 1H), 5.06 (t, J = 9.9 Hz, 1H), 4.71 (d, J = 1.4 Hz, 1H), 3.9–3.85 (m, 
1H), 3.68–3.64 (m, 1H), 3.43–3.40 (m, 1H), 2.15-1.99 (s, 3 X 3H) , 1.63–1.56 (m, 2H), 1.33–
1.30 (m, 2H), 1.28 (br s, 16H), 1.22 (d, 3H), 0.88 (t, J = 7.1 Hz, 3H). Spectroscopic data is 
consistent with reported literature.
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Dodecyl-α-rhamnoside, ADαR (9): Colorless powder, 0.03g, 12 % . 
1
H NMR (300 MHz, 
CD3OD): δ 4.62 (br, s, 1H), 3.76 (br, s, 1H), 3.67-3.52 (m, ~ 3H), 3.39-3.27 (m, 3H, overlapping 
with MeOD), 1.55-1.53 (m, 2H), 1.27 (br, s, 18 H), 1.24 (d, J = 8 Hz, 3H), 0.89 (t, J = 6 Hz, 3H). 
13
C NMR (75 MHz, MeOD): δ 102.8, 102.4, 78.9, 76.3, 76.0, 74.6, 73.1, 73.0, 69.5, 69.2, 60.6, 
60.0, 31.3, 29.0, 28.9, 28.8, 28.7, 25.3, 22.0, 12.7.
 13
C NMR (100 MHz, CD3OD): δ 104.2, 76.8, 
76.5, 75.0, 74.9, 72.3, 71.8, 35.6, 33.3, 33.3, 33.3, 33.2, 33.1, 33.0, 29.9, 26.3, 20.5, 17.0. HRMS 
(ESI): Calcd. (C19H38O5)Na
+
 {[M +Na] 
+ 
= 369.2611; Found: 369.2610, Difference = < -1.0 
ppm. 
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Acetylated undecylene-β-cellobioside, UDβC (10a): Colorless powder, 0.350g, 15.2 % (2-
step), Rf = (0.53, 60% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.88-5.74 (m, 1H), 
5.21-5.02 (m, 4H), 4.95-4.86 (m, 3H), 4.52-4.42 (m, 3H), 4.37 (dd, J1-3 = 12.3 Hz, J1-2 = 4.2 Hz, 
1H), 4.12-4.02 (m, 2H), 3.86-3.55 (m, 4H), 3.44 (q, J1-2 = 6.6 Hz, 1H), 2.13-1.98 (s, 7 x 3H), 
1.57-1.40 (br, s, 2H), 1.34 (br, s, 12H). 
13
C NMR (75 MHz, CDCl3): δ 170.1, 169.9, 169.8, 
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169.4, 169.1, 168.9, 168.6, 138.7, 113.7, 100.3, 100.2, 72.5, 72.2, 72.1, 71.5, 71.2, 70.4, 69.9, 
69.8, 67.3, 61.0, 33.3, 29.1, 29.0, 29.0, 28.9, 28.8, 28.7, 28.5, 25.3, 20.4, 20.2, 20.1, 20.1, 20.0. 
HRMS (ESI) m/z: Calcd. (C37H56O18)Na
+
: 811.3359; Found: 811.3343, Difference: <-1.9 ppm 
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Undecylene-β-cellobioside, UDβC (10): Colorless powder, 0.200 g, 94.0 %. 
1
H NMR (300 
MHz, CD3OD) δ 5.88-5.75 (m, 1H), 5.01 (d, J = 1.8 Hz, 1H), 4.96 (d, J = 1.8, 1H, overlapped 
with H2O), 4.42 (d, J = 7.8, 1H), 4.29 (d, J = 7.8 Hz, 1H), 3.93-3.85 (m, 4H), 3.70-3.61 (m, 1H), 
3.58-3.48 (m 3H), 3.41-3.31 (m 4H, overlapping with MeOD), 3.23-3.20 (m, 2H), 2.05(q, J1-2 = 
6.6 Hz, 2H), 1.62 (q, J1-3 = 13.5 Hz, J1-2 = 6.6 Hz, 2H), 1.32 (br, s, 12H). δ 
13
C NMR (100 MHz, 
CD3OD): δ 138.7, 113.3 103.2, 102.8, 79.3, 76.7, 75.1, 75.0, 73.5, 73.4, 70.0, 69.5, 61.0, 60.5, 
33.5, 29.4, 29.3, 29.2, 29.1, 28.8, 28.7, 25.7. (ESI) m/z: Calcd. (C23H42O11)Na
+
: 517.2619; 
Found: 517.2619, Difference: <-1.0 ppm 
Acetobromo-cellobiose, AC (11a): Synthesis of acetobromo-cellobiose was done as reported 
earlier. Aceto-bromo cellobiose was purified using gradient elution (100 % hexane to 40 % ethyl 
acetate in hexane). Rf = 0.3 (40 % ethyl acetate in hexane). 
1
H NMR (300 MHz, CDCl3): 6.54 
(d, J= 6.0 Hz, 1H), 5.55(t, J= 9.0Hz, 1H, 5.20-5.06(m, 2H), 4.96(t, J = 6.0 Hz, 1H), 4.78(dd, J1-3 
= 9.0 Hz, J1-2 = 3.0 Hz, 1H), 4.57-4.53(m, 2H), 4.39(dd, J = 12.0 Hz, J = 3.0 Hz, 1H), 4.20-
4.16(m, 2H), 4.07(d, J =12.0 Hz, 1H), 3.85(t, J = 9.0 Hz, 1H), 3.71-3.67(m, 1H), 2.15-2.00(s, 7 
X 3H).  
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Acetylated farnesyl-β-cellobioside, AFβC (11b): Glycosylation of acetobromo cellobiose with 
farnesol was achieved by using Hg(CN)2. To a round bottom flask acetobromo-bromo cellobiose 
(0.5 g, 7.0 mmol) and farnesol (0.158g, 7.0 mmol) were added and dissolved in benzene (10 
mL). Hg(CN)2 (0.182g, 7.15 mmol) was then added and the mixture was allowed to stir at 50 ⁰C 
for ~ 2 hours. After 2 hours H2O (25 mL) was added and the organic phase was extracted with 
ethyl acetate (2 X 15 mL). The combined organic phase were washed with brine and dried with 
Na2SO4 (anhydrous), and concentrated in vacuo. The product was purified using a gradient 
solvent system (100 % hexane to 40 ethylacetate in hexane). Colorless powder, 0.143 g, 23.8 %. 
Rf = (0.50, 60% EtOAc: Hexane).
 1
H NMR (300 MHz, CDCl3): δ 5.24 (br, s, 1H), 5.17-5.02 (m, 
5H), 4.90 (q, J1-2 = 6.9 Hz, 2H), 4.46 (br, s, 3 H), 4.35-4.25 (m, 1H), 4.16 (br, s, 2H), 4.05 (t, J 
=14.7 Hz, 2H), 3.75(t, J =10.8 Hz, 1H), 3.66-3.63 (m, 1H), 3.57-3.56 (m, 1H), 2.11-1.97 (s, 7 x 
3H), 1.66-1.59 (s, 4 x 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.9, 170.7, 170.6, 170.3, 170.0, 
169.7, 169.5, 142.8, 135.9, 131.1, 124.7, 124.0, 119.5, 101.2, 99.0, 73.3, 73.1, 73.0, 72.3, 72.0, 
71.9, 68.1, 65.6, 62.4, 61.9, 40.1, 40.0, 27.1, 26.7, 26.1, 21.2, 21.1, 21.1, 21.1, 21.0, 20.9, 18.1, 
16.8, 16.4. HRMS (ESI) m/z: Calcd. (C41H60 O18)Na
+
: 863.3671; Found: 863.3652, Difference: -
2.3 ppm  
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Farnesyl-β-cellobioside, FβC (11): The deprotection of acetylated-farnesyl cellobioside (11b) 
was done using Zemplén deacetylation conditions as reported above. Colorless powder, 0.020g, 
95.3 %. 
1
H NMR (300 MHz, CD3OD): δ 5.39 (t, J = 6.3, 1H), 5.10 (q, J1-2 = 6.9 Hz, 2H), 4.24-
4.21 (m, 4H), 3.91-3.85 (m, 3H), 3.69-3.47 (m, 3H), 3.40-3.19 (m, 7H overlapping with MeOD), 
2.19-1.93 (m, 8H), 1.69 (s, 3H), 1.67 (s, 3H), 1.61 (s, 3H), 1.60 (s, 3H). 
13
C NMR (75 MHz, 
CD3OD): δ 140.9, 135.3, 131.1, 124.4, 124.1, 120.9, 103.6, 101.5, 79.7, 77.1, 76.8, 75.5, 75.4, 
73.9, 73.8, 70.3, 65.3, 61.4, 60.8, 39.9, 39.7, 26.8, 26.4, 24.9, 16.8, 15.5, 15.1. HRMS (ESI) m/z: 
Calcd. (C27H46 O11)Na
+
: 569.2932; Found: 569.2926, Difference: -1.1 ppm.  
HO  
Saturated farnesol, SF (12b) The reduction of trans-trans farnesol was done using H2, Pd/C 
conditions using reported literature procedure (Scheme 3).
211
 Briefly, a flask containing farnesol 
(0.887g, 3.96 mmol) and Pd/C (10% Pd) (0.1 g) in 10 mL MeOH was evacuated and filled with 
H2 gas. The reaction mixture was allowed to stir at room temperature for ~ 24 hours, following 
which Pd/C was filtered off and purification was done over silica column to obtain a viscous oil 
as product (0.300 g, 32.9%) 
1
H NMR (300 MHz, CDCl3): δ 3.63-3.73 (m, 2H), 1.49-1.62 (m, 
4H), 1.05-1.38(m, 13H), 0.84-0.90 (m, 12H). Spectroscopic data is consistent with reported 
literature. 
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Acetylated saturated farnesyl-β-cellobioside, ASFβC (12a): Colorless powder, 0.080g, 21.0 % 
(2-step), Rf = (0.53, 60% EtOAc: Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.21-5.03 (m, 3H), 
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4.91 (q, J1-2 = 7.8 Hz, 2H), 4.52-4.49 (m, 2H), 4.44 (dd, J1-3 = 8.1 Hz, J1-2 = 1.8 Hz, 1H), 4.37 
(dd, J1-3 = 12.3 Hz, J1-2 = 4.2 Hz, 1H), 4.06-4.02 (m, 2H), 3.92-3.83 (m, 1H), 3.77 (t, J = 9.3 Hz, 
1H), 3.68-3.56 (m, 2H), 3.52-3.44 (m, 1H), 2.13-1.98 (s, 7 x 3H), 1.54-1.04 (m, 18 H), 0.88 (s, 
3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.83 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.7, 170.6, 170.5, 
170.1, 169.8, 169.5, 169.3, 101.8, 100.8, 76.8, 73.2, 72.9, 72.8, 72.7, 72.2, 71.9, 68.8, 68.8, 62.2, 
61.8, 39.6, 37.7, 37.6, 37.5, 33.0, 30.0, 29.7, 28.2, 25.0, 24.6, 23.0, 22.9, 21.1, 20.9, 20.8, 20.7, 
20.0, 19.9, 19.8, 19.7, 19.5. HRMS (ESI) m/z: Calcd. (C41H66 O18)Na
+
: 869.4141; Found: 
869.4123, Difference: -2.1 ppm  
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Saturated farnesyl-β-cellobioside, SFβC (12): Colorless powder, 0.034g, 85.7 % 
1
H NMR (300 
MHz, CD3OD) δ 4.42 (d, J = 7.8 Hz, 1H), 4.29 (d, J = 7.8 Hz, 1H), 3.94 (br, s, 4H), 3.60-3.41 
(m, 4H), 3.38-3.26 (m, 4H, overlapping with MeOD), 3.23 (t, J = 5.7 Hz, 2H), 1.75-1.13 (m, 18 
H), 0.92-0.87 (s, 4 x 3H). 
13
C NMR (75 MHz, CD3OD): δ 103.6, 103.3, 79.7, 77.1, 76.8, 75.4, 
73.9, 73.8, 70.3, 68.3, 61.4, 60.8, 39.5, 37.7, 37.5, 37.4, 33.0, 29.9, 28.1, 24.9, 24.5, 22.1, 19.2, 
19.1, 19.0, 18.9. HRMS (ESI) m/z: Calcd. (C27H52 O11)Na
+
: 575.3401; Found: 575.3394, 
Difference: -1.3 ppm  
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Acetylated Saturated farnesyl-α-cellobioside, ASFαC (13a): Colorless powder, 0.059 g, 21.0 
% (2-step), Rf = (0.48, 60% EtOAc: Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.46 (t, J = 10.2, 
1H), 5.19-5.05 (m, 2H), 4.99-4.91 (m, 2H), 4.78 (dt, J1 = 4.5 Hz, J2 = 3.0 Hz, 1H), 4.39 (dd, J1-3 = 
12.6 Hz, J1-2 = 4.8 Hz, 1H), 4.17 (dd, J1-3 = 12.3 Hz, J1-2 = 4.8 Hz, 1H), 4.05 (dd, J1-3 = 12.3 Hz, 
J1-2 = 2.4 Hz, 1H), 3.96-3.89 (m, 3H), 3.42 (p, J1-3 = 15.6 Hz, J1-2 = 7.8 Hz, 1H), 2.14-1.99 (s, 7 x 
3H), 1.57-1.00 (m, 18 H), 0.90-0.84 (s, 4 x 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.9, 170.8, 
170.8, 170.7, 169.7, 169.5, 101.3, 96.1, 95.9, 73.5, 72.3, 72.1, 72.1, 71.5, 71.4, 70.2, 68.5, 68.2, 
62.3, 62.0, 39.7, 37.8, 37.7, 36.6, 33.2, 30.1, 28.4, 25.2, 24.8, 23.1, 23.0, 21.3, 21.1, 21.0, 21.0, 
19.9. 19.8, 19.7. HRMS (ESI) m/z: Calcd. (C41H66 O18)Na
+
: 869.4141; Found: 869.4120, 
Difference: -2.4 ppm  
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Saturated farnesyl-α-cellobioside , SFαC (13a): Colorless powder, 0.020g, 95.3 % 
1
H NMR 
(300 MHz, CD3OD): δ 4.77 (d, J = 3.6 Hz, 1H), 4.40 (d, J = 8.1 Hz, 1H), 3.92-3.88 (m, 2H), 
3.81-3.63 (m 4H), 3.57-3.33 (m, 3H), 3.36-3.29 (m, 2 H, overlapping with MeOD), 3.23 (t, J = 
8.1 Hz, 2H), 1.79-1.50 (m, 3H), 1.46-1.22 (m, 10 H), 1.21-1.03 (m, 5H), 0.92-0.86 (s, 4 x 3H). 
13
C NMR (75 MHz, MeOD): δ 103.9, 99.0, 98.9, 79.8, 77.1, 76.9, 73.9, 72.5, 72.3, 71.1, 70.3, 
61.4, 60.8, 39.6, 37.8, 37.5, 36.7, 33.0, 30.1, 28.2, 24.9, 24.4, 22.1, 22.0, 19.2, 18.9.HRMS (ESI) 
m/z: Calcd. (C27H52 O11)Na
+
: 575.3401; Found: 575.3395, Difference: -1.3 ppm  
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Acetylated saturated farnesyl-β-maltoside, ASFβM (14a): Colorless powder, 0.040g, 29.0 % 
(2-step), Rf = (0.41, 60% EtOAc: Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.43-5.36 (m, 2H), 
5.25 (t, J = 9.3 Hz, 1H), 5.07 (t, J = 4.5 Hz, 1H), 4.97-4.79 (m, 2H), 4.53-4.42 (m, 2H), 4.29- 
4.20 (m, 2H), 4.07-3.85 (m, 4H), 3.70-3.65 (m, 1H), 3.53-3.44 (m, 1H), 2.14-2.01 (s, 7 x 3H), 
1.66-1.16 (m, 18 H), 0.89 (br, s, 12H). 
13
C NMR (75 MHz, CDCl3): δ 169.5, 169.4, 169.2, 169.1, 
169.0, 100.0, 99.8, 72.4, 72.3, 71.8, 71.6, 69.6, 68.9, 68.1, 67.6, 62.1, 61.1, 60.0, 37.1, 36.9, 32.4, 
29.3, 27.5, 24.4, 23.9, 22.3, 22.2, 20.6, 20.5, 20.4, 20.3, 20.2, 19.3, 19.2, 19.1, 18.8, 13.8. HRMS 
(ESI) m/z: Calcd. (C41H66 O18)Na
+
: 869.4141; Found: 869.4130, Difference: -1.2 ppm  
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Saturated farnesyl-β-maltoside, SFβM (14): Colorless powder, 0.022g, 96.0 % 
1
H NMR (300 
MHz, CD3OD): δ 5.17 (br, s, 1H), 4.27 (d, J = 9 Hz, 1H), 3.95-3.92 (m, 4H), 3.88-3.43 (m, 6H, 
overlap with CD3OD peak), 3.27-3.20 (m, 4H), 1.79-1.13 (m, 18 H), 0.90 (s, 3H), 0.89 (s, 3H), 
0.88 (s, 3H), 0.87 (s, 3H). 
13
C NMR (75 MHz, CD3OD): δ 102.6, 101.6, 79.5, 76.1, 74.8, 73.3, 
72.9, 72.5, 72.4, 69.7, 67.5, 67.4, 60.9, 60.4, 38.7, 36.9, 36.7, 36.6, 32.2, 29.1, 27.4, 24.1, 23.7, 
21.3, 21.2, 18.4, 18.3, 18.2, 18.2. HRMS (ESI) m/z: Calcd. (C27H52 O11)Na
+
: 575.3401; Found: 
575.3399, Difference: < -1.0 ppm  
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Acetylated saturated farnesyl-β-lactoside, ASFβL (15a): Colorless powder, 0.059 g, 21.0 % 
(2-step), Rf = (0.48, 60% EtOAc: Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.53-5.47 (m, 1H), 
5.30-5.16 (m, 1H), 5.12-5.07 (m, 1H), 4.94-4.86 (m, 3H), 4.66-4.60 (m, 1H), 4.54-5.41 (m, 3H), 
4.33-4.23 (m, 1H), 4.15-4.07 (m, 2H), 3.99-3.59 (m, 4H), 3.53-3.26 (m, 2H), 2.17-1.96 (s, 7 x 
3H), 1.70-1.02 (m, 18 H), 0.88,(s, 3H), 0.85 (s, 3H), 0.84 (s, 3H), 0.82 (s, 3H). 
13
C NMR (100 
MHz, CDCl3): δ 169.4, 169.0, 168.8, 168.5, 168.3, 168.1, 99.6, 98.3, 76.3, 76.2, 76.0, 75.7, 75.1, 
72.6, 71.5, 70.8, 70.7, 70.0, 69.0, 68.4, 67.9, 67.4, 67.0, 66.2, 61.3, 61.0, 60.5, 47.1, 38.9, 36.4, 
36.2, 35.3, 31.8, 28.7, 28.5, 27.0, 26.2, 23.8, 23.3, 21.7, 21.6, 20.0, 19.9, 19.9. HRMS (ESI) m/z: 
Calcd. (C41H66 O18)Na
+
: 869.4141; Found: 869.4135, Difference: < 1.0 ppm 
O
HO OH
HO
O
HO
OH
O
OH
O
2
OH
 
Saturated farnesyl-β-lactoside, SFβL (15): Colorless powder, 0.020g, 95.3 % 
1
H NMR (300 
MHz, CD3OD): δ 4.41 (t, J = 6.8 Hz, 1H), 4.33-4.29 (m, 1H), 4.09-4.08 (m, 1H), 3.95-3.88 (m 
2H), 3.83-3.76 (m, 3H), 3.76-3.66 (m, 2 H), 3.56-3.32 (m, 6H), 3.31-3.21 (m, 1H), 3.17 (d, J = 
5.2 Hz, 1H), 1.57-1.06 (m, 18 H), 0.92 -0.87 (s, 4 x 3H). 
13
C NMR (75 MHz, CD3OD): δ 103.9, 
103.4, 79.6, 75.4, 74.9, 73.4, 73.1, 72.0, 67.9, 66.2, 60.4, 54.4, 48.2, 48.1, 47.9, 37.1, 37.0, 36.4, 
32.6, 29.5, 29.0, 27.7, 24.5, 24.0, 21.6, 18.8, 18.7.HRMS (ESI) m/z: Calcd. (C27H52 O11)Na
+
: 
575.3402; Found: 575.3403, Difference: < 1.0 ppm. 
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Acetylated-2-octyl-dodecyl-β-cellobioside, 2-AODβC (16a): Colorless powder, 0.240g, 9.0 % 
(2-step), Rf = (0.53, 60% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.21-5.03 (m, 3H), 
4.92 (q, J1-2 = 6.6 Hz, 2H), 4.53-4.50 (m, 2H), 4.43-4.34 (m, 2H), 4.07 (t, J = 16.8, 2H), 3.81-
3.74 (m, 2H), 3.68-3.54 (m, 2H), 3.27 (t, J = 6.3 Hz, 1H), 2.13-1.99 (s, 7 x 3H), 1.59-1.48 (m, 
1H), 1.26 (br, s, 32H), 0.89 (t, J = 6.3 Hz, 6H). HRMS (ESI) m/z: Calcd. (C46H76O18)Na
+
: 
939.4923; Found: 939.4910, Difference: -1.5 ppm  
O
HO OH
HO
O
HO
HO
OH
O
OH
O 7
6  
2-Octyl-dodecyl-β-cellobioside , 2-ODβC (16): Colorless powder, 0.05 g, 94.0 %. 
1
H NMR 
(300 MHz, CD3OD): δ 4.43 (d, J = 7.8 Hz, 1H), 4.26 (d, J= 9.9, 1H), 3.93 (br, s, 3H), 3.84-3.78 
(m, 4H), 3.70-3.49 (m, 3H), 3.42-3.31 (m, 5H, overlapping with MeOD), 3.29-3.21(m, 2H), 
1.69-1.57 (m, 1H), 1.31 (br, s, 32 H), 0.92 (t, J = 6.3 Hz, 6H). 
13
C NMR (75 MHz, CD3OD): δ 
102.8, 79.0. 76.3, 76.0, 74.7, 74.6, 73.1, 73.0, 72.3, 69.6, 60.6, 60.2, 37.6, 31.3, 30.4, 29.4, 29.4, 
29.0 (8 carbons), 28.9, 28.9, 28.7, 26.1, 22.0, 12.7. HRMS (ESI) m/z: Calcd. (C32H62O181)Na
+
: 
645.4184; Found: 645.4179, Difference: <-1.0 ppm  
O
AcO OAc
AcO
O
AcO
AcO
OAc
O
OAc O 7
6  
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Acetylated-2-octyl-dodecyl-α-cellobioside, 2-AODαC (17a): Colorless powder, 0.040g, 1.5 % 
(2-step), Rf = (0.48, 60% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 5.43 (t, J = 9.3 Hz, 
1H), 5.11 (p, J1-3 = 18.3 Hz, J1-2 = 9.0 Hz, 2H), 4.96 -4.90 (m, 2H), 4.77 (dd, J1-3 = 10.2 Hz, J1-2 = 
3.3 Hz, 1H), 4.52-4.45 (m, 2H), 4.38 (dd, J1-3 = 12.6 Hz, J1-2 = 4.5 Hz, 1H), 4.15-4.02 (m, 2H), 
3.88-3.73 (m, 1H), 3.69-3.55 (m, 4H), 3.20 (t, J = 6.3 Hz, 1H), 2.13-1.98 (s, 7 X 3H), 1.62 -1.55 
(m, 1H), 1.26 (br, s, 32H), 0.88 (t, J = 6.6 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 170.1, 169.9, 
169.8, 169.8, 169.1, 168.8, 168.5, 100.5, 95.3, 76.8, 76.4, 72.6, 71.5, 71.3, 71.1, 70.8, 69.4, 67.6, 
67.3, 61.4, 61.1, 37.3, 31.4, 30.8, 30.4, 29.6, 29.2, 29.2, 28.9, 26.3, 26.2, 22.2, 13.7. HRMS 
(ESI) m/z: Calcd. (C46H76O18)Na
+
: 939.4923; Found: 939.4910, Difference: <-1.4 ppm  
O
HO OH
HO
O
HO
HO
OH
O
OH O 7
6  
2-Octyl-dodecyl-α-cellobioside, 2-AODαC (17): Colorless powder, 0.015 g, 83.5.0 % 
1
H NMR 
(300 MHz, CD3OD): δ 4.44 (t, J = 3.6 Hz, 1H), 4.27 (t, J = 3.6 Hz, 1H), 3.89 (br, s, 3H), 3.77-
3.71 (m, 2H), 3.63-3.60 (m, 2H), 3.49-3.21 (m, 8H, overlapping with MeOD peak), 1.68-1.57 
(m, 1H), 1.31 (br, s, 32H), 0.91 (m, 6H). 
13
C NMR (75 MHz, MeOD): δ 102.8, 98.4, 79.2, 76.3, 
76.0, 73.0, 71.6, 71.5, 70.7, 70.3, 69.5, 60.6, 59.9, 37.5, 31.2, 30.5, 30.5, 29.3, 29.3, 29.2, 28.9, 
28.9, 28.7, 28.6, 28.6, 28.5, 26.1, 26.0, 26.0, 21.6, 13.0. HRMS (ESI) m/z: Calcd. 
(C32H62O181)Na
+
: 645.4184; Found: 645.4178, Difference: -1.0 ppm  
OO
OOF
F F
F
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Difluoro phenoxy squarate, DPSq (18a) - (Scheme 2) Finely powdered 1, 2-
Dihydroxycyclobutene-3,4-dione (1.10 g, 9.6 mmol), carbon tetrachloride (20 mL), and DMF 
(0.05mL), were introduced into a 50 mL round-bottomed flask previously filled with argon. The 
mixture was frozen by immersing in dry ice-acetone and oxalyl chloride (2.10 mL, 24 mmol) 
was introduced at once through the condenser’s outlet. Then the flask was allowed to warm to 
room temperature, agitation started at 300 rpm, and the flask was then 28 lowered into an oil 
bath thermostatted to 50-60 ⁰C. Regular gas evolution started immediately and was no more 
apparent after 50 min. After heating further for 3 h the agitation was discontinued. The solvent 
was removed to give 1,2-dichlorocyclobutene -3,4-dione as yellow crystal. (Yield = 1.15 g, 80 
%)  
(1.15 g, 7.6 mmol) of 1,2-dichlorocyclobutene-3,4-dione was dissolved in benzene (50 mL), and 
the solution was cooled to 0⁰C. 3,5-Difluorophenol (2.0 g, 15.3 mmol) was added to the above 
solution in one portion, followed by slow addition of excess Et3N (2.090 g, 20.674 mmol), and 
the reaction mixture was stirred at room temperature overnight.The reaction mixture was filtered, 
and the residue obtained was washed with benzene to yield a white solid. The solid obtained was 
purified using flash silica gel column (20% EtOAc in hexanes) to give 2 (0.80 g, 27%) as a white 
solid. Rf = 0.59 (20% EtOAc in hexanes). Yield = {white powder, 0.282 g, 12 % (2-step)}, Rf = 
(0.40, 1:1 Hexane:EtOAc). 1H NMR (300 MHz, CDCl3): δ 6.906.88 (m, 4H), 6.846.78 (m, 2H). 
Spectroscopic data are consistent with reported values
. 212 
OO
N
H
O
F
F 10  
Dodecylamine-phenoxy squarate, DPSq (18b): A round bottom flask was charged with 
difluoro-bis phenoxy squarate (0.04 g, 1.18 mmol) and THF (5 mL, anhydrous distilled over 
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CaH2) was added. The solution was cooled to -78 ⁰C in a dry-ice/acetone bath. Dodecyl amine 
(0.0153 g, 0.8 mmol) dissolved in THF (5 mL, anhydrous) was then added dropwise over 30 
minutes. The mixture was stirred at -78 ⁰C for 2 hours. Column chromatographic separation 
using a gradient of 100 % hexane to 30 % ethyl acetate in hexane yielded product as a viscous 
oil, 0.025 g, 54.3 % ( Rf = 0.46 (30 % ethyl acetate in hexane). 
1
H NMR (400 MHz, CDCl3): δ 
6.92- 6.87 (m, 2H), 6.73-6.68 (m, 1H), 3.76-3.52 (m, 2H), 1.70-1.68 (m, 2H), 1.38-1.25 (m, 
18H), 0.88 t, J = 6.0 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ 189.9, 180.2, 173.3, 171.8, 102.6, 
102.5, 102.4, 102.3, 101.3, 101.0, 45.2, 31.9, 31.0, 29.6. 29.5, 29.4, 29.3, 29.1, 26.4, 26.3, 22.7, 
14.1.HRMS (ESI) m/z: Calcd. (C22H29 F2NO3)Na
+
: 416.2008; Found: 416.2005, Difference: <-
1.0 ppm. 
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Dodecyl βCD squarate, DβCDS (18b): Synthesis of βCD-NH2 (18c) was done via a 3 step 
reported literature procedure.
212
 The synthesized βCD-NH2 (0.028 g, 0.02 mmol) was dissolved 
in distilled water (2 mL). To this βCD-NH2 solution was added dropwise a solution of phenoxy 
amino dodecyl squarate (0.02 mmol ) dissolved in a binary solvent mixture of DMF (2 mL) and 
acetone (1 mL). The reaction mixture was allowed to stir at room temperature, monitoring with 
TLC to check for consumption of starting material squarate (~ 4 days) (TLC solvent system; 30 
% ethyl acetate in hexane). Formation of new spot was also monitored using a polar TLC system 
(i-PrOH: EtOAc: H2O: NH4OH:: 5: 2: 3: 1, Rf = 0.7) followed by staining with Ceric 
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Ammonium Molybdate (CAM) stain. The product (DβCDS) (14) was precipitated by addition of 
excess of acetone (10 mL) and separated by centrifuging at 3000 rpm for 10 mins. The obtained 
white solid was washed several times with acetone followed by centrifugation. Colorless powder, 
yield 0.02 g, 56.0%).
1
H NMR (300 MHz, CD3OD): 3.95-3.64 (m, 30 H), 3.57-3.38 (m, 14H), 
1.92-1.88 (m, 1H), 1.22 (br, s, 12H), 0.89 (br, s, 3H). Analyzed by MALDI and matched on 
[C58H96N2O36]Na
+
 at 1420.37 Expected Mass of sodium adduct: 1420.37. 
 
Biological assays 
Materials and methods of biological assays. Rhamnolipids (R95; 79:16 percent ratio of di-
rhamnolipids:mono-rhamnolipids, 95 % pure, average molecular weight 626 g/mole) was 
obtained from Agae technologies, Corvallis, OR and was used as received. Water was purified 
using a Millipore Analyzer Feed System. Flat-bottomed polystyrene 96-well microtiter plates 
(untreated) (Costar 3370, VWR) were used to perform antibiofilm assays (biofilm inhibition, 
biofilm dispersion). For measuring fluorescence for adhesion and gene reporter assays, flat-
bottomed 96-well microtiter plates with black walls (μClear, Greiner-One 655096, Sigma 
Aldrich) were used. Measurement of absorbance at 600 nm (OD600) for growth assay was 
performed with 200 μL of culture-media in microtiter plate well on a Biotek ELx800
 TM
 
absorbance microplate reader (BioTek Instruments, Inc., Winooski, VT), and the data was 
analyzed with Gen5
TM
 data analysis software. Quantification of biofilm (inhibition and 
dispersion) was done using a crystal violet (CV) dye-based static-biofilm assay.
213
 For 
quantifying fluorescence for adhesion and gene reporter assays, Synergy 2 multi-mode 
microplate reader (BioTek Instruments, Inc., Winooski, VT) with Gen5 data analysis software 
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was used to detect green fluorescent protein (GFP) signal at an excitation wavelength of 500 nm 
and emission wavelength of 540 nm. For biofilm inhibition and dispersion, bacterial adhesion, 
and gene reporter assays, controls contained the same volume of deionized water without any 
added agents. For each biological assay, at least 3 triplicates were conducted, and data shown are 
the average of readings from at least 4-replicates wells. Half maximal inhibitory concentration 
for both biofilm inhibition and dispersion (IC50 and DC50) were calculated by fitting values into a 
logarithmic equation, y = mln(x) + C 
Bacterial strains and plasmids. Pseudomonas aeruginosa strains PAO1 and PAO1-EGFP were 
obtained from Dr. Guirong Wang (Upstate Medical University). Pseudomonas aeruginosa 
transposon mutant strain PW6886 (rhlA-E08::ISphoA/hah) was obtained from two-allele 
library.
202
 PAO1 (plasI-LVAgfp), PAO1 (prhlI-LVAgfp) strains were prepared by literature 
reported protocol.
214
 The plasmid plasI-LVAgfp and prhlI-LVAgfp were obtained from Dr. 
Hiroaki Suga (The University of Tokyo) and were maintained by adding 300 μg/mL of 
carbenicillin in culture media. Freezer stocks of all strains were stored at -80 ⁰C in LB media 
with ~20% glycerol. All strains were grown at 37 ⁰C in a rotary-shaker (at 250 rpm) in Luria 
Bertaini (LB) media (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl). All biofilm 
inhibition, dispersion and adhesion assays were performed in LB-media and plates were 
incubated at 37 ⁰C under static conditions.  
Stock solution and delivery of disaccharide derivatives (DSDs). All but three saccharide 
derivatives were water-soluble. For the water soluble DSDs, no organic solvents were used to 
assist the mixing and delivery for all biological assays. Stock solution (~11.5 mM) of DSDs were 
prepared in autoclaved water and further sterilized by filtering through cellulose acetate syringe 
filter (0.2 µm pore size, GVS filter technology) into sterilized vials. The sterilized DSDs stock 
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solutions were stored at -20 °C and thawed prior to each use. Aliquots of DSD stock solutions 
were added to the cultures in wells. Sterile water (same volume as the DSD stock solution used) 
was used as positive controls (no agents) in all assays to eliminate the effect of water from the 
stock solution. Three agents DβL (7), SFβL (15) and 2-ODαC (17) exhibited low water 
solubility, and were prepared in mixed solution of sterile water (90%) and 200 proof EtOH (10 
%). Controls for these agents consisted of the same mixed water-ethanol solution.  
Toxicity of disaccharide derivatives against planktonic bacteria. Overnight inoculum of 
PAO1 was sub-cultured to an OD600 ~ 0.01 and the sub-culture was allowed to reach an OD600 of 
~0.1, from which 200 μL was aliquoted into the wells of a microtiter plate, followed by 3 μL of 
DSDs stocks (to achieve a final 160 μM). Wells without added agents were used as a positive 
control. The microtiter plate was shaken (250 rpm at 37 ⁰C), and the optical density was 
measured after regular intervals of time over 24 h using Biotek ELx800
 TM
 absorbance 
microplate reader (BioTek Instruments, Inc., Winooski, VT). The OD600 values were plotted 
against time to obtain a growth curve for planktonic growth with or without agents (see 
supporting information Figure S2).  
Swarming assays. Semisolid gel for swarming assays were prepared using M8 medium 
supplemented with 0.2 % glucose, 0.5 % casamino acid, 1 mM MgSO4 and 0.5 % Bacto agar.
204
 
For each set of swarming experiment, the plates were poured from same batch of agar and 
allowed to dry for 1 h before inoculation of bacteria. Bacterial culture (3 µL) (wild type PAO1 or 
rhlA mutant) with OD600 between ~0.4-0.6 was inoculated on the semisolid agar gel. These 
“swarm plates” were incubated at 37 °C for 12 h and then incubated for additional 12 h at room 
temperature After a total 24 h period, pictures of the swarming plates were taken. 
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Swarm area measurement. To measure swarming area, images of “swarm plates” were 
adjusted to keep the diameters of all the petri dishes containing the semisolid gel to a constant 
4.4 inches. The adjusted images were printed and the swarming patterns were cut and weighed. 
With 1 cm
2
 square of the copy paper weighing 8.0 mg, the swarming areas were calculated.                        
 
Figure 2S1. Plot of the rhlA mutant’s swarm area (after 24 h) versus increasing 
concentrations of rhamnolipids and SFβM (14) in the semisolid gel (~ 0.5% agar). The 
experiment was repeated on three different plates. The error bars are obtained from the mean of 
the three different experiments. 
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Chapter 3 
Disaccharide derivatives Inhibit and Disperse Biofilm of P. aeruginosa 
Abstract 
 Bacterial sessile multicellular lifestyle leads to formation of communities known as 
biofilms that are highly resistant to the action of antibiotics. Agents that can prevent biofilm 
formation or alternatively disrupt preformed biofilms are therefore highly desired. Additionally, 
if such antibiofilm agents are also nonmicrobicidal against bacteria, they will be less likely to 
invoke resistance over time as compared to antibiotics that are microbicidal. 
  Here, the ability of certain disaccharide derivatives (DSDs) to inhibit P. aeruginosa 
adhesion, biofilm formation and cause dispersion of existing biofilm via a nonmicrobicidal 
action was evaluated. The structure activity relationship show that DSDs having disaccharide 
stereochemistries (cellobiose or maltose) and a bulky aliphatic tail (3, 7, 11-trimethyl-dodecanyl) 
were potent antibiofilm agents. The half-maximal inhibitory concentrations of few DSDs for 
biofilm inhibition (IC50) and dispersion (DC50) were comparable to known potent antibiofilm 
agents against P. aeruginosa. One agent, having cellobiose head and 3, 7, 11-trimethyl-
dodecanyl tail (SFβC (12)) was a more potent antibiofilm agent than the natural ligands, 
rhamnolipids. The mechanism of action of such DSDs is not via the known las or rhl quorum 
sensing systems of P. aeruginosa. Results also indicate that the P. aeruginosa adhesin potein, 
pilin maybe a likely target for such DSD molecules. 
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3.1 Introduction 
3.1.1 P. aeruginosa is a prominent pathogen associated with medical bacterial infections 
The multi-drug resistance (MDR) phenomenon exhibited by a broad range of bacteria is a 
major health concern, and a prime bacterium in the midst of this grave problem is P. aeruginosa. 
P. aeruginosa is a gram negative rod shaped pathogen which is ubiquitously found in soil, water 
and within humans. P. aeruginosa is one of the most common pathogens isolated from hospital 
acquired infections. This bacterium is also the prime pathogen found in the lungs of patient with 
chronic respiratory disease, Cystic fibrosis. To add to the medical woes associated with P. 
aeruginosa infections, the present day strains isolated from disease organisms display resistance 
against most antimicrobials including, Penicillins, Ceftazidime, Carbapenems, Aminoglycosides 
and Ciprofloxacin.  
 Presently, the primary pharmaceutical approach to fight P. aeruginosa infections focuses 
on finding newer protein targets on the bacteria, against which potent antagonists can be 
developed and used to disrupt bacterial cellular processes and hence cause bacterial death. The 
major disadvantage of such a microbicidal approach is that the bacteria will over time acquire 
resistance against the new drug, and the futile task of finding newer targets and drugs requiring 
billions of dollars on research and government approvals would have to be repeated over and 
over again.  
 Contemporarily newer nonmicrobicidal approaches, that focus on the multicellular 
behaviors like biofilm formation and swarming (for review on bacterial biofilm formation and 
swarming see Chapter 1, sections 1.2 and 1.3) are being developed to treat bacterial infections 
while at the same time limiting the risks of inducing MDR. While no nonmicrobicidal strategy 
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focusing on bacterial biofilm inhibition has made it to the clinic, there is consensus that for 
countering MDR the future bacterial therapeutics would have to be centered around this 
approach. The reasons for this consensus are two; (i) Around 65-80% bacterial infections in 
humans are biofilm related; (ii) With the use of nonmicrobicidal agents against them, the bacteria 
would have a lesser or ideally no propensity to acquire resistance. With a distinct hope for a long 
term and probably a more permanent solution to bacterial infections, the nonmicrobicidal 
strategies offer some advantages over the existing microbicidal strategies. Therefore, in recent 
times, there has been a flurry of discoveries primarily focused on inhibiting and disrupting 
bacterial biofilms with agents that do not kill the microbe. A brief summary of many such 
nonmicrobicidal strategies has been reviewed in Chapter 1 (Section 1.3.4).  
3.1.2 Motile and sessile multicellular behaviors in P. aeruginosa are inversely regulated 
When bacteria land on a surface, they make a calculated choice between forming a sessile 
community or moving further ahead on the surface in search of more conducive 
microenvironments for colony formation (Figure 3.1). It is therefore conceived that both these 
multicellular processes, sessile (biofilm formation) and motile (swarming) are controlled by a 
common set of genes, whose expression inversely regulates the two bioprocesses. Many such 
genes and gene products have been identified in P. aeruginosa whose role is to make that 
calculated choice between motile and sessile life styles. In P. aeruginosa, the presence of surface 
attachment defective (SadB) protein is critical for both biofilm formation and swarming motility. 
While SadB protein was shown to be critical for progression from reversible to irreversible 
attachment during biofilm formation, this cytoplasmic protein was also shown to be important 
for sensing rhamnolipids, which are crucial virulence factors necessary during swarming. O' 
Toole et al created a mutant (WT/pSadB) strain of type P. aeruginosa  by inserting a plasmid 
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(pSadB
+
) that caused overexpression of SadB protein. When the biofilm formation of such a 
mutant strain was quantified and compared to the biofilm content of wild type, there was a 3 fold 
increase in biofilm formation. Contrary to the enhanced biofilm formation, the swarming motility 
of such a SadB overexpressing mutant was reduced by 2.5 fold. When the gene encoding for 
SadB was deleted, the resulting mutant strain was hyperswarming. These results by O'Toole et al 
alluded to the notion that the sadB gene inversely regulates biofilm formation and swarming in 
P. aeruginosa. Further studies by O'Toole et al showed that another gene known as sadC, which 
expresses the membrane-localized diguanylate cyclase protein inversely regulated biofilm 
formation and swarming motility in P. aeruginosa. Later studies by O'Toole et al identified 
another gene bifA that can also inversely regulate swarming and biofilm formation, and they 
tentatively assigned the gene product of this gene, BifA as functioning upstream to the 
previously identified SadB protein. 
Figure 3.1 Inverse regulation of swarming and biofilm formation. [Modified and Reprinted 
with permission from Citation:
45
 Caiazza et al, Inverse regulation of biofilm formation and 
swarming motility by Pseudomonas aeruginosa PA14, J. Bacteriol. 2007, 189, 3603-3612] 
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3.1.3 Apart from being critical during swarming, rhamnolipids are important biomolecules 
secreted by P. aeruginosa during biofilm formation 
The biosynthetic pathway for the secretion of rhamnolipids by P. aeruginosa has been 
discussed in Chapter 2, section 2.1.5.4. Also, the biological importance of rhamnolipids secretion 
by P. aeruginosa with respect to swarming motility has been discussed in chapter 2, section 
2.1.5.4.1. Secretion of rhamnolipids is also associated with the sessile mode of living, i.e biofilm. 
The biofilm architecture is quite complex and the component of its matrix varies from species to 
species. However, it is well documented that most biofilm architectures are "mushroom" shaped 
that contain voids and channels. The voids and channel are critical elements of biofilm 
architecture and it is thought that such inter connected channels are important for supplying  
nutrients, oxygen and water throughout the community.
215
 Davey et al showed using 
fluorescence microscopy that while both the wild type and the rhlA mutant strain of P. 
aeruginosa were able to form a biofilm architecture containing macrocolonies separated by 
voids, only the wild type strain was able to maintain the voids over six days, where as the rhlA 
mutant could not. In comparison to wild type, the critical element that the rhlA mutant cannot 
secrete are rhamnolipids, hence they concluded that secretion of rhamnolipids during biofilm 
formation of P. aeruginosa is necessary for ensuring formation of sturdy biofilm. Apart from the 
role in maintaining voids in the biofilm, Gilbert et al showed that over production of 
rhamnolipids by P. aeruginosa could lead to dispersal of bacteria from the biofilm.
216
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3.1.4 Bacteria employ surface proteins known as adhesins to recognize and bind carbohydrate 
epitopes found on host cells 
The initiation of many infections begin with adherence of bacteria to a host surface with 
the use of certain surface-exposed bacterial proteins known as adhesins. These bacterial adhesin 
proteins initiate adherence by recognizing many different kinds of carbohydrate epitopes present 
on host surfaces. The adhesin proteins used by bacteria may be present either on the cell surface 
(lectins)
217
 or on specialized appendages (pili and fimbriae). Four different kinds of fimbriae 
present on E.Coli (P, type 1, S, and F1C) are known to exhibit affinity for galabiose (Galα-(1-4)-
Gal), mannose, sialic acid ligands, and GalNAcβ(1-4)Gal, respectively.
218-222
 Galabiose epitope 
is also known to be recognized by Streptococcus suis (S. suis), a gram positive bacteria that 
causes meningitis in human.
219,223
 It has also been reported that H. pylori, a common stomach 
bacterium recognizes a prominent carbohydrate epitope (2’3-sialyllactose, Neu5Acα(2-3)Galβ(1-
4)Glc) found on human cells.
219,224
 
 Pseudomonas aeruginosa use surface proteins as well as adhesins to interact with 
carbohydrates moieties on host surfaces. Proteins used by Pseudomonas aeruginosa for surface 
adhesion include flagellin (on flagella), pilin (on pili) and lectins (LecA and LecB).
225
 While the 
flagella proteins on P. aeruginosa can bind to carbohydrate epitopes found on mucin protein and 
to glycolipids (asialo-GM1) on mammalian cells, pilin protein has a specificity for D-GalNac-β-
(14)D-Gal-β disaccharide moiety found on glycosphingolipids.
226
 The P. aeruginosa lectins, 
LecA and LecB, on the other hand are known to be specific for binding to galactose
197,227
 and 
fucose moieties, respectively. Molecular intervention of bacterial adhesion process via the use of 
synthetic carbohydrate ligands also known as the "antiadhesive strategy" is therefore viable 
therapeutic approach for preventing infection. Reymond and co-workers have demonstrated that 
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multivalent fucosyl-peptide dendrimers targeting LecB could be used as molecular intervention 
to inhibit and disperse P. aeruginosa biofilm on steel coupons.
228
 
 In P. aeruginosa, pilin protein is known to mediate up to ~90 % of the adhesion events. 
The pili assisted epithelial cell binding domain is located between residues 128-144 on the C-
terminal region of PilA, the pili structural protein.
229
 Irwin and co-workers have demonstrated 
that the presence of Type IV pili is critical for adherence of P. aeruginosa to steel coupons. Also, 
synthetic pili peptide sequence (residues 128-144) can also bind to polyvinyl chloride (PVC) and 
polystyrene (PS) surfaces.
230
 The binding specificity of D-GalNac-β–(14)-β-D-Gal 
disaccharide ligand with minimum binding amino acid sequence of P. aeruginosa pili (peptide 
sequence PAK(128-144)) was also studied and it was determined that increasing the hydrophobicity 
of disaccharide side chain increased the binding to the PAK(128-144) pili peptide.
231
  
 Here, the three key points to summarize are; (i) Swarming and biofilm formation in P. 
aeruginosa are inversely regulated; (ii) Rhamnolipids secretion by P. aeruginosa is important for 
building sturdy biofilms; (iii) P. aeruginosa is able to recognize and hence bind with ligands that 
offer various saccharide stereochemistries. In Chapter 2, the use of certain saccharide derivatives 
(SDs) to modulate P. aeruginosa swarming was shown. Also, the results show that the 
modulation of swarming by such SDs was probably a result of them mimicking the functions of 
rhamnolipids. Since, SDs mimicked rhamnolipids during swarming of P. aeruginosa, and since 
swarming and biofilm formation in P. aeruginosa are inversely regulated, the potencies of such 
nonmicrobicidal agents (i.e SDs) to inhibit P. aeruginosa surface adhesion and biofilm formation 
and cause dispersal of preformed biofilm was evaluated in this chapter. As P. aeruginosa has 
many surface proteins that can recognize different saccharide epitopes, a preliminary study to 
identify the putative target protein of such SDs was also carried out.  
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3.2 Results and Discussion 
The rationale of synthesizing the chemical structures in Figure 3.2 is the same as 
mentioned in Chapter 2 (Section 2.2.1). In summary, saccharide derivatives (SDs) comprising of 
different saccharide stereochemistries and various aliphatic structures were included in the study. 
The structure-activity relationship between structural details and corresponding effects on 
biofilm inhibition and bacterial adhesion was investigated. 
The antibiofilm activities (biofilm inhibition and dispersion) of the SDs and rhamnolipids 
were screened by using the crystal violet (CV) based static biofilm assay. In this assay, wild type 
Pseudomonas aeruginosa (PAO1) was grown in LB-media with or without 160 μM SDs or 
rhamnolipids at 37 ºC in the wells of microtiter plates for 24 hours. After the initial incubation 
period of 24 hours, the biofilm formed on the bottom of the wells was stained with crystal-violet 
dye and quantified by measuring the absorbance at 600 nm (OD600) (for procedure see Materials 
and Methods).
115,213
 Comparing the content of biofilm in control wells (no added SD) to that of 
wells containing various SDs, gave the percent inhibition. The initial analysis of the SDs’ 
antibiofilm (both inhibition and dispersion) activities were assessed at a concentration of ~ 160 
μM. In the dispersion assay, the SDs or rhamnolipids were added after the initial incubation 
period of 24 hours and then the plates were incubated for additional 24 hours before 
quantification with CV-dye. Those agents that exhibited >50% antibiofilm activities were further 
analyzed in a concentration dependent manner to obtain half-maximal inhibitory concentrations 
for biofilm inhibtion (IC50) and dispersion (DC50). Additionally, the antibiofilm activities of a 
few SDs were also examined via fluorescence based biofilm assay (for procedure see Materials 
and Methods).  
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Further, the ability of SDs to prevent initial bacterial adhesion to polystyrene surface was 
analyzed using a fluorescence based adhesion assay. Here a strain of P. aeruginosa that 
constitutively expresses green fluorescent protein (PAO1-EGFP) was inoculated in the wells of a 
microtiter plate for 2 hours with LB media as the nutrition source along with (160 μM) or 
without various SDs or rhamnolipids. After the initial adhesion period, the amount of fluorescent 
bacteria (PAO1-EGFP) on the surface of the microtiter plate was quantified by measuring the 
fluorescence at 510 nm. The ability of pili peptide (minimum binding segment of pilin protein) to 
reduce the potency of a SD was also analyzed. 
The quantitative values of all bioassays (biofilm inhibition & dispersion, IC50, DC50 and 
bacterial adhesion inhibition) are the average obtained from four identical wells. Each 
experiment was repeated at least 3 times, each time giving similar results (repeat results are not 
shown).  
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Figure 3.2. Structures of synthetic saccharide based derivatives that include maltose, 
cellobiose, lactose, glucose, rhamnose, and β-cyclodextrin stereochemistries; and hydrocarbons 
derived from farnesyl and “saturated” farnesyl molecules. The structures of di-rhamnolipid and 
mono-rhamnolipid are also shown. 
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3.2.1 Effect of generic surfactants on biofilm formation 
 Swarming motility had exhibited no correlation with the surface activity of the molecule 
(see Chapter 2, Section 2.2.3). The preliminary screening of four generic surfactants (dodecyl-β-
maltoside, DβM (1); tetra-(ethylene glycol) monododecyl ether, C12EG4OH; sodium dodecyl 
sulfate, SDS; and dodecyl trimethyl ammonium chloride, DTAC) for the ability to reactivate the 
swarming of the rhlA mutant (see Chapter 2, Section 2.2.3), showed that only DβM (1) alone 
was able to exhibit reactivation, similar to the natural ligand, rhamnolipids while other 
surfactants could not. Further, to assess whether surfactant action had an effect on biofilm 
formation, the four generic surfactants were also tested for the ability to inhibit P. aeruginosa 
biofilm. The biofilm inhibition assay in presence of 110 µM of various generic surfactants 
showed that only one molecule, DβM (1) exhibited significant reduction in biofilm content 
(Figure 3.3). 
                              
Figure 3.3 Inhibition of P. aeruginosa (PAO1) biofilm by 110 μM of generic surfactants; 
Dodecyl-β-maltoside (DβM, 1, -ionic surfactant); tetra (ethylene glycol) monododecyl ether 
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(C12EG4OH, nonionic surfactant); sodium dodecyl sulphate (SDS, anionic surfactant); dodecyl 
trimethyl ammonium chloride, (DTAC, cationic surfactant). Only DβM exhibited antibiofilm 
activity at tested concentration. Percent PAO1 biofilm remaining after 24 hours of inoculation 
with (110 μM) or without various generic surfactant. The percentages were obtained by 
comparing biofilm content of control (no agent) to biofilm content in presence of an agent. 
Bacteria were cultured in LB-media. Error bar is standard error of the mean from 4 replicates. 
 
3.2.2 Structure-activity relationship (SAR) for biofilm inhibition                                                                     
(a) Structure and size of sugar head group is critical for biological activity  
Initial screening of saccharide derivatives (SDs) at a concentration of 160 μM brought 
forward following SARs. Saccharide derivatives with a monosaccharide moiety and having a 
aliphatic chain of twelve carbons (glucose; DβG (8) and mono-rhamnoside; DαR (9)) had poor 
antibiofilm activities (Figure 3.4). In contrast to the poor potencies of monosaccharide 
derivatives (MSDs),  a SD having a disaccharide stereochemistry (maltose) and a twelve carbon 
aliphatic chain DβM (1) reduced the biofilm content by ~50% (Figure 3.4). Saccharide 
derivative with a large cyclicheptasaccharide moiety (β-cyclodextrin) and a twelve carbon 
aliphatic chain (DβCDS (18)  was incapable of exhibiting any biofilm inhibition, in fact this 
agent seemed to increase the biofilm content slightly (Figure 3.4). Therefore, amongst the 
various tested SDs, the one with a disaccharide stereochemistry seemed to work best at inhibiting 
the biofilm of P. aeruginosa at a concentration of 160 μM. 
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(b) Inhibition of Pseudomonas aeruginosa (PA) biofilm by disaccharide derivatives (DSDs) is 
sensitive to stereochemistry of the sugar head group  
Antibiofilm potencies of three different disaccharide derivatives (DSDs) each bearing a 
twelve carbon aliphatic chain with either lactose (Galβ(1→4)Glc, DβL (7); poor solubility in 
water), cellobioise (Glcβ(1→4)Glc, DβC (4)) or maltose (Glcα(1→4)Glc, DβM (1)) head group 
revealed that cellobiose stereochemistry, Glcβ(1→4)Glc out-performed other stereochemistries 
(Figure 3.4). While lactose stereochemistry severely compromised the antibiofilm activity, 
cellobiose stereochemistry exhibited ~ 62% biofilm inhibition. In general, cellobiose derived 
DSD compared better than those of maltose derived DSD having similar aliphatic chains (~46% 
biofilm inhibition activity). 
(c) Chain length of twelve carbons is optimum for observing maximum biofilm inhibition 
Inorder to evaluate the importance of aliphatic chain length, the aglycone moiety of SDs 
with cellobiose stereochemistry was systematically altered from 10 to 13 carbons. On comparing 
the effect of carbon chain length on biofilm inhibition activity, DSD with an aliphatic chain 
length of ten carbons, DeβC (2) was inactive, where as those with eleven UβC (3), and twelve 
TβC (5) carbons had moderate activity (29 % and 40 %, respectively), while DSD with twelve 
carbons DβC (4) exhibited best activity (62 % ) (Figure 3.4). This reliance of activity on 
aliphatic chain length of the chemical signal is also observed during quorum sensing, when each 
species is able to produce, secrete and recognize its own chemical signal based on the length of 
the aliphatic chain.
167,232
 In Gram-Negative bacteria, different species are able to distinguish their 
own chemical signal from that of others by recognizing the difference in the length of acyl side 
chain of acyl-homoserine lactone (AHL) auto inducers (chemical signals).
233-236
 Not surprisingly, 
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the AHL cognate receptor (LuxR type protein) is homologous amongst different species.
167,233
 
The optimization of DSD antibiofilm activity with aliphatic chain length of twelve carbons is 
therefore an indication of a ligand-receptor type of phenomenon. 
(d) Introducing short methyl branches off the main aliphatic chain enhanced the antibiofilm 
activity of DSDs greatly with low IC50 values (as low as ~9.9 µM) 
The effect of aglycone part of the DSD was further evaluated by introducing short methyl 
branches coming off the main aliphatic chain. This aliphatic chain was obtained by 
hydrogenating farnseol molecule (3,7,11-trimethyldodeca-2,6,10-trien-1-ol) to obtain saturated 
farnesol (3, 7, 11-trimethyl-dodecanyl) group. At 160 μM, DSDs with saturated farnesyl 
aliphatic chain and cellobiose head group, SFβC (12) and SFαC (13) were strong inhibitors (up 
to ~ 80% ) of P. aeruginosa biofilm (Figure 3.4). In an attempt to further optimize antibiofilm 
activity, DSDs bearing saturated farnesyl aliphatic chain and either maltose or lactose groups 
were synthesized (SFβM (14) and SFβL (15), respectively). Synthetic lactose analog exhibited 
poor solubility in water and hence was not tested for antibiofilm activity. But SFβM (14) at a 
concentration of 160 μM exhibited antibiofilm activity of around 60 % (Figure 3.4). Contrary to 
the enhanced antibiofilm activities of DSDs with saturated farnesyl chain, the antibiofilm activity 
of cellobiose based DSD with unsaturated farnesyl aliphatic chain FβC (11) was a meager ~12% 
(Figure 3.4).This decrease in antibiofilm activity when unsaturation is introduced into the 
aliphatic chain (leading to less bulky chain structure) was also consistent for another set of 
DSDs; i.e DβC (4) (62% inhibition) and UDβC (10) (13% inhibition) (Figure 3.4). Also, the 
effect of anomeric position of the aliphatic chain (from β to α) on biofilm activities was difficult 
to predict; for example at 160 μM, DβC (4) gave 62% inhibition where as to DαC (6) gave only 
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28% inhibition, but on comapring another set of anomers, i.e SFβC (12) and SFαC (13), SFβC 
(12) gave 76 % inhibition where as SFαC (13) gave 82 % inhibition (Figure 3.4).  
(e) Polyol-derivatized hydrocarbons with the alkyl chain having lipid-like structure are not 
potent antibiofilm agents 
Aliphatic chain with methyl branches seemed to enhance bioactivity, therefore the 
bulkiness of the aliphatic chain was further increased by attaching a 2-octyldodecyl chain, 
forming two lipid-like DSDs (2-ODβC (16) and 2-ODαC (17)). However, when tested at a 
concentration of 160 μM, this modifications lead to structures with poor antibiofilm activities 
(33% and 15%, respectively) (Figure 3.4). 
(f) At a concentration of 160 μM, rhamnolipids seemed to enhance biofilm production  
Since, SDs were able to mimic the swarming biofunction of rhamnolipids, and since 
rhamnolipids also help maintain biofilm architecture, a comparitive study between antibiofilm 
activities of SDs and rhamnolipids was also performed. At 160 μM of rhamnolipids the biofilm 
content seemed to increase (Figure 3.4).  
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Figure 3.4 Biofilm inhibition potencies of DSDs and rhamnolipids quantified by CV-dye 
based assay. Percent PAO1 biofilm remaining after 24 hours of inoculation with bacterial 
culture supplemented with (160 μM) or without various DSDs or with rhamnolipids. The 
percentages were obtained by comparing biofilm content of control (no agent) to biofilm content 
in presence of an agent. Bacteria were cultured in LB-media. Error bar is standard error of the 
mean from 4 replicates. 
3.2.3 Antibiofilm ability of certain DSDs were qualitatively assesed by performing a confocal 
microscopy assay 
The antibiofilm activities of five DSDs, SFβC (12), SFαC (13), DβC (4), DeβC (2) and 
DβL (7) were also qualitatively validated by using confocal laser scanning microscopy (CLSM) 
to measure the amount of fluorescent bacteria, PAO1-EGFP adhered on stainless steel coupons 
grown in LB-media for 24-h supplemented with either of the five DSDs.
237
 The CLSM 
micrographs (Figure 3.5) showed that 160 μM of SFβC (12), SFαC (13) and DβC (4) decreased 
the fluorescence signal significantly as compared to the steel coupon placed in just LB-media. 
This decrease in fluorescence signal by three DSDs indicated a lesser bacterial cell density on the 
surface of the steel coupons as compared to control steel coupon. The mean thickness of biofilm 
obtained from Z-stacked images showed a much thinner biofilm coverage on steel coupons 
placed in media containing 160 μM of SFβC (12), SFαC (13) and DβC (4). In contrast, with 160 
μM of DeβC (2) or DβL (7), biomass surface coverage had similar thickness as that of control 
without the agents. These fluorescence results were consistent with the results of CV-dye based 
assays for biofilm inhibition. 
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Figure 3.5 Biofilm inhibition activities of DSDs was also validated qualitatively by a 
confocal fluorescence based biofilm assay. Steel coupons inoculated with PAO1/EGFP for 24 
h with (~160 μM) or without various disaccharides derivatives (DSDs). After 24-h, the steel 
coupons with biofilms were viewed under confocal laser scanning microscope (CLSM). Scale 
bar ~ 76 μM. Reduced fluorescence due to the presence of DSDs (in comparison to the Control) 
indicates lesser amount of biofilm on the steel coupons.  
3.2.4 Rhamnolipids antibiofilm activity increases and then decreases with increasing doses 
exhibiting an “activity reversal”  
 The antibiofilm activities of those DSDs that exhibited >50% inhibition at 160 μM along 
with rhamnolipids extract were further probed in a concentration dependent manner to obtain the 
half-maximal inhibitory concentrations (IC50) of these agents (Figure 3.6). As concentration of 
SFαC(13)SFβC (12)
No agent
76 μM
DβC (4)
DβL (7) DeβC (2)
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rhamnolipids were increased, the antibiofilm activity initially increased and then declined 
sharply tracing a bell shaped or an “activity reversal” profile. The antibiofilm activity of 
rhamnolipids increased gradually to a maximum value of ~65% at a concentration of 42 μM 
followed by decrease to 46% at 85 μM and then to -14% at 160 μM with respect to biofilm 
formed in control. The unusual “activity reversal” profile of rhamnolipids observed during 
antibiofilm assays was also observed during a dose dependent study with many SDs and 
rhamnolipids itself during swarming assays. The unusual dose dependent bell shaped graph of 
rhamnolipids prevented calculation of its IC50. Rhamnolipids is a glycolipids and another lipid-
like molecule included in this study was 2-ODβC. Consistently, the antibiofilm activities of both 
these lipid-like structures at relatively higher concentration (160 μM) is rather low. However, 
unlike the bell-shaped profile of swarming dose-dependence, none of the four DSDs, SFβC (12), 
SFαC (13), SFβM (14) and DβC (4) exhibited any "activity reversal". Instead, the biofilm 
inhibition of these four DSDs increased over a concentration range and then leveled off at a 
particular maximum value. The calculated half maximum inhibitory concentrations (IC50s) of the 
four DSDs were; ~9.9 μM for SFβC (12); ~ 32 μM for SFαC (13); ~72 μM for DβC (4); and 
~102 μM for SFβM (14). The dose-dependence study demonstrates SFβC (12) is more potent 
antibiofilm agent than rhamnolipids at all the tested concentrations. This antibiofilm dominance 
over rhamnolipids is also shown by the other three DSDs, SFαC (13), SFβM (14) and DβC (4) 
but only at concentrations higher than 42 μM. The low IC50 values of the four DSDs are 
comparable to some of the most powerful synthetic agents that have been reported to 
nonmicrobicidally inhibit P. aeruginosa biofilm.
115,213
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Figure 3.6 Disaccharide derivatives' (DSDs) and rhamnolipids' dose-response curves for P. 
aeruginosa (PAO1) biofilm inhibition. The biofilm was allowed to form with increasing 
concentrations or without agents for 24-h old biofilm and then quantified by staining with crystal 
violet (CV) dye. The images on the right show the CV-dye stained biofilms formed on the wells 
of the microtiter plate for each agent and each concentration tested. Error bar is standard error of 
the mean from 4 replicates. 
3.2.5 Strong biofilm inhibitors were also good biofilm dispersers 
Both in industrial and medical settings one commonly encounters biofilms that have 
already formed and dispersing these preformed biofilms is usually a daunting task. Therefore, 
while discovering agents that prevent onset of biofilm formation is important, identifying agents 
that are able to disperse preformed biofilms is more critical from application 
standpoint.
80,115,238,239
 With this objective in mind, the ability of DSDs to disperse 24-h old PAO1 
biofilm was evaluated. In general (with a few exceptions), the dispersing activities of the DSDs 
displayed an overall similar trend as the SAR for biofilm inhibition (Figure 3.7). When tested at 
a concentration of 160 μM against 24-h old biofilms, the agents with good antibiofilm activities, 
SFβC (12), SFαC (13), SFβM (14) and DβC (4) also displayed good biofilm dispersing abilities 
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(>60% dispersion as compared to control). At 160 μM, the rest of the DSDs barring DβCDS (18) 
had biofilm dispersion activities ranging between 20-60%. The saccharide derivative, DβCDS 
(18) was unique as it was the only tested agent that seemed to increase biofilm content when it 
was added to a 24-h old biofilm.  
 
Figure 3.7 Biofilm dispersion potencies of DSDs and rhamnolipids quantified by CV-dye 
based assay. PAO1 biofilms were grown in microtiter plates without agents for 24-h in LB-
media and then fresh LB-media supplemented with various DSDs or rhamnolipids (160 μM) was 
added. The percent PAO1 biofilm remaining after inoculating for another 24 hours with (160 
μM) or without various DSDs or rhamnolipids were calculated by comparing biofilm content of 
control (no agent) to biofilm content in presence of an agent. Error bar is standard error of the 
mean from 4 replicates. 
3.2.6 The potent DSDs strongly dispersed the preformed biofilm of P. aeruginosa while 
rhamnolipids could not 
The moderately active antibiofilm rhamnolipids were not able to display much dispersing ability 
against 24-h old biofilms. The highest biofilm dispersion activity of 34% displayed by 
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rhamnolipids was at a concentration of 42 μM beyond which the activity continuously dropped 
(only 17% dispersion at 85 μM) (Figure 3.8). Contrasting the poor dispersive bioactivity of 
rhamnolipids, the dispersion dose-response curve of three active DSDs, SFβC (12), SFαC (13) 
and SFβM (14) brought forward structures that exhibited half-maximal dispersion concentration 
(DC50) values that compare favorably to known dispersive agents of Pseudomonas aeruginosa 
biofilm.
80,115
The DC50s calculated for SFβC (12) was ~44 μM, for SFαC (13) was ~89 μM and 
for SFβM (14) was ~126 μM. 
 
Figure 3.8 Disaccharide derivatives' (DSDs) and rhamnolipids' dose-response curves for 
dispersion of 24-h old P. aeruginosa (PAO1) biofilms. PAO1 biofilms were grown in 
microtiter plates without agents for 24-h in LB-media and then fresh LB-media supplemented 
with various DSDs or rhamnolipids was added at different concentrations. The percent PAO1 
biofilm remaining after inoculating for additional 24 hours with or without various DSDs or 
rhamnolipids was calculated by comparing biofilm content of control (no agent) to biofilm 
content in presence of an agent. Error bar is standard error of the mean from 4 replicates. 
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3.2.7 Some DSDs and even rhamnolipids reduce the initial adhesion of bacteria to a polystyrene 
surface 
Adhesion of bacteria to biotic surfaces is usually the first step of infection; the first step of 
biofouling on abiotic surfaces is also the initial attachment of bacteria. Therefore, agents that 
prevent this initial attachment of bacteria to surfaces offer potential therapeutic and industrial 
benefits. To evaluate the DSDs' bacterial adhesion inhibition potencies, a mutant strain of P. 
aeruginosa that constitutively expresses green fluorescent protein (PAO1-EGFP) was inoculated 
for 2 hours in LB media with (160 μM) or without various SDs or rhamnolipids. After the initial 
adhesion period, the amount of fluorescent bacteria (PAO1-EGFP) adhered on the surface was 
quantified by measuring the fluorescence at 510 nm. With the exception of two DSDs, DαR (9) 
and DβCDS, the overall SAR trend of bacterial adhesion inhibition was consistent with the trend 
obtained from biofilm inhibition (Figure 3.9). Another disparity between biofilm inhibition and 
bacterial adhesion inhibition was the activity of rhamnolipids, while at 160 µM exhibited 
negative biofilm inhibition, it showed 39% inhibition of bacterial adhesion. The DSDs that had 
good biofilm inhibition and dispersion activities, also displayed good bacterial adhesion 
inhibition potencies including 77% for SFαC (13), 66% for SFβC (12),  and 70% for SFβM 
(14). 
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Figure 3.9 Percent bacterial adhesion inhibition potencies of the various DSDs and 
rhamnolipids. Percent PAO1-EGFP remaining adhered on the wells of polystyrene microtiter 
plate after 2 hours from inoculation with bacterial culture supplemented with (160 μM) or 
without various DSDs or with rhamnolipids. Fluorescent signal emitted by the bacteria (PAO1-
EGFP) at 510 nm was quantified to measure the amount of bacteria on the surface. The 
percentages were obtained by comparing PAO1-EGFP content of control (no agent) to PAO1-
EGFP content in presence of an agent.  Error bar is standard error of the mean from 4 replicates. 
3.2.8 Bioactivities of DSDs depend on structural details 
Important results from activation of swarming (Chapter 2), inhibition (IC50) and dispersion 
(DC50)  of biofilm (Chapter 3) are summarized in Table 3.1. Analyzing this data reveals that 
potent antibiofilm DSDs (SFβC (12)  & SFβM (14) having low IC50 and DC50) generally 
activated the swarming of the rhlA mutant at a relatively lower concentration than DSD that had 
poor antibiofilm activities (TβC (5) and DβG (8). Also, the potent antibiofilm DSDs were the 
only agents that exhibited dominance over rhamnolipids during swarming motilities. While 
others have shown that under natural settings, rhamnolipids help maintain biofilm architecture of 
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P. aeruginosa,
240
 the results in this study showed that adding low concentration of rhamnolipids 
externally inhibits biofilm formation. The addition of rhamnolipids externally into the growing 
media could add to the in situ secreted rhamnolipids that the bacteria secretes, hence the local 
concentration of this biosurfactant may increase dramatically, leading to a possible washing 
effect on the biofilm. The dose-response curves of rhamnolipids depicts "activity reversal" for 
both swarming activation and biofilm inhibition. This a first documentation for the effect of 
different concentrations of rhamnolipids on biofilm formation and swarming. The "activity 
reversal" phenomenon has been noticed earlier by others while studying concentration effects of 
bacterial signalling molecules on light simulation (another bacterial multicellular behavior). The 
reversal in antibiofilm activity at higher doses of rhamnolipids underscores the chances of this 
being a physical phenomenon because the surface activity should only increase with higher 
doses.  
3.2.9 A more stringent structural requirement on DSD is needed for controlling biofilm 
formation than for controlling swarming motility 
Some structures that activated rhlA swarming motility including DeβC (2), UβC (3), DβG (8) 
and TβC (5) exhibited poor antibiofilm activities. On the contrary some structures including 2-
ODβC (16) and DαR (9) had poor antibiofilm capabilities but seemed to effectively inhibit the 
swarming process of wild type PAO1. However, the DSDs that had good antibiofilm activities 
like SFβC (12), SFαC (13) and SFβM (14), were generally strong inhibitors of PAO1 swarming. 
Thus, the structure-activity relationships (SAR) indicate that poor antibiofilm agents do not have 
a predictive effect on swarming, whereas effect of good antibiofilm agents on swarming was 
generally predictive. The SAR also revealed that combination of certain glycone and aglycone 
elements generally generated DSDs with poor capabilities to modulate both swarming and 
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biofilm formation. These elements include short aliphatic chain, DeβC (2), aliphatic chains with 
unsaturation, UDβC (10) and FβC (11), sugar head groups that are either small 
monosaccharides, DβG (8) and DαR (9) or large cyclic oligosaccharide, DβCDS (18). Together, 
these results suggest that the swarming motility, bacterial adhesion and biofilm formation are 
intertwined together, and designs of disaccharide derivatives can control selectively some or all 
of these three biological activities.  
Table 3.1. Transition concentrations of DSDs that exhibit activity reversal from activating to 
inhibiting swarming motilities of the rhlA mutant and PAO1, and IC50 and DC50 of DSDs for 
PAO1 biofilm inhibition and dispersion. Antibiofilm activities (inhibition & dispersion) at 160 
µM of various agents. 
Compound  
a 
Transition 
concentration 
(rhlA)  
b 
Transition 
concentration 
(PAO1) 
IC50  
(PAO1) 
DC50 
(PAO1) 
Antibiofilm activity  
160 µM (PAO1)  
Inhibition      
Dispersion 
Rhamnolipids  ~10 μM  ~20-30 μM  
c 
-- 
d 
-- -14%
 
13%
 
 SFβM (14)  ~10 μM  ~7.5 μM  ~102 μM ~126 μM 60% 60% 
 SFβC (12)  ~8 μM  ~10-20 μM  ~9.9 μM ~44 μM 76% 60% 
 DβC (4)  
e 
~45-56 μM
 
 ~20-30 μM  ~72 μM 
d
 -- 62% 60% 
 TβC (5)  ~40 μM  ~20-30 μM  
d 
-- 
d 
-- 40% 43% 
 DβG (8)  ~35-50 μM  ~50-60 μM  
d 
-- 
d 
-- 46% 50% 
SFαC (13) 
d
-- 
d
-- ~32 μM ~89 μM 82% 77% 
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a
From activating to inhibiting swarming motility of the rhlA mutant. 
b
From promoting to 
inhibiting swarming motility of PAO1; 
c
rhamnolipids exhibits “activity reversal,” IC50 was not 
calculated; 
d
not determined, weak antibiofilm activities  
3.2.10 DSDs do not interfere with the known las and rhl quorum sensing circuits of P.aeruginosa 
The onset of multicellularity in bacteria is controlled by quorum sensing.
39
 For this quorum 
sensing process, bacteria use small molecule chemical signals to communicate with one another. 
Therefore, one effective antibiofilm strategy is to make use of chemical mimics of quorum 
sensing molecules that interfere with cellular communication and hence disrupt biofilm 
formation.
115,213,241
 To identify antagonists for the two quorum sensing circuits of P. aeruginosa, 
las and rhl, gene reporter assays were constructed for reporting activation or suppression of such 
systems.
171
 In this assay, the plasmids, plasI-LVAgfp and prhlI-LVAgfp were transformed into 
the wild type strain PAO1
115,242
 to report activity against the las and rhl systems, respectively. 
Natural autoinducers N-3-(oxododecanyoyl)-L-homoserine lactone (PAI-1) and N-(butyryl)-L-
homoserine lactone (PAI-2) bind the las and rhl gene product, respectively, resulting in 
expression of green fluorescent protein (GFP) encoded by the plasmids. Agents that antagonise 
the las or rhl system, will have to compete with the naturally secreted autoinducers and as such 
cause a decrease in the expression of GFP.
167
 When two potent antibiofilm agents, SFβC (12) 
and SFαC (13) were tested for antagonistic activity against the two reporter strains, PAO1/ 
plasI-LVAgfp and PAO1/ prhlI-LVAgfp, both agents did not seem to change the expression of 
GFP (Figure 3.10). Hence, these agents do not interfere with either the las or the rhl quorum 
sensing circuit of P. aeruginosa. 
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Figure 3.10 Gene-reporter assay with two reporter strains of Pseudomonas aeruginosa, 
PAO1/plasI-LVAgfp and PAO1/prhlI-LVAgfp, showed that DSDs did not interfere with 
either the las or the rhl quorum sensing systems. Fluoresence (GFP) signal by PAO1 having 
plasmid; (A) plasILVAgfp and (B) prhlILVAgfp in the absence and in the presence of SFαC 
(13) and SFβC (12). Fluorescence signals were corrected for cell density by dividing with OD600 
of bacterial cell culture. Errors bar is a standard error of the mean of the readings from 4 
replicate wells. 
3.2.11 Competitive biofilm inhibition assay with one DSD and synthetic pili peptide reduced 
antibiofilm potency of the DSDs 
 The involvement of pili in promoting the swarming motility of P. aeruginosa has been 
documented by Kohler and coworkers.
123
 Randall and coworkers have shown that the receptor 
domain on pilin protein that recognizes carbohydrate moieties on tissues cells is a 17-amino acid 
residue on the C-terminal region (residues 128-144). This 17-amino acid residue has been shown 
to be semi-conserved amongst various strains of P. aeruginosa with two specific conserved 
cysteines (at position 129 and 142) in all strains being oxidized to form a di-sulfide loop.
229
 
Randall and workers have also shown that both the pilin receptor domain and it's synthetic 
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peptide is also critical for enabling bacteria to adhere onto abiotic surface.
183,225,243
 To date the 
minimum binding carbohydrate epitope that binds both the pilin receptor domain and it's 
synthetic peptide has been shown to be D-GalNac(14)-β-D-Gal moiety.
199,244
 The pili assisted 
epithelial cell binding domain is located between residues 128-144 on the C-terminal region of 
PilA, the pili structural protein.
229
 To explore the identity of the putative receptor for such DSDs 
and rhamnolipids, the minimum seventeen amino acids residues receptor domain (N -Ac-
AC ST DPMFTP GCDN-OH-C ')
245,246
 of P. aeruginosa strain PAO was synthesized via a 
solid phase strategy. In order to replicate the disulfide loop formed by natural receptor domain, 
the synthesized pili peptide was subjected to oxidizing conditions to oxidize the cysteines at 
positions 129 and 142 to form a intra-molecular disulfide loop (called as pili peptide henceforth). 
To serve as a control a scrambled (N-Ac-AA ST DPMFTP GADN-OH-C ') version of the pili 
peptide was also synthesized where in the cysteines at positions 129 and 142 position were 
exchanged to alanines (here in referred to as scrambled pili peptide). Both the synthetic peptides 
were tested along with a potent antibiofilm DSD, SFαC (13) at concentration of 85 μM in a 
competitive antibiofilm assay against wt P. aeruginosa (PAO1) (see Figure 3.11). The DSD, 
SFαC (13) by itself exhibited ~70% biofilm inhibition, but when 85 μM of pili peptide was 
added along with 85 μM of SFαC (13), the antibiofilm activity of the DSD dropped to only 
~30% inhibition. Contrary to the effect of pili peptide, when 85 μM of both SFαC (13) and the 
scrambled pili were added to the culture, DSD still seemed to inhibit close to 65% of the biofilm. 
These results suggest that the synthetic pili peptide likely interferes with the binding between the 
the DSD SFαC (13) and the natural pili receptor domain on the bacteria, whereas the scrambled 
version of the synthetic pili peptide had little interference. 
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Figure 3.11 Crystal violet (CV) stained PAO1 biofilm within the wells of the microtiter plate 
after biofilm was allowed to develop for 24 hours in LB-media without any agents and in LB-
media that is supplemented with SFαC (13) ~85 μM; SFαC (13) ~85 μM + Pili peptide ~ 85 μM; 
SFαC (13) ~85 μM + Scrambled pili peptide ~ 85 μM; Pili peptide ~ 85 μM; Scrambled pili 
peptide ~ 85 μM. 
3.2.12 Mechanistic understanding 
         Biofilm inhibition  and swarming results brought forward some key mechanistic points. 
Rhamnolipids are amphiphilic molecules and their role in biofilm formation and swarming has 
always been debated to either be biological or physical. 
204 
 Similarly, the effects on biofilm 
formation and swarming by various DSDs, which are amphiphilic in structure could have been 
hypothesized to either mere washing effect due to surfactant properties (physical) or biological in 
which a receptor on bacterial surface may bind to these molecules leading to either an 
antagonistic or an agonistic signaling event. However, few results in this study clearly suggested 
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that the effects by both rhamnolipids and DSDs on the various bioactivities of  P. aeruginosa are 
probably of biological nature. Firstly, generic surfactants that lacked amphiphilic structure with 
sugar head group (C12EG5OH , DTAC and SDS) exhibited no effects on biofilm formation and 
swarming, but DβM (1) possessing a maltose head group activated swarming as well as inhibited 
biofilm formation.
247
 Secondly, bioactivities of each DSD were sensitive to its structural details. 
Thirdly, swarming activation reversal caused by increasing concentrations of both rhamnolipids 
and the active DSDs indicated a trait of a cell-signaling molecule. A similar concentration 
dependent activity reversal has been reported before for N-(3-oxohexanoyl)-3-aminodihydro-
2(3H)-furanone molecule, which was eventually identified as a bacterial signaling molecule.
120
  
The gene reporter assays showed that neither of the two quorum sensing circuits of P. 
aeruginosa were perturbed by the two most active DSDs, SFβC (12) and SFαC (13). 
Preliminary studies indicate that the receptor of such DSDs and also rhamnolipids maybe the cell 
surface adhesins, pilin protein. 
3.3 Conclusion  
The SAR brought forward specific structural elements that were important for imparting 
potent bioactivities to disaccharide derivatives (DSDs). The DSDs with either cellobiose or 
maltose stereochemistries having a bulky aliphatic tail, 3, 7, 11-trimethyl-dodecanyl were both 
good inhibitors of P. aeruginosa adhesion and biofilm formation and also potent dispersers of 
pre-formed (1-day old) biofilm. Making structural changes on DSDs revealed that alteration in 
the disaccharide stereochemistry produced lesser variation in bioactivity than changes made to 
the aglycone part of the molecule. From previous chapter (Chapter 2), it was evident that the 
most active DSDs and also rhamnolipids caused a swarming activation at lower concentrations 
followed by a reversal in swarming activation at higher concentrations for the rhlA mutant. 
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Contrary to the effect on swarming, the concentration studies with most active DSDs for biofilm 
inhibition and dispersion showed that the bioactivities plateaued off at higher concentrations with 
no indication of reversal. However, in a dose-dependent study with the naturally secreted 
molecule rhamnolipids being added externally for dispersion assay showed an activity reversal 
phenomenon. Surfactant action associated with amphiphilic structures like DSDs and 
rhamnolipids was shown to be less likely to cause such biological events. These DSDs did not 
perturb the known las and rhl quorum sensing circuits of P. aeruginosa. Therefore, the mode of 
action of such amphiphilic molecules is through a yet to be identified pathway. Preliminary 
studies showed that these molecules could be recognizing the adhesin protein pilin present on P. 
aeruginosa pili appendage. The search for putative receptor/s for such DSDs molecules and also 
rhamnolipids is ongoing. Importantly, the ability of such DSDs molecules to control P. 
aeruginosa motile lifestyle, i.e adhesion, biofilm formation and dispersion and also motile 
behavior, i.e swarming, while at the same time being nonmicrobicidal to the growth of the 
bacteria offers a viable alternative strategy to fight bacteria related problems with lower 
propensity to cause multi-drug resistance (MDR).  
3.4 Materials and methods   
Bacterial strains and plasmids. Pseudomonas aeruginosa strains PAO1 and PAO1-EGFP were 
obtained from Dr. Guirong Wang (Upstate Medical University). Pseudomonas aeruginosa 
transposon mutant strain PW6886 (rhlA-E08::ISphoA/hah) was obtained from two-allele 
library.
202
 PAO1 (plasI-LVAgfp), PAO1 (prhlI-LVAgfp) strains were prepared by literature 
reported protocol.
214
 The plasmid plasI-LVAgfp and prhlI-LVAgfp were obtained from Dr. 
Hiroaki Suga (The University of Tokyo) and were maintained by adding 300 μg/mL of 
carbenicillin in culture media. Freezer stocks of all strains were stored at -80 
o
C in LB media 
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with ~20% glycerol. All strains were grown at 37 
o
C in a rotary-shaker (at 250 rpm) in Luria 
Bertini (LB) media (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl). All biofilm 
inhibition, dispersion and adhesion assays were performed in LB-media and plates were 
incubated at 37 
o
C under static conditions.   
Stock solution and delivery of disaccharide derivatives (DSDs). All but three saccharide 
derivatives were water-soluble. For the water soluble DSDs, no organic solvents were used to 
assist the mixing and delivery for all biological assays. Stock solution (~11.5 mM) of DSDs were 
prepared in autoclaved water and further sterilized by filtering through cellulose acetate syringe 
filter (0.2 µm pore size, GVS filter technology) into sterilized vials. The sterilized DSDs stock 
solutions were stored at -20 °C and thawed prior to each use. Aliquots of DSD stock solutions 
were added to the cultures in wells. Sterile water (same volume as the DSD stock solution used) 
was used as positive controls (no agents) in all assays to eliminate the effect of water from the 
stock solution. Three agents DβL (7), SFβL (15) and 2-ODαC (17) exhibited low water 
solubility, and were prepared in mixed solution of sterile water (90%) and 200 proof  EtOH (10 
%). Controls for these agents consisted of the same mixed water-ethanol solution.  
Crystal violet (CV) dye based-biofilm inhibition assay.
213,214
 Overnight culture of PAO1 were 
sub-cultured in LB media to obtain an OD600 of 0.01, and further cultured to reach an OD600 of ~ 
0.1. The bacterial culture (200 μL) was added into the wells of a microtiter plate, followed by 
predetermined volumes from DSDs stocks. The microtiter plate was then wrapped in GLAD 
Press n’ Seal® (Saran wrap) and further incubated under stationary conditions for 24 h at 37 °C. 
After incubation, the culture media was discarded by careful pipetting, and the wells were 
washed once with 200 μL sterile water and the plate was dried at 37 °C in the incubator for 30 
mins. Surface attached biofilms in the wells were then stained with 200 μL of 0.1% aqueous 
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solution of crystal violet (CV) for 30 mins at ambient temperature.  The CV stain was then 
removed by pipetting, and each well was washed with 200 μL sterile water. The resulting surface 
attached CV stain in the wells was then solubilized by adding 100 μL of 30 % AcOH solution (in 
water) and mixing gently by pipetting. Adding 100 μL of 30% AcOH solution only solubilizes 
the biofilm attached to the bottom of the well surface (termed as “surface attached biofilm”)
115
 
and not the “liquid-air interface” biofilm that is formed at the interface of culture media (200 μL) 
and air. The amount of biofilms were inferred and quantified by measuring absorption at 600 nm 
(OD600.) of the AcOH solution. A negative control that contained only the media without 
bacterial inoculum and without agents was also stained. The OD600 values of the negative control 
were subtracted from the OD600 values of the wells containing bacteria and treated with DSDs. 
The difference in OD600 values of wells with DSDs and wells with no agent (positive controls) 
was divided by the OD600 value of control to obtain percent biofilm inhibition. 
Antiadhesion assay.
247
 Overnight culture of PAO1-GFP (supplemented with 300 μg/mL of 
carbenicillin) in LB medium was sub-cultured (250 rpm and 37 °C) to an OD600 of 0.01.  When 
the OD600 of the sub-culture reached ~ 0.1, 200 µL aliquot of the sub-culture was transferred to 
the wells of 96-well black microtiter plate, followed by designated volumes of DSD stock 
solutions  to achieve desired concentrations of DSD. Positive controls used sterile water in place 
of DSD stock solution. The black microtiter plate was wrapped by Saran wrap (GLAD Press n’ 
Seal®) and incubated at 37 °C for 2 h. The bacterial culture was then discarded by pipetting, and 
each well was washed once with saline water (0.85 w/v% aqueous NaCl). Aliquot of  fresh LB 
medium (200 μL) was then added into the wells and the fluorescence was measured at an 
excitation wavelength of 500 nm and an emission wavelength of 540 nm by using Synergy 2 
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multi-mode microplate reader with Gen5 data analysis software. The absorption from wells 
containing just LB medium was subtracted from wells treated with DSDs.    
Confocal laser scanning microscopy (CLSM) based biofilm inhibition assay. Steel coupons 
(316L, thickness 0.012  , 1 in. × 1 in.) were washed with EtOH, dried under a stream of nitrogen 
and then sterilized in an autoclave. Overnight culture of PAO1/EGFP (OD600 ~ 1.0) grown in LB 
media (supplemented with 300 μg/mL of carbenicillin), was sub-cultured to OD600 ~ 0.01, and 
further cultured to an OD600 of ~ 0.1. Aliquots  of 600 μL PAO1/EGFP subculture was added 
into the wells of a 24-well microtiter plate, followed by 9 μL of stock solutions of DSDs to 
obtain the concentration of 160 μM. Bacterial sub-culture with no agent served as positive 
controls. Sterile steel coupouns were then placed into the wells and the plates were wrapped with 
Saran wrap and incubated for 24 h at 37 ⁰ C under static conditions. The steel coupons were then 
removed and washed by dipping in PBS buffer twice and then gently dabbed on a bleached paper 
(KIM wipes) to remove the excess solution. The dried steel coupons were viewed under a 
confocal laser scanning microscope (CLSM). Images were taken at 4 random locations on each 
steel coupon.  The Z-stacked images were also taken to determine the relative thickness of the 
biofilm. 
Biofilm dispersion assays. Crystal violet dye-based assay for quantifying dispersion of 1-day 
old PAO1 biofilms were similar to the biofilm inhibition assay. Wells of the microtiter plate 
were inoculated with 200 μL PAO1 subculture (OD600 ~ 0.1). The plates were incubated at 37 
o
C 
for 24 hours to allow biofilm formation. After 24 hours, bacterial culture was gently pipetted out 
and predetermined volumes of DSDs were added followed by addition of 200 μL of fresh LB 
medium. The microtiter plate was then incubated for an additional 24 hours at 37 
o
C. The amount 
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of the biofilm in the wells was measured using the same procedures for biofilm inhibition assays 
with the same control solutions.  
Dose dependence assays for biofilm inhibition and dispersion. Disaccharide derivatives 
(DSDs) that were most potent at 160 μM (exhibiting  > 60 % biofilm inhibition and dispersion) 
were selected for determining the dose dependence. For both biofilm inhibition and dispersion 
assays, predetermined volumes of DSD stock solutions were added to the assigned wells to 
achieve a concentration between 0.5 to 170 μM. Percent biofilm inhibition of dispersion was 
calculated by dividing the difference in biofilm content (absorbance at 600 nm, OD600) between 
wells with DSDS and control wells (no agents) by biofilm content of controls. The percent 
biofilm inhibition or dispersion was plotted versus the concentrations of DSDs. The graph was 
curve fitted using equation y = mln (x) + C, where y is % of inhibition (or % dispersion) and x is 
the concentration. The half maximal inhibitory concentration for both biofilm inhibition and 
dispersion (IC50 and DC50) were obtained by solving for y = 50. 
Synthesis of oxidized pili peptide PAO(128-144)ox and scrambled pili peptide 
PAO(C129A/C142A)Scrambled. Synthesis of the peptides were done according to previously reported 
procedure.
199
   Fmoc-based solid phase peptide synthesis was used and the purification was done 
by reversed-phase high performance liquid chromatography (HPLC). Air oxidation was 
employed to oxidize the two cysteines residues in PAO(128-144) sequence to generate a di-sulfide 
linkage. For this a dilute solution (6mg/ 4mL) of unoxidized pili peptide was made PBS buffer 
(pH ~7.8) containing 10 % DMSO, and solution was stirred in air and monitored by reversed 
phase HPLC and MALDI-TOF. Following the oxidation of pili peptide, purification was done 
over reverse phase HPLC. PAO(128–144)ox sequence is N’Ac-A-C-K-S-T-Q-D-P-M-F-T-P-K-G-C-
D-N-OH-C’. While for generating scrambled pili peptide, cysteines at positions 129 and 142 
 
169 
 
were replaced with alanines to generate the following sequence; PAO (C129A/C142)Scrambled; N’Ac-
A-A-K-S-T-Q-D-P-M-F-T-P-K-G-A-D-N-OH-C. 
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Chapter 4 
Synthetic Disaccharide Derivatives Inhibit the Biofilm Formation of Candida albicans by 
Preventing Hyphal Adhesion 
Abstract 
Disaccharide derivatives (DSDs) with either cellobiose or maltose head groups and 
having either n-alkyl, farnesyl, hydrogenated farnesyl or 2-octyl dodecyl aliphatic chains were 
used to nonmicrobicidally inhibit biofilm formation of Candida albicans. The tested DSDs did 
not inhibit the growth of either fungal blastospores or hyphae. Microscopic evaluation showed 
that none of the tested DSDs (except FβC (1) prevented hyphal germination. The DSDs were 
only effective at inhibiting the biofilm of Candida albicans when applied within five minutes of 
seeding the test surface with fungal cells. The half-maximal inhibitory concentrations (IC50s) of 
14.7 and 21.5 μM for some DSDs like saturated farnesyl-β-maltoside (SFβM, 6) and 2-octyl 
dodecyl-β-cellobioside (2-ODβC, 7), respectively are comparable to IC50s of known 
nonmicrobicidal agents that inhibit Candida albicans’ biofilm. Tri(ethylene glycol) terminated 
self-assembled monolayers (SAMs) on gold surface are able to resist Candida albicans hyphal 
adhesion where as pentadecanethiol SAMs allow hyphal adhesion. Using a modified gold 
surface that contained patterns of pentadecanethiol SAMs surrounded by regions of tri(ethylene 
glycol) terminated SAMs it was shown that in a media that supports hyphae formation (RPMI-
1640), addition of one DSD, saturated farnesyl-α-cellobioside (SFαC, 5) dramatically reduced 
the adhesion of Candida albicans hyphae onto the pentadecanethiol SAMs. It is therefore 
predicted that, the DSDs’ ability to prevent initial adhesion of Candida albicans hyphae 
translates into their ability to inhibit biofilm formation.  
 
171 
 
4.1 Introduction 
Both bacteria and fungi can reside harmoniously in the same environment including on 
mucosal surfaces like skin, the oral cavity, and the gastrointestinal tract.
248
 The co-colonization 
of bacteria and fungi is particularly common in the respiratory tracts of chronic lung-diseased 
patients. A number of pathogenic fungi like, Candida,
249
 Aspergillus,
250
 Cryptococcus,
251
 
Trichosporon,
252
 Coccidioides,
253
 and Pneumocystis
254
 have been identified as biofilm dwellers. 
Importantly, the biofilms of these pathogenic fungi have been reported to display severe to mild 
resistance against the common antifungals like, fluconazole, amphotericin B, nystatin, and 
voriconazole. In the United States alone, an estimated ~$2.6 billion dollars is spent being 
annually to treat fungal related hospital nosocomial infections.
255
 Unfortunately, the increase in 
the occurrence of fungal biofilm within medical settings parallels the rapid increase in the use of 
more number of medical devices and implants. The most common fungal commensal known to 
infect medical equipments is Candida albicans.
256,257
 The opportunistic pathogen Candida 
albicans is the most common fungi associated with hospital acquired infections, particularly on 
medical devices, implants, tissue surfaces, oral and vaginal mucosal epithelial cells. 
258,259
 
Presently, the approximate mortality rate for device related Candida albicans infections in the 
United States is about ~30%.  
4.1.1 Biofilm development in Candida albicans involves morphogenesis                                                 
Candida albicans is a dimorphic fungi that exhibits at least two kinds of morphological cells, 
budding blastospores and filamentateous hyphae. The onset of fungal biofilm progresses through 
various stages, similar to the step-by-step biofilm formation process exhibited by bacteria. One 
important difference between bacteria and fungus, is that upon surface attachment fungal cells 
known as blastospores form filamentous structures known as hyphae that invade into the surface, 
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where as biofilm dwelling bacterial cells do not show any such morphogenesis. The next step in 
biofilm progression is secretion of extracellular matrix which coincides with acquisition of drug 
resistance. Under normal biofilm progression, small oval shaped yeast cells, blastospores first 
form germ tubes that give rise to pseudohyphae and ultimately tubular hyphae.
260
 The existence 
of dimorphic cells (blastospores and hyphae)  within fungal biofilms was confirmed via the 
genetic studies done by Finkel et al.
255
 Douglas et al, showed that dimorphic morphogenesis was 
true under both natural and laboratory settings (Figure 4.1).
261
 The final step in Candida 
albicans’ biofilm development is the release of yeast cells to initiate colonization of newer 
surfaces. It has been reported that the biofilm development in Candida albicans is under genetic 
control and many such genes may display opposite regulation depending upon which step of 
biofilm is involved i.e. formation or dispersion.
255
  
             
Figure 4.1 Dimorphic nature of Candida albicans where both blastospores and hyphae co-
exist is evident in both (a) in vitro and (b) in vivo biofilm.The scanning electron microscopic 
(SEM) micrographs of in vitro biofilm (a) shows lower region comprising of blastospores, 
middle region containing mainly hyphae and an upper region consisting of both hyphae and 
blastospores. The in vivo biofilm sample obtained from a rat catheter model (b) shows a mixture 
of blastospores and hyphae. [Reprinted with permission from Citation:
8
 Finkel, J. S.; Mitchell, A. 
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P., Genetic control of Candida albicans biofilm development. Nature Reviews Microbiology 
2011, 9, (2), 109-118]. 
4.1.2 Farnesol is the key quorum sensing molecule 
The occurrence of cell-to-cell communication via secretion of various chemical signals 
during biofilm formation by bacteria has been well documented.
41,155-157,166,167,262,263
 Similar 
cellular communication process through the use of chemical signals has also been reported in 
many fungal species.
264
 The first autoregulatory molecule that was identified to play a crucial 
role in Candida albicans signaling process was 3,7,11-trimethyl-2,6,10-dodecatrienoate 
(farnesoic acid).
265
 By adding the farnesoic acid into the growth media, Oh and coworkers 
showed that 3,7,11-trimethyl-2,6,10-dodecatrienoate was able to prevent the morphological 
differentiation from yeast to hyphae.
266
 After the discovery of the farnesyl based autoregulatory 
signal, Ramage and coworkers employed trans-trans farnesol molecule for effective inhibition of 
Candida albicans biofilm. The biofilm inhibition ability of farnesol was mediated through its 
ability to prevent yeast to hyphae morphogensis.
267
 Later, Alem and coworkers discovered a 
second QS molecule secreted by Candida albicans. This, second QS chemical signal was an 
alcohol derived from tyrosine.
268
 Apart from these two chemical signals, many small molecules 
like, phenylethyl alcohol, dodecanol and nerodiol have been identified as autoregulators secreted 
by Candida albicans during QS and biofilm formation 
264
 The later three molecules are also 
known inhibitors of hyphal formation therefore, these agents have good biofilm dispersion 
properties.
269
 Similar to genetic regulation of virulence genes in bacteria, the secretion of many 
extracellular factors responsible for both intercellular and cell-to-substrate adhesion by Candida 
albicans are controlled by a set of genes.
270
 Two such Candida albicans genes regulate the 
expression of hyphal wall proteins (Hwp1) and adhesin Eap1. While the expression of hwp1 is 
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critical for formation of hyphal wall protein,  adhesin Eap1 mediates binding of fungal cells to 
other cells and to surfaces. 
271
 Both, hyphal wall proteins (Hwp1) and adhesin Eap1 have become 
targets for effective therapeutics against Candida albicans. 
4.1.3 Interspecies interactions between fungus and bacteria can be cooperative as well as 
uncooperative 
From clinical perspective, the mixed biofilm formed by bacteria and fungi probably has 
more adverse effects than biofilm formed by a single species alone. One work consistent with the 
medical perspective about mixed biofilms was done by Azoulay, E. et al in which they showed 
that the risk of contracting ventilator associated pneumonia (VAP) caused by 
Pseudomonas aeruginosa was increased when the patients respiratory tract was colonized with  
Candida spp. Therefore, exploring ways to treat mixed biofilms is important primarily because 
dual infection by bacteria and fungus are known to lead to increased mortality rates.
272
 
Mechanistically, co-existence of bacteria and fungi can exhibit many diverse interactions, that 
affect either microbial physiology or growth or both, and of these interactions some are 
symbiotic but most are inhibitory.
273,274
 The autoregulatory signal farnesol secreted by Candida 
albicans has been reported to inhibit the formation of biofilm by Staphylococus aereus.
275,276
 
Likewise, the autoinducers secreted by Pseudomonas aeruginosa have been shown to prevent 
Candida albicans hyphal formation and hence inhibit biofilm formation.
277
  
4.1.4 Three broad classes of fungicidal agents against Candida albicans 
Overall antifungal agents can be classified into three broad classes; echinocandins, 
polyenes and azoles. The mode of action for all the three types of antifungal agents is via 
blocking some fungal metabolic activity or by targeting an important structural element on yeast 
cells. Apart from theses traditional antifungal agents, Cheng et al isolated and characterized 
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Flocculosin (octadecyl cellobiosides) which is a class of cellobiose-based lipids from a fungus, 
Pseudozyma flocculosa and reported that such agents possessed antifungal activities.
278
 Mimee et 
al used flocculosin isolated from Pseudozyma flocculosa for effective antibacterial activity.
279
  
Cellobiose based molecule isolated from Trichosporon porosum by Nifantiev and co-worker was 
shown to have antifungal activity too.
280
 
4.1.5 Antibiofilm strategies developed so far 
 Farnesol is the cell-signalling molecule of Candida albicans and its secretion controls 
induction of hyphal phase. Ramage et al demonstrated that biofilm formation could be prevented 
when farnesol was applied in the early stages of biofilm formation.
267
 As farnesol prevented 
biofilm formation via blocking germ tube formation, Nickerson et al performed a comprehensive 
structure activity relationship (SAR) study with farnesol analogues to understand how structural 
changes affected germ tube formation in Candida albicans.
281
 In that study, a chemical library of 
forty molecules that differed from farnesol either in head group, or aliphatic chain structure, or in 
chain unsaturation, or in occurrence of hetero atoms in the backbone were studied for their effect 
on germ tube formation. Of the forty molecules, only twenty two molecules inhibited the germ 
tube formation by >50%, and the rest did not even come close to the activity of farnesol. 
Amongst the better twenty two molecules, the activity of the most potent agent was only ~7% of 
the activity exhibited by farnesol. The extracellular factors of both bacteria and fungi can affect 
the physiology and morphology of each other and vice-versa. The prime example of this 
inhibitory relationship between bacteria and fungus was reported by Hogan et al when they 
showed that two auto inducers secreted by Pseudomonas aeruginosa, 3-oxo-C12 homoserine 
lactone (HSL) and C12-acyl homoserine lactone (AHL) can inhibit hyphal germination in 
Candida albicans.
277
 Inhibitory relationship was further elucidated by Holcombe et al  who 
 
176 
 
showed that supernatants taken from Pseudomonas aeruginosa cultures could decrease the 
ability of Candida albicans to form biofilms on silicone.
282
 Dispersion of Candida albicans 
biofilms by an amphiphilic molecule, dodecyl glucoside was reported by Dusane et al. Apart 
from the antibiofilm agents mentioned here, many other small molecules have also been applied 
to prevent biofilm formation and disperse existing biofilms of Candida albicans.
283-285
 Amongst 
these, the antibiofilm activities of a class of small molecules isolated from natural sources by 
Cichewicz et al. against Candida albicans are the the most potent reported to date.
286,287
 
       In the previous chapters (2&3), the effective use of disaccharide derivatives (DSDs) for 
modulating multiple multicellular behaviors of bacteria Pseudomonas aeruginosa was reported. 
Here, these synthetic DSDs were functional mimics of a class of amphiphilic molecules, 
rhamnolipids secreted by Pseudomonas aeruginosa. Since external factors secreted by both 
bacteria and fungus have been shown to impact the morphology and physiology of one another, 
it was but logical to test the effect of DSDs on Candida albicans. Since certain DSDs were 
potent inhibitors of Pseudomonas aeruginosa biofilm, their corresponding effect on Candida 
albicans biofilms formation was evaluated. Second compelling reason to test DSDs on Candida 
albicans stemmed from their structural details. The most potent DSDs against Pseudomonas 
aeruginosa biofilm were composed of cellobiose head group and a farnesyl aliphatic tail. The 
effect of both farnesyl based molecules and cellobiose based molecules on Candida albicans has 
been document earlier. Primarily, many fungicidal agents have been shown to posses cellobiose 
moieties while farnesol is a known cell-signalling molecule secreted by Candida albicans. But a 
study to understand the effect of structures possessing both the farnesyl and cellobiose moieties 
on Candida albicans morphology and physiology had never been done before.  
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4.2 Results and Discussions 
4.2.1 Structural design of disaccharide derivatives (DSDs) selected for biofilm inhibition of 
Candida albicans 
 
Figure 4.2 Synthetic disaccharide derivatives (DSD) used in this study. Inset: Structure of 
Candida albicans quorum sensing molecule (QSM), farnesol. 
 The structural design of the agents incorporated disaccharide head group (either 
cellobiose or maltose) and an aliphatic tail (either n-alkyl, or farnesyl, or saturated farnesyl, or 
lipid). The DSDs that had cellobiose stereochemistry include, farnesyl-β-cellobioside, FβC (1); 
dodecyl-β-cellobioside, DβC (3); saturated farnesyl-β-cellobioside, SFβC (4); saturated farnesyl-
α-cellobioside, SFαC (5) and 2-octyl-dodecyl-β-cellobioside, 2-ODβC (7); and those with 
maltose stereochemistry included, dodecyl-β-cellobioside, DβC (3); saturated farnesyl-β-
maltoside, SFβM (6) (Figure 4.2). The DSDs could also be classified via their aliphatic tail; 
having a farnesyl tail; FβC (1, cellobiose based); or those having a saturated farnesyl tail; SFβC 
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(4, cellobiose based); SFαC (5, cellobiose based) and SFβM (6, maltose based); or those having 
n-alkyl tail; DβM (2, maltose based); and DβC (3, cellobiose based); or the one having a 
branched lipid tail; 2-ODβC (7, cellobiose based); Since farnesol is a known QSM secreted by 
Candida albicans that has been shown to inhibit biofilm formation, it was also included in the 
chemical library as a control. Synthesis of all DSDs molecules was done according to previously 
reported route and the synthetic procedures and characterizations are mentioned in Chapter 2 
(Materials & Methods).  
4.2.2 None of the DSDs were toxic to the growth of Candida albicans blastospores 
  At the onset it was necessary to establish whether the effect on Candida albicans biofilm 
formation by these DSDs did not originate from their ability to impede growth. For this, the toxic 
effect of DSDs was evaluated on the growth of Candida albicans blastospores grown in yeast- 
peptone-dextrose (YPD) media. The concentration of DSDs selected 340 μM, was higher or 
equal to the highest concentration at which all the other bioassays were done (fungal 
susceptibility assay, biofilm inhibition assay, adhesion assay etc). The growth of blastospores 
with or without 340 μM of various DSDs in YPD media was monitored by observing absorbance 
at 600 nm (OD600).
288,289
 The growth curves (Figure 4.3) so generated over 24 hours revealed 
none of the tested DSDs impeded the growth of Candida albicans blastospores at 340 μM.  
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Figure 4.3 Candida albicans growth curves in YPD medium. Growth was monitored in the 
presence (340 μM) or in absence of various DSDs by measuring the optical density of the culture 
at 600 nm (OD600) over 24 hours. 
4.2.3 The disaccharide derivatives (DSDs) were not fungicidal  
 The fungicidal activity of the DSDs on Candida albicans was done according to the 
standard protocol outlined in the NCCLS 2002 CLSI M27-A2 method (micro-broth dilution 
assay).
290
 The fungal susceptibility assay was done in RPMI-1640 media and the highest 
concentration of the DSDs (340 μM) were serially diluted to obtain a minimum inhibitory 
concentration (MIC90). Here again, like the growth studies with blastospores, the highest 
concentration tested was either higher than or equal to the concentrations at which biofilm 
inhibition studies were done. Images of the micro-broth dilution assay results after 24 hours 
(Figure 4. 4) shows that all the DSDs did not inhibit the growth of Candida albicans in the tested 
concentration range. With no effect on growth of blastospores and no fungicidal activity, the 
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subsequent effect of these DSDs on the biofilm formation of Candida albicans cannot be 
attributed to the inhibitory effect on growth. 
 
 
4.2.4 Most DSDs did not inhibit Candida albicans hyphae formation 
 Although, the DSDs were not fungicidal nor had any inhibitory effect on the growth of 
blastospores, it was also necessary to establish whether such agents affected the germination of 
hyphae. Aliquots from the microbroth dilution susceptibility assays after 48 hours of inoculation 
(Section 4.2.3) with few of the DSDs were viewed under a microscope to physically characterize 
the fungal morphology. Two concentrations of DSDs selected for being viewed under the 
microscope were 340 and 40 μM and the fungal morphology within cultures containing these 
concentrations were compared to that of control (observed with 0 μM concentration of the 
agent). The content of the cultures with the mentioned concentrations was aspirated and then a 
drop of the culture was gently dispensed atop a microscope slide and viewed under the 
microscope. The optical micrograph images of some of these DSDs obtained at the two 
0 μM  2.5      5      10     20     40     85     170   340
SFβM (6)
SFαC (5)
DβC (3)
2-ODβC (7)
SFβC (4)
FβC (1)
DβM (2)
Figure 4.4 Microbroth 
dilution antifungal 
susceptibility assays. Images 
of micotiter plate wells 
inoculated with Candida 
albicans in 1640-RPMI media 
YPD supplemented with 
various concentrations of 
different DSDs. The images 
were taken 48 hours after 
inoculation. 
 
181 
 
concentrations (340 and 40 μM) and at 0 μM (control) in RPMI-1640 media are shown in Figure 
4.5. Amongst the four tested DSDs, FβC (1), DβC (2), SFβC (4) and SFαC (5) none (except 
one, FβC (1)) seemed to inhibit the hyphal formation of Candida albicans at both the selected 
concentrations. However, FβC (1) did seem to prevent hyphae formation at 340 μM. Therefore, 
overall, it could be concluded that all DSDs were nonfungicidal at tested concentration range and 
one DSD prevented hyphal formation at 340 μM. 
                                                   
Figure 4.5 Optical micrograph images of Candida albicans grown in RPMI-1640 media  
with (at 340 or 40 μM) or without (0 μM; control) DSDs. The aliquots were obtained from 
microbroth dilution antifungal susceptibility assays after 48 hours of inoculation. Scale bar ~76 
μm 
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4.2.5 DSDs were screened for biofilm inhibition potencies at 170 μM using a semi-quantitative 
XTT-dye based assay 
291,292
  
 The quantification of Candida albican biofilm was done by using a XTT-based semi-
quantitative analysis. Since, Candida albican under goes yeast to hyphae morphogenesis over 
time, therefore, it was important to establish what stage of biofilm development did the DSDs 
inhibit. Therefore, Candida albican cells were allowed to adhere for two different time-frame 
(seeding of cells), 5 minutes and 4-hours (see Materials and Methods for detailed procedure). 
After the seeding time, wells were washed with PBS buffer and fresh media containing 170 μM 
of various DSDs was introduced in experimental wells where as no agent was added to control 
wells. The biofilm was allowed to form for 24 hours, following which quantification was done 
by adding XTT dye, then storing the microtiter plates in the dark for 3 hours followed by 
measuring the absorbance of the culture at 490nm.
267,286,292
 The results of the XTT-dye based 
quantification are shown in Figure 4.6. When the initial seeding time of 4 hours is allowed, none 
of the DSDs were able to inhibit biofilm formation of Candida albicans. However, when the 
Candida albicans cells were seeded for only 5 minutes followed by addition of fresh media and 
170 μM of various DSDs, the percent biofilm inhibited by all agents was > 60 %. The biofilm 
inhibition potency of two DSDs, SFβC (4) and SFβM (6) at 170 μM was particularly high, >85 
%.  
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Figure 4.6 Candida albicans percent biofilm inhibition caused by various DSDs with two 
different seeding times (5 minutes & 4-hours). The biofilm was allowed to form for 24 hours 
in RPMI-1640 media with or without the agent and then the quantification was done using XTT-
dye assay. Error bars are the mean standard deviation of biofilm inhibition from 4-replicate 
wells. 
4.2.6 Dose response assays brought forward potent DSDs 
  After getting preliminary evidence that with initial seeding time of five minutes, 170 μM 
of the most DSDs could effectively inhibit Candida albicans biofilm, a dose-response curve for 
all agents was plotted to obtain the half-maximal inhibitory concentrations (IC50) for inhibition 
of Candida albicans biofilm. The IC50 values of DSDs for inhibiting Candida albicans biofilm 
are shown in Table 4.1. The corresponding dose-response curves have also been plotted (see 
Materials and Methods). The dose-response study brings forward highly potent antibiofilm 
agents with SFβM (6) having IC50 ~ 14.7 μM and 2-ODβC (7) having IC50 ~ 21.5 μM (Table 
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4.1). We note that structure activity study reveals that DSDs with bulky aliphatic and branched 
aliphatic chains were generally more potent than DSDs with n-alkyl or unsaturated chains. The 
activity of FβC (1) with IC50 ~ 129 μM was lesser than all of the DSDs having hydrogenated 
farnesol aliphatic chain SFβC (4), SFαC (5) and SFβ M (6). Therefore, reducing the number of 
double bonds in the aliphatic chain from three to zero increased the potency and lowered the IC50 
for SFβC (4) to ~14.7 μM (31 % reduction in IC50 value as compared to FβC (1)). Apart from 
inhibition, none of the DSDs exhibited any ability to disperse the pre-formed (24-hours old) 
biofilm of Candida albicans. 
 
4.2.7 DSD prevent surface adhesion of Candida albicans hyphae 
 The next step was to understand the mechanism of action of such DSDs on Candida 
albicans biofilm. Results had indicated that the DSDs did not inhibit growth of Candida albicans 
blastospores or hyphae but yet they were effective at inhibiting it's biofilm when applied within 
five minutes of seeding the wells with cells. As, DSDs had exhibited good antiadhesion property 
against bacteria P. aeruginosa (Chapter 3), the antiadhesive ability against fungus Candida 
Agents IC50
SFβM (6) 14.7 μM
2-ODβC (7) 21.5 μM
SFβC (4) 71.5 μM
DβC (3) 73.6 μM
SFαC (5) 82.8 μM
DβM (2) 122.0 μM
FβC (1) 129.0 μM
Table 4.1. Half-maximal inhibitory 
concentrations (IC50) for inhibition of 
Candida albicans biofilm by various 
DSDs. DSDs were immediately added 
after seeding the microtiter plate wells 
with Candida albicans cells (1 X 10
5
 
cell/mL) for 5 minutes. 
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albicans was therefore evaluated. For this, a surface-study was employed where firstly, a 
modified gold surface was created by micro-contact printing the patterns of alkane terminated 
self-assembled monolayers (SAMs) surrounded by regions of tri-(ethylene glycol) terminated 
SAMs on gold. Secondly, the adherence of Candida albicans blastospores and hyphae on such a 
modified gold surface in presence and in absence of a DSD was studied. In a study performed by 
Luk and workers previously, it was shown that SAMs with tri(ethylene glycol) termination resist 
attachment of C. albicans hyphae but not blastospores, where as SAMS terminating with alkyl 
groups allow adherence of both blastospores and hyphae.
289
 Using the adhesion assay, the effect 
of a DSD, SFαC (5) on adhesion of C. albicans blastospores and hyphae to modified gold 
surface was evaluated. For observing the effect of SFαC (5) on attachment of blastospores, the 
C. albicans cells were grown in yeast-peptone-dextrose (YPD) growth media whereas for 
analyzing the effect on hyphal attachment, the cells were grown in a media that supports hyphae 
i.e RPMI-1640 media. The control contained no agent where as the experimental well contained 
170 μM of DSD, SFαC (5). The adhesion of C. albicans blastospores and hyphae to 
microcontact printed gold surface in presence and in absence of 170 μM SFαC (5) was observed 
at two different time points 3 and 6 hours (Figure 4.7). C. albicans grown on gold slides under 
these conditions was viewed under phase contrast microscope. The phase contrast micrographs 
are reported in Figure 4.7. From the micrographs, it is evident that at 6 hours, both in presence 
and in absence of 170 μM of SFαC (5) blastospores appear to adhere everywhere on the 
microcontact printed gold surface. At 6 hours, under a condition that supports hyphae, dense 
square patterns were formed on alkane terminated SAMs for control experiment. Whereas, 
addition of 170 μM of SFαC (5) caused significant reduction in hyphal adhesion onto alkane 
terminated SAM surface as compared to control. The reduction in adherence of hyphae to 
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modified gold surface in presence of SFαC (5) could be due to either microbicidal action of such 
an agent on C. albicans cells or prevention of blastospores to hyphae morphogenesis or such an 
agent preventing hyphae adhesion. From growth studies in presence of 340 µM of SFαC (5), it is 
evident that the DSD neither inhibits the growth of blastospores (Figure 4.3) nor the growth of 
hyphae (Figure 4.4 & 4.5). Therefore, SFαC (5) inhibits surface adhesion of hyphae which 
possibly leads to inhibition of surface attached biofilm. 
 
Figure 4.7. Analysis of antiadhesive property of DSD, SFαC (5) against Candida albicans 
blastospores and hyphae. Phase contrast optical micrographs of Candida albicans grown in 
medium supporting either blastospores (left box) or hyphae (right box) growth in presence (170 
μM) or in absence of DSD, SFαC (5). Candida albicans were grown on gold slides having 
squares patterns of pentadecanethiol SAMs surrounded by regions of tri-(ethylene glycol) 
terminated SAMs. Scale bar ~ 76 μm. Candida albicans sells were inoculated for mentioned 
time-frame and then viewed under phase contrast microscope.  
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4. 3 Conclusion 
 This study brought forward a new way to inhibit biofilm formation of fungus Candida 
albicans by making use of DSDs. The growth assays indicated that such DSDs do not inhibit the 
growth of both blastospores and hyphal cells. Adhesion assay using modified gold surface 
showed that one DSD, SFαC (5) prevented surface adherence of hyphae. The antibiofilm activity 
of DSDs against Candida albicans was only apparent when these agents were applied within 5 
minutes of seeding the surface with fungus cells. Results suggest that the DSDs are not effective 
antibiofilm agent when applied after 4-hours because longer seeding times would allows hyphae 
to form and adhere to the surface. Therefore, the antibiofilm activity of such DSDs is probably 
due to their ability to prevent initial adhesion of hyphae to the surface.  Some agents like, SFβM 
(6) and 2-ODβC (7) exhibited potent antibiofilm activities with IC50s of 14.7 and 21.5 μM, 
respectively. The “antihyphal adhesion” property of such DSDs could be used as an approach to 
design new therapeutics that prevent C. albicans colonization. 
4.4 Materials and Methods 
General experimental information for synthesis. Synthesis of a DSDs used here are reported 
in Chapter 2 under Materials and Methods. Fluconazole and trans-trans-farnesol were bought 
from Sigma Aldrich. 
General information for biological assays 
Chemicals. Phosphate buffer saline (PBS), 1-Pentadecanethiol, sulfuric acid (95-98%), (3-N-
morpholino) propane sulfonic acid (MOPS) were purchased from Sigma-Aldrich. The piranha 
cleaning reagents, hydrogen peroxide (30%) and methanol were purchased from Fisher chemical 
(Fair Lawn, NJ). 200-proof ethanol used for washing and cleaning glass-slides were purchased 
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from Pharmaco-Aaper (Shelbyville,  Y). Gold deposition was done on piranha cleaned Fisher’s 
finest premium microscope slides (Pittsburgh, PA). For preparing yeast peptone dextrose (YPD) 
media to support growth of blastospores, yeast extract was purchased from Fulka (St. Louis, 
MO), bacto peptone was purchased from BD and Co (Sparks, MD) and dextrose was purchased 
from Sigma (St. Louis, MO). Media supporting hyphae was prepared from commercially 
available RPMI-1640 media containing glutamine and NaHCO3 by buffering with 0.165 M 
MOPS to a pH (~6.9-7.1. Flat bottom 96-well microtiter plates (untreated) (Costar 3370) and U-
bottom 96-well microtiter plates (nontissue culture, BD-falcon) were used for biofilm inhibition 
and fungicidal assays respectively. For assays involving patterned gold slides 24-well plate were 
purchased from Nunc (Thermofisher Scientific, Pittsburgh, PA). Synthesis of tri(ethylene 
glycol)-terminated undecanethiol was done by previous group member.  
Fungal strains and growth media condition. Clinical isolate of C. albicans SC5314 were 
obtained from Dr. Dacheng Ren (Syracuse University). To culture blastospores, a loopful of C. 
albicans SC5314 glycerol stock maintained at -80°C was cultured in 5mL yeast peptone dextrose 
(YPD) media (1%, w/v yeast extract; 2%, w/v of peptone, 2%, w/v of dextrose in autoclaved 
water) overnight in orbital shaker (250 rpm) overnight at 35 °C to produce phase of budding 
blastospores. For experiments involving surface adhesion, working stocks of blastospores were 
prepared by subculturing overnight culture to an optical density OD600 ~ 0.05 as measured by 
Biotek ELx800 absorbance plate reader which uses Gen 5TM data analysis software. Hyphal 
induction was achieved by harvesting cells from 5 mL of overnight YPD culture by 
centrifugation at 3000g for 5min at room temperature, followed by discarding supernatant, 
resuspending yeast cells in 20 mL of sterile PBS buffer (pH ~7.4) twice followed by addition of  
prewarmed (37°C) RPMI 1640 media (20 mL) buffered to pH 7.04 with 0.165M MOPS. From 
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this suspension, a working cell suspension containing 1 x 10
5
 cell mL
-1
 of C. albicans was 
obtained by doing a 1:100-fold dilution with buffered RPMI 1640 media followed by counting 
cells with a hematocytometer.  
Effect of disaccharide derivatives on growth of Candida albicans. Yeast cells were grown 
overnight in yeast-dextrose peptone (YPD) media at 35 
o
C with constant shaking (250 rpm).  The 
overnight culture was subcultured to an initial optical density at 600 nm (OD600) of ~0.05 
measured by Biotek ELx800 absorbance plate reader which uses Gen 5TM data analysis 
software. The sub culture was then grown in presence (340 μM) or in absence of various DSDs 
to a final OD600 of ~1.0 under constant rotatory conditions (250 rpm) at 35 
o
C. The OD600 at 
various time intervals were plotted to obtain a growth curve (Figure 4.3). 
Micro-broth based anti fungal susceptibility assay 
Preparing the microtiter plates and delivering agents. The DSD agents were prepared as 11.5 
mM stock solution in sterile water. To the wells of 96-wells microtiter plate was added 100 μL of 
RPMI-1640 media (buffered to pH ~7.00 by adding MOPs buffer). To the wells in column 11 
was added additional 100 μL of RPMI-1640 media. Aliquots of various DSD stock solutions 
were added to wells in column number 11 at double the required concentration. The media in 
column 11 wells was aspirated ~ six times with the use of a pipette set at withdrawing 100 μL of 
solution. After mixing the DSD stock solution six times with the RPMI-1640 media, 100 μL of 
the mixture was withdrawn an added into the adjoining wells on the left (i.e column 10). The 
contents were aspirated and again 100 μL was removed and added to wells of column nine and 
so on. Following this serial dilution of DSD, the extra 100 μL of solution remaining after last the 
dilution was discarded away. Appropriate amount of water was added into wells serving as 
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positive controls. The micro-titer plate containing RPMI-1640 media with serially diluted DSD 
agent was now ready to receive 100 μL of Candida albicans working culture stock. 
Culturing C. albicans for fungicidal studies. Yeast cells were grown in YPD media (5mL) at 35 
o
C with constant shaking (250 rpm) for ~16 hours. After 16 hours the yeast cells were harvested 
by centrifuging at 3000g for 5 mins at room temperature. The harvested cells were washed twice 
(20 mL) with PBS buffer solution (pH ~ 7.4, 10 mM). After washing, the yeast cells were 
suspended in 20 mL of RPMI-1640 media to obtain the culture stock. The stock culture was 
diluted 100 times and cells were counted using a hematocytometer to a final cell count of 2 X 10
5
 
cells/mL to obtain a working stock of culture. Aliquots (100 μL) of the working culture stock 
were then added into each well of the microtiter plate having serial dilution of the DSD agent. 
The resultant culture in each well was mixed gently by swirling the solution with clean pipette 
tips. The plates were then covered with lids and placed at 35 ºC for 48 hours. After 48 hours, the 
amount of cellular growth in each well was visually inspected and compared to the wells having 
no agent (positive control). Images of the wells after 48 hours of growth were taken with a 
camera. Micro-titer plate containing serially diluted flucanazole was also optimized to serve as a 
control. 
Inspecting for hyphal growth. For observing the growth inhibition of hyphae in presence of 
various DSDs, 3 μL of culture from the wells (340, 60 and 0 μM) of the micro-broth dilution 
experiments were spotted on a microscope slide and viewed under a microscope (Olympus BX51 
microscope) and images were taken under 10X zoom using a mounted Olympus wide zoom 
camera. 
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XTT-based biofilm inhibition assays.  
Preparation of the  reagents for the assay. A semi-quantitative XTT [2, 3-bis(2-methoxy-4-nitro-
5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide]-reduction assay was used to quantify biofilm 
formed by C. albicans SC5314. For this, XTT was prepared as 0.5 mg/mL solution in 10 mM 
sterile PBS buffer (pH ~7.4) and filtered through 0.22 μm filter, aliquoted (5 mL) into vials 
wrapped with aluminum foil and stored at -80 ⁰ C in the dark. A solution of menadione (5 mM) 
in acetone was also prepared, aliquoted as 50 μL working stock into eppendorf tubes and stored 
at  -80 ⁰ C. During the day of quantitative measurement for biofilm, a freezer aliquot of both 
XTT and menadione was removed, thawed to room temperature prior to use. Leftover solution 
was never reused for a subsequent assay. Stock solutions of all antibiofilm agents were prepared 
in sterile water (11.5 mM), filtered through a 0.22 μm filter and stored at -20 ⁰ C. A stock 
solution of trans-trans-farnesol was also prepared (11 mM) in MeOH to serve as a control for 
biofilm assay. 
Serial dilution of DSDs for dose-response assay. Aliquots (100 μL) of C. albicans (1 x 10
5
 cell 
mL
-1
) from a working culture stock prepared in RPMI-1640 media were seeded into the wells of 
a 24-well microtiter plate. Two different seeding times, 5 mins and 4 hours were chosen. After 
the seeding time, the culture was removed and the wells were washed and aspirated with 200 μL 
of PBS buffer (10 mM, pH~7.4) to remove nonadherent cells. Following this, fresh media 
(RPMI-1640) (200 μL) containing the highest concentration of agent (340 μM) was added to 
wells in column number 11. Fresh media (100 μL) was also added to the remaining wells 
(column 2-10). Serial dilution of the agent was performed by mixing with pipette the content of 
column 11 gently, then removing 100 μL of culture media and adding to wells in column 10. 
Again the contents of column 10 were mixed gently and 100 μL was removed and added to the 
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next column (9) and so on. After serial dilution of column 3, the extra 100 μL was discarded. 
Column 2 served as positive control. Column 12 content only RPMI-1640 media to serve as a 
negative control. Following the serial dilution of agent, the microtiter plate was wrapped in 
GLAD press (saran wrap) and incubated at 37 
o
C under static conditions for 24 hours. 
XTT-reduction assay. Prior to each assay, 1 μL of thawed menadione was added to the thawed 
XTT solution (5 mL). After 24 hours incubation, the culture was removed and the wells of the 
microtiter plates were gently washed and aspirated twice with 100 μL of PBS buffer solution to 
remove nonadherent and planktonic cells. Following this 100 μL of XTT/menadione solution 
was added into the wells and the plates were incubated in the dark for 3 hour at 37 
o
C. The 
surface attached metabolically active cells can reduce XTT into a water soluble orange dye, 
formazan. A semi-quantitative measurement of surface attached biofilm was therefore made by 
measuring the absorbance from different wells at 490 nm and comparing the A490 to the readings 
obtained from the wells without any agent.   
 
Figure S1. Schematic depicting XTT-dye based biofilm assay for Candida albicans with two 
different seeding times (5 minutes and 4 hours). 
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Figure S2. Dose-response curves for inhibition of Candida albicans biofilms by various 
disaccharide derivatives (DSDs). 
Adhesion studies with a modified gold surface 
Piranha Cleaning of Glass Substrates. Piranha solution (7 parts of concentrated sulfuric acid and 
3 parts of hydrogen peroxide (30 % in water)) was used to clean glass substrates prior to gold 
deposition. For this, the glass substrates were first washed with 200-proof ethanol and dried 
under a stream of nitrogen, followed by dipping the slides for 45 min in a piranha solution 
maintained at 70
 o
C. Following this, the piranha solution was allowed to cool to room 
temperature and slowly poured off. Multiple washes (~20 times) of the slides was done with 
deionized water, followed by 10 washes with ethanol and 10 washes with methanol. The slides 
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
SFβM (6)
2-ODβC (7)
SFβC (4)
SFαC (5)
DβC (3)
DβM (2)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
5
3
-1
2
4
6
8
0
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
5
3
-1
2
4
6
8
0
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y  16.701l (x) + 5.72
²  .8375
y  29.645l (x) - 76.6
²  .9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. (DbM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497ln(x) - 84.688
R² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y  16.701l (x) + 5.72
²  .8375
y  29.645l (x) - 76.6
²  .9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
5
25
45
65
85
105
125
0 50 100 150 200 250 300 350
sfaC
DbM
DbC
sfdm
sfbc
2-ODbC
Log. (sfaC)
Log. ( bM)
Log. (DbC)
Log. (sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497l (x) - 84.688
² = 0.8426
y = 30.882ln(x) - 98.383
R² = 0.8725
y = 23.48ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
2
4
6
8
10
12
0 50 100 150 200 250 300 350
sfa
DbM
D C
sfdm
sfbc
2-ODbC
sfa
DbM
D C)
sfdm)
Log. (sfbc)
Log. (2-ODbC)
y = 30.497l (x) - 84.688
² = . 4 6
y = 3 . 8 ln(x) - 98.383
R² = 0.8725
y = 23.4 ln(x) - 50.95
R² = 0.8328
y = 16.701ln(x) + 5.7203
R² = 0.8375
y = 29.645ln(x) - 76.603
R² = 0.9252
y = 7.2763ln(x) + 27.67
R² = 0.8801
-55
-35
-15
2
4
6
8
10
12
0 50 100 150 200 250 300 350
sfa
DbM
D C
sfdm
sfbc
2-ODbC
sfa
DbM
D C)
sfdm)
Log. (sfbc)
Log. (2-ODbC)
B
io
fi
lm
re
m
ai
n
in
g
  (
%
) 
af
te
r 
in
h
ib
it
io
n
Concentration (μM)
 
194 
 
were dried off by placing under a stream of nitrogen gas and then kept in the oven overnight at 
100 ºC. The dried slides were subsequently used for gold deposition. 
 
Gold deposition on gold slides. An electron beam evaporator system (Thermionics, Port 
Townsend, WA) was used to deposit a semi-transparent film of gold on the piranha cleaned glaas 
slides. Deposition of titanium followed by gold was done by placing the glass slides in a holder 
such that the deposition angle was 45° to the glass surface. The first coating applied on glass to 
enhance adhesion of gold was that of titanium (~70 Å). Following deposition by titanium, gold 
was deposited on the surface at a rate of 0.1 Å/s to achieve a final gold thickness of ~280 Å. 
 
Micropatterning of pentadecanethiol SAMs surrounded by tri(ethylene glycol) terminated 
alkanethiols. Previous protocol reported by Luk et al. was used to create micropatterned regions 
of pentadecanethiol SAMs surrounded by tri(ethylene glycol) terminated alkanethiols. Briefly, 
the gold deposited glass slides were cut into 1 cm x 1 cm squares and washed with 200 proof 
ethanol followed by drying under a stream of nitrogen gas. A polydimethylsiloxane (PDMS) 
stamp having size (380 X 380 μm
2
) washed with 200 proof of ethanol and dried under nitrogen 
gas. The clean PDMS stamp was dabbed with a thin film of 2 mM ethanolic solution of 
pentadecanethiol and later stamped for 20 seconds on the gold slides. Following the stamping the 
glass slide was rinsed with ethanol, dried under nitrogen and then immersed in 2mM ethanolic 
solution of tri(ethylene glycol) terminated undecanethiol for 18h. After 18 h, the micropatterned 
gold slides (called gold slides henceforth) were removed from the solution, rinsed with ethanol 
and dried under a stream of nitrogen gas. 
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Figure S3. Schematic representation of a micropatterned gold slide containing regions of 
pentadecanethiol SAMs surrounded by SAMs formed by tri(ethylene glycol)-terminated 
undecanethiol. 
Adhesion of blastospores and hyphae on micropatterned gold slides.  
Three separate 24-well microtiter plates were prepared such that each plate contained four 
micropatterned gold slides in the inner four wells. Two wells in each plate was inoculated with 
YPD culture containing blastospores (OD600 ~ 0.05; 600 μL), while in the remaining two wells 
were inoculated with C. albicans (1 x 10
5
 cell mL
-1
) in RPMI-1640 media (600 μL). In each 
plate, one well with YPD yeast inoculum was supplemented with SFαC (5; 170 μM) and one 
well with RPMI inoculum was also supplemented with SFαC (5; 170 μM). The remaining wells 
containing no agents served as controls for YPD and RPMI conditions, respectively. In the 
remaining outer wells, sterile water (600 μL) was added to limit evaporation and drying from the 
inner wells. The microtiter plates containing the gold slides and culture media were then 
wrapped in GLAD Press n’ Seal® (saran wrap) and further incubated under stationary conditions 
at 37 °C. The time of incubation was noted and for observation. The gold slides were removed 
from the media after three, six and twenty four hours and washed gently by slowly dipping in 
Bioinert
Non-
bioinert
Resist hyphae
Do not resist hyphae
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sterile water once followed by dabbing the edge of the gold slide on a kim wipe to remove excess 
water. The gold slides were viewed under phase contrast microscope (Motic, AE31, equipped 
with Infinity 2 Camera) under 4X magnification. 
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Chapter 5 
Future directions 
 
One future direction of the Pseudomonas aeruginosa project (chapters 2 & 3) would be to 
create activity based probes to identify the target protein.  Results in this thesis have indicated 
that the three bioactivities, i.e biofilm inhibition, adhesion inhibition and swarming modulation 
associated with the saccharide derivatives are less sensitive to the sugar sterochemistry in 
comparison to the aliphatic structure. Hence, making chemical modifications like epoxides on 
the sugar head groups are less likely to reduce the molecule's activity when compared to the 
same change done to the aliphatic chain. In future, sugar derivatives having epoxide modification 
could serve as good activity based probes for making covalent linkage with the active site.  
Once the receptor protein has been identified, the next goal would be target validation, 
identification of the active site and ultimately performing binding studies. Structure of active site 
and identification of key interactions will be important for creating more optimized saccharide 
structures. 
Rhamnolipids and its aliphatic chain variants are produced by a few bacteria including 
Pesudomonas aeruginosa, Burkholderia glumae and Burkholderia pseudomallei,
23
 and such 
secreted rhamnolipids have also been used to inhibit the biofilm formation for a wide range of 
other bacterial species, including Rhodococcus erythropolis, L. monocytogenes, Staphylococcus 
aureus, Bacillus pumilus.
24
  These findings call for a deeper understanding of how rhamnolipids 
function with respect to their specific biological activities that other generic surfactants and 
biosurfactants cannot perform.  Because of the versatile bioactivities, this class of secreted 
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molecules has the potential to be developed as nonmicrobicidal therapeutic agents that can 
control bacterial behaviors without invoking drug resistance.  
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